<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> Xenetic Biosciences, Inc. (Form: 10-K, Received: 03/30/2016 15:22:04) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_NAME_AND_TITLE **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_BALANCE_SHEET **FIS_AUDITORS_OPINION **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET_2 **FIS_CASH_FLOW **FIS_STOCKHOLDERS_EQUITY **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_VALUATION_AND_QUALIFYING_ACCOUNTS **FIS_PART_II_2 **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_EXHIBIT_INDEX **FIS_BENEFICIAL_OWNERS FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="90">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="XENETIC_10K-123115_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	UNITED
	STATES SECURITIES AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Washington,
	DC 20549
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Form
	10-K
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 7%; BORDER-TOP: BLACK 1PT SOLID; FONT: BOLD 10PT CAMBRIA, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</TD>
<TD STYLE="WIDTH: 93%; BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ANNUAL
	REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For
	the fiscal year ended December 31, 2015
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="FONT: BOLD 10PT CAMBRIA, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT CAMBRIA, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT CAMBRIA, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	TRANSITION
	REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For
	the transition period from to
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Commission
	File Number: 333-178082
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	XENETIC
	BIOSCIENCES, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Exact
	name of registrant as specified in its charter)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 50%; BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Nevada
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(State
	or other jurisdiction of
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	incorporation
	or organization)
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	45-2952962
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(IRS
	Employer
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Identification
	No.)
</B>
</FONT>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	99
	Hayden Ave, Suite 230
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Lexington,
	Massachusetts 02421
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Address
	of principal executive offices and zip code)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	781-778-7720
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Registrant&rsquo;s
	telephone number, including area code)
</B>
</FONT>
</P>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="TEXT-ALIGN: CENTER">
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Title
	of Each Class
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	None
</B>
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Name
	of Each Exchange
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	on
	Which Registered
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	None
</B>
</FONT>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Securities
	registered pursuant to Section 12(b) of the Act:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	None
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Securities
	registered pursuant to Section 12(g) of the Act:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	None
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark if the registrant is a well known seasoned issuer, as defined in Rule 405 of the Securities Act: Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	o
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 10PT">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act:
</FONT>
	Yes
<FONT STYLE="FONT: 10PT WINGDINGS">
	o
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
	Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
	and (2) has been subject to such filing requirements for the past 90 days): Yes
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	o
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
	Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the
	preceding 12 months (or for such shorter period that the registrant was required to submit and post such files): Yes
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	o
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect; 229.405) is not contained herein,
	and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated
	by reference in Part III of this Form 10-K or any amendment to this Form 10-K: Yes
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	x
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	o
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
	reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
	reporting company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 41%; FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Large
	accelerated filer
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</TD>
<TD STYLE="WIDTH: 28%; FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Accelerated
	filer
</FONT>
</TD>
<TD STYLE="WIDTH: 17%; FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Non-accelerated
	filer
</FONT>
</TD>
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</TD>
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Smaller
	reporting company
</FONT>
</TD>
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(Do
	not check if a smaller reporting company)
</FONT>
</TD>
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Indicate
	by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2): Yes
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	o
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT: 10PT WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	approximate aggregate market value of voting common stock held by non-affiliates of the registrant, based upon the last sale price
	of the registrant&rsquo;s common stock on the last business day of the registrant&rsquo;s most recently completed second fiscal
	quarter June 30, 2015 (based upon the shares of common stock at the closing sale price of the registrant&rsquo;s common stock
	listed as reported on the OTCQB), was approximately $9,500,000.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	of March 30, 2016 the number of outstanding shares of the registrant&rsquo;s common stock was 151,980,084.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	DOCUMENTS
	INCORPORATED BY REFERENCE
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 2.25PT 0 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	registrant intends to file a proxy statement pursuant to Regulation 14A or a Form 10-K/A, not later than 120 days after the close
	of the fiscal year ended December 31, 2015. Portions of such proxy statement or Form 10-K/A are incorporated by reference into
	Part III of this Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 2.25PT 0 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 2.25PT 0 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	XENETIC BIOSCIENCES, INC.
<BR>
	2015 ANNUAL REPORT ON FORM 10-K
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<B>
	TABLE OF CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 2.25PT; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	I
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 83%; FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 5%; FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	1
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Business
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	1A
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Risk
	Factors
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	30
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	1B
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Unresolved
	Staff Comments
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	30
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	2
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Properties
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	30
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	3
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Legal
	Proceedings
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	30
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	4
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mine
	Safety Disclosures
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	30
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	II
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	5
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Market
	for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	6
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Selected
	Financial Data
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	34
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	7
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	35
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	7A
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Quantitative
	and Qualitative Disclosures About Market Risk
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	45
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	8
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial
	Statements and Supplementary Data
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	46
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	9
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Changes
	in and Disagreements with Accountants on Accounting and Financial Disclosure
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	49
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	9A
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Controls
	and Procedures
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	49
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	9B
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other
	Information
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	50
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	III
</B>
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
	51
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	10
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Directors,
	Executive Officers and Corporate Governance
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
	51
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	11
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Executive
	Compensation
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
	51
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	12
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Security
	Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
	51
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	13
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certain
	Relationships and Related Transactions, and Director Independence
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
	51
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	14
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Principal
	Accounting Fees and Services
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
	51
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PART
	IV
</B>
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
	51
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Item
	15
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibits,
	Financial Statement Schedules
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	52
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Signatures
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	53
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	Index
</FONT>
</TD>
<TD STYLE="PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-TOP: 2PT; PADDING-BOTTOM: 2PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	54
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CAUTIONARY
	NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	report contains both historical and forward-looking statements. The forward-looking statements in this annual report are not based
	on historical facts, but rather reflect the current expectations of our management concerning future results and events. These
	forward-looking statements include, but are not limited to, statements concerning our plans to continue the development of our
	proposed drug candidates; our expectations regarding the nature, timing and extent of clinical trials and proposed clinical trials;
	our expectations regarding the timing for proposed submissions of regulatory filings, including but not limited to any Investigational
	New Drug (&ldquo;IND&rdquo;) filing or any New Drug Application (&ldquo;NDA&rdquo;); the nature, timing and extent of collaboration
	arrangements; the expected results pursuant to collaboration arrangements including the receipts of future payments that may arise
	pursuant to collaboration arrangements; the outcome of our plans to obtain regulatory approval of our drug candidates; the outcome
	of our plans for the commercialization of our drug candidates; our plans to address certain markets, engage third party manufacturers,
	and evaluate additional drug candidates for subsequent commercial development, and the likelihood and extent of competition to
	our drug candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	some cases, these statements may be identified by terminology such as &ldquo;may&rdquo;, &ldquo;will&rdquo;, &ldquo;should&rdquo;,
	&ldquo;expect&rdquo;, &ldquo;plan&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;estimate&rdquo;, &ldquo;predict&rdquo;,
	&ldquo;potential&rdquo;, or &ldquo;continue&rdquo;, or the negative of such terms and other comparable terminology. Although we
	believe that the expectations reflected in the forward-looking statements contained herein are reasonable, we cannot guarantee
	future results, the levels of activity, performance or achievements. These statements involve known and unknown risks and uncertainties
	that may cause our or our industry's results, levels of activity, performance or achievements to be materially different from
	those expressed or implied by forward-looking statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Management's Discussion and Analysis of Financial Condition and Results of Operations (the &ldquo;MD&amp;A&rdquo;) should be read
	together with our financial statements and related notes included elsewhere in this annual report. This annual report, including
	the MD&amp;A, contains trend analysis and other forward-looking statements. Any statements in this annual report that are not
	statements of historical facts are forward-looking statements. These forward-looking statements made herein are based on our current
	expectations, involve a number of risks and uncertainties and should not be considered as guarantees of future performance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	single most pressing factor that could cause actual results to differ materially and adversely is our need to raise additional
	working capital for the purpose of further developing our various drug candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other
	factors that could cause actual results to differ materially include without limitation:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to continue to finance our
	business, including our plans to complete a capital raise during 2016;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to successfully close on the
	transactions contemplated in the Asset Purchase Agreement (the &rdquo;APA&rdquo;) entered into on November 13, 2015;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to complete a planned up-list
	to a national securities exchange;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to achieve milestone and other
	payments associated with our co-development collaborations and strategic arrangements;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the impact of new technologies on our
	drug candidates and our competition;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in laws or regulations of governmental
	agencies;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	interruptions or cancellation of existing
	contracts;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	impact of competitive products and pricing;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	product demand and market acceptance and
	risks;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the presence of competitors with greater
	financial resources;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	product development and commercialization
	risks;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	continued availability of supplies or
	materials used in manufacturing at the current prices;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the ability of management to execute plans
	and motivate personnel in the execution of those plans;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	adverse publicity related to our products
	or the Company (as defined below) itself;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	adverse claims relating to our Intellectual
	Property (&ldquo;IP&rdquo;);
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the adoption of new, or changes in, accounting
	principles;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the costs inherent with complying with
	new statutes and regulations applicable to public reporting companies, such as the Sarbanes-Oxley Act of 2002; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	other new lines of business
	that the Company may enter in the future.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These
	factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed
	in the forward-looking statements in this annual report. Other unknown or unpredictable factors also could have material adverse
	effects on our future results. The forward-looking statements in this annual report are made only as of the date of this annual
	report, and we do not have any obligation to publicly update any forward-looking statements to reflect subsequent events or circumstances.
	Please also refer to Item 1A - Risk Factors in this Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PART
	I
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	1 &ndash; BUSINESS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Trademarks
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Xenetic
	Biosciences, Inc.&rsquo;s brand and product names, including but not limited to PolyXen&trade;, Virexxa
<SUP>
	&reg;
</SUP>
	, OncoHist&trade;
	and ImuXen&trade; contained in this document are trademarks, registered trademarks or service marks of Xenetic Biosciences, Inc.
	and or its subsidiaries in the United States of America (&ldquo;USA&rdquo; or &ldquo;U.S.&rdquo;) and certain other countries.
	This document contains references to trademarks and service marks of other companies that are the property of their respective
	owners. As used in this annual report, unless otherwise indicated, all references herein to &ldquo;Xenetic&rdquo;, the &ldquo;Company&rdquo;,
	&ldquo;we&rdquo; or &ldquo;us&rdquo; refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Significant
	Transactions and Recent Developments
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Financing
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	November 13, 2015, the Company entered into an Asset Purchase Agreement (the &ldquo;APA&rdquo;) with AS Kevelt, an Estonian
	biotech company (&ldquo;Kevelt&rdquo;) and OJSC Pharmsynthez (&ldquo;Pharmsynthez&rdquo;, and together with Kevelt,
	&ldquo;Sellers&rdquo;). Pursuant to the APA, the Sellers will transfer to the Company certain intellectual property rights
	held by the Sellers with respect to Virexxa
<SUP>
	&reg;
</SUP>
	, and the Company will receive the worldwide rights to
	develop, market and license Virexxa
<SUP>
	&reg;
</SUP>
	for certain uses, except for excluded uses within the Commonwealth
	of Independent States (the &ldquo;CIS&rdquo;), in exchange for 111.5 million shares of Company common stock and certain
	other consideration.&nbsp; Virexxa
<SUP>
	&reg;
</SUP>
	is a Phase II oncology drug candidate which is under investigation for
	the treatment of certain endometrial cancers.&nbsp; As part of this total consideration, the Company will also acquire
	Kevelt's U.S. Orphan Drug designation for the use of Virexxa
<SUP>
	&reg;
</SUP>
	in the&nbsp;treatment of progesterone receptor
	negative endometrial cancer in conjunction with progesterone therapy.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	APA also contains a financing component wherein the Company received from Pharmsynthez up to $3.5 million in bridge financing
	commitments and a commitment of an additional $6.5 million in financing as part of a planned capital raise and up-list to a national securities exchange.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	of March 30, 2016, the Company has received $3.5 million of the $3.5 million bridge financing. In addition, the Company issued
	11 million shares in November 2015 as a prepayment toward completing the APA transaction. However, transfer of all of the Virexxa
<SUP>
	&reg;
</SUP>
	intellectual property and development rights and issuance of 100.5 million shares of the total 111.5 million shares of the
	Company&rsquo;s common stock was not completed as of March 30, 2016. The Company expects these transfers, along with the balance
	of the transactions contemplated in the APA, to be consummated during the second quarter of 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	is not intended to be a full description of the APA. Please refer to the SEC Form 8-K filed on November 16, 2015 for a more complete
	description of this transaction.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	July 1, 2015, the Company entered into a Securities Purchase Agreement (the &ldquo;SPA&rdquo;) with Pharmsynthez providing for
	the issuance of a minimum of a $3 million, 10% Senior Secured Collateralized Convertible Promissory Note (the &ldquo;SPA Note&rdquo;).
	The SPA also provides for the issuance of certain warrants up to the amount of the SPA Note. In July 2015, the Company issued
	the SPA Note for $3 million plus a warrant to purchase 10 million shares of common stock (the &ldquo;Warrant&rdquo;) in accordance
	with the terms of the SPA. The SPA Note carries a term of one year and is convertible, in whole or in part, at the option of Pharmsynthez
	into shares of common stock at a conversion price of $0.15. In the event that the SPA Note remains outstanding at April 1, 2016,
	Pharmsynthez shall be granted an additional warrant to purchase an additional number of shares of the Company&rsquo;s common stock
	equal to 50% of the number of shares issuable under the SPA Note. The Warrant has a five-year term and is exercisable commencing
	January 1, 2016. The SPA was amended in November concurrent with the execution of the APA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	is not intended to be a full description of the SPA. Please refer to the SEC Form 8-K filed on July 3, 2015 for a more complete
	description of this transaction.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Acquisition
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	January&nbsp;23, 2014, the Company consummated an acquisition pursuant to a written plan of reorganization, in which we merged
	with Xenetic Biosciences (UK) Limited (formerly Xenetic Biosciences plc) (&ldquo;Xenetic UK&rdquo;), a company incorporated in
	England and Wales under the Companies Act of 1985, such that Xenetic UK became a wholly owned subsidiary of the Company (the &ldquo;Acquisition&rdquo;).
	Upon completion of the Acquisition, we acquired all issued and outstanding shares of capital stock of Xenetic UK. As a result,
	132,545,504 shares of our common stock were newly issued and, immediately following the Acquisition, there were 136,045,504 shares
	of common stock issued and outstanding. At that time, because former Xenetic UK shareholders owned approximately 97% of the combined
	company on a fully diluted basis and all members of the combined company&rsquo;s executive management were from Xenetic UK, Xenetic
	UK was deemed to be the acquiring company for accounting purposes and the transaction was accounted for as a reverse acquisition
	in accordance with accounting principles generally accepted in the United States (&ldquo;U.S. GAAP&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Prior
	to the Acquisition, the Company changed its name from General Sales and Leasing, Inc. to Xenetic Biosciences, Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Stock
	Purchase Agreement
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	January 29, 2014 the Company entered into a stock purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with Baxter Healthcare
	SA (&ldquo;Baxter SA&rdquo;), pursuant to which the Company sold to Baxter SA 10,695,187 shares of the Company&rsquo;s common
	stock, par value $0.01 per share, (the &ldquo;Shares&rdquo;) for $10 million (the &ldquo;Purchase Price&rdquo;) at a price of
	$0.935 per share yielding a market cap of approximately $140 million. During June 2015, in connection with the separation of its
	biopharmaceuticals business to form Baxalta Incorporated (&ldquo;Baxalta&rdquo;), Baxter assigned the Shares to Baxalta.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Shares were sold in a private placement and were not registered under the Securities Act, or the securities laws of any state,
	and were offered and sold in reliance on the exemption from registration afforded by Section 4(a)(2) and Regulation D (Rule 506)
	under the Securities Act and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving
	any public offering. Baxter SA is an &ldquo;Accredited Investor&rdquo; as such term is defined in Regulation D promulgated under
	the Securities Act. For a further discussion of the Purchase Agreement please refer to &ldquo;Market for Registrant&rsquo;s Common
	Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities &ndash; Recent Sales of Unregistered Securities&rdquo;
	in this Annual Report filed on Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Overview
	of Business
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Xenetic
	Biosciences, Inc. is a clinical stage biopharmaceutical company that is focused on the research and development of certain pharmaceutical
	products for use in humans that incorporate the use of its patented and proprietary platform technologies that we believe will
	enable the creation of next-generation biologic drugs and novel oncology therapeutics with an emphasis primarily on orphan indications.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	hold more than 201 United States (&ldquo;U.S.&rdquo;) and international patents
	in addition to certain proprietary rights to four core technologies that are designed to treat a variety of indications with potential
	use advantages over competing products, in addition we have approximately 90 pending
	patents. In June 2014, the U.S. Patent and Trademark Office (the &ldquo;USPTO&rdquo;) has granted the Company U.S. Patent No.
	8,735,557, entitled &quot;Activated Sialic Acid Derivatives for Protein Derivatization and Conjugation,&quot; which contains claims
	that cover lead compound, ErepoXen&trade;, and Xenetic's broader polysialic acid technologies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company&rsquo;s core technologies are summarized below:
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 13%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 87%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PolyXen&trade;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	An
	enabling technology that utilizes Polysialic Acid (&ldquo;PSA&rdquo;), a biopolymer, consisting of a chain of sialic acids,
	which is a natural constituent of the human body. PSA is designed to extend the half-life in circulation in the human body
	for a variety of existing drug molecules and, thereby, to create potentially superior next generation drug candidates.
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Virexxa&reg;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Virexxa&reg;,
	sodium cridanimod, belongs to a class of low-molecular weight synthetic interferon inducers. In addition to its immunomodulatory
	properties, Virexxa&reg; has been shown to increase levels of &nbsp;progesterone receptor expression in tumor tissue of patients
	who are progesterone receptor deficient, and thus may restore sensitivity of non-responsive endometrial cancers to hormonal
	(e.g. progestin) therapy. Based on preclinical observations, Virexxa&reg; may also be therapeutically relevant in other hormone-resistant
	cancers, such as triple-negative breast cancer.&nbsp;&nbsp;Virexxa&reg; has been granted an Orphan Drug Designation by the
	USFDA for use in conjunction with medroxyprogesterone in progesterone receptor negative endometrial cancer.
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OncoHist&trade;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	novel therapeutic platform that utilizes the properties of the human histone H1.3 (&ldquo;H1.3&rdquo;) for the development
	of drug candidates for the treatment of a broad range of cancer indications. OncoHist&trade;, unlike many competing oncology
	therapies, is based on a molecule occurring naturally in the human body, in the cell nucleus, and is therefore expected to
	be less toxic and immunogenic than other oncology therapies.
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ImuXen&trade;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	novel liposomal co-entrapment encapsulation technology designed to create new vaccines and improve the use and efficacy of
	certain existing vaccines for use in the human body. The technology is based on the co-entrapment of the nominated antigen(s)
	in a liposomal vesicle, a design that is intended to maximize both cell and immune system mediated responses.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	of the Company&rsquo;s current drug candidates are in the development stage and none has yet received regulatory approval for
	marketing in the U.S. by the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) or by any applicable agencies in other
	countries.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Our
	Business Strategy
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	strategy is to develop our orphan oncology drug candidates through to market launch. We plan to bring our orphan candidates to
	full and final regulatory approval and commercialization primarily in the U.S. and Europe. For the Company&rsquo;s PolyXen
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	&reg;
</SUP>
</FONT>
	based next generation biologics vested in our pipeline via its various collaborations, e.g. ErepoXen&trade;, we will
	develop to a stage that will enable us to seek profitable out-licensing arrangements with major pharmaceutical companies for further
	development and eventual commercialization, in exchange for milestone payments and royalties from product sales. We are also pursuing
	outlicensing PolyXen
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	&reg;
</SUP>
</FONT>
	for use with a partner&rsquo;s proprietary molecule,
	e.g. Baxalta, in exchange for upfront payments, clinical milestones and royalties linked to sales. Our collaborative out-licensing
	agreements relating to the platforms are an integral part of our early-stage monetization strategy.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	advance our drug candidates through a combination of conducting our own in-house research and through the use of the outside services
	of contract manufacturing and research organizations in order to efficiently manage the Company&rsquo;s overheads. Continuous
	pipeline growth and advancement of outlicensed drug candidates is dependent, in part, on several important co-development collaborations
	and strategic arrangements. Together with our collaborative associates, Baxalta (formerly Baxter Healthcare Corporation), SynBio
	LLC (&ldquo;SynBio&rdquo;), a Russian pharmaceutical company and significant shareholder in the Company, OJSC (&ldquo;Open Joint
	Stock Company&rdquo;) Pharmsynthez (&ldquo;Pharmsynthez&rdquo;), a Russian pharmaceutical company and Serum Institute of India
	Limited (&ldquo;Serum Institute&rdquo;), one of India&rsquo;s largest biotech companies and a shareholder in the Company, we are
	focused on developing our pipeline of next generation bio-therapeutics and novel orphan drugs in oncology based on the Company&rsquo;s
	PolyXen&trade;, OncoHist&trade; and Virexxa&reg; proprietary technologies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Even
	with regard to our strategy of current and planned future co-development collaborations and out-licensing, we must raise significant
	additional capital in order to develop our drug candidates to the point of commercialization. Although we are optimistic, there
	can be no assurance that we will be successful in raising additional working capital. If not successful, our business could be
	adversely affected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Reliance
	on Principal Customer
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Since
	August 2005, Baxalta (formerly Baxter Healthcare Corporation) has been a principal customer of the Company, accounting for the
	substantial portion of the Company&rsquo;s revenue in years prior to 2014, through up-front payments and fee for services. Please
	refer to the agreement with Baxalta under the caption &ldquo;Significant Co-Development Collaborations and Strategic Arrangements&rdquo;
	below for further information regarding the importance of the Company&rsquo;s relationship with Baxalta.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Our
	Technologies
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	PolyXen
</I>
</B>
<I>
	&trade;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PolyXen&trade;
	is a platform technology based on the concept of polysialylation. PSA is a polymer chain composed of sialic acids linked together.
	Sialic acid is found on the external membrane of a number of cell types in the body. In addition, it is a natural component expressed
	on the external membrane on a number of bacterial types. The chain of sialic acid molecules can be anywhere from four to over
	200 individual sialic acid molecules in length. The Company uses the linear form of PSA called colominic acid. It is a natural,
	hydrophilic polymer isolated from a bacterial strain of E. coli K1. This natural glycan is negatively charged, non-toxic and is
	biodegradable. The PSA chain is extensively purified from large-scale bacterial cultures under Current Good Manufacturing Practices
	conditions, modified to specified sizes and then attached to defined sites on the therapeutic. Both the site of attachment and
	the length of the PSA chain can enhance the properties of the therapeutic.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	major effect of PSA addition to a therapeutic is to change the apparent hydrodynamic radius of the molecule. This physical alteration
	then changes a number of the biological characteristics of the therapeutic. The most noticeable, and perhaps the most relevant,
	is an extension of the lifetime of the therapeutic in blood circulation. This is due to the increase in the size of the drug,
	which results in a decrease in the clearance rate of the molecule in the kidney by glomerular filtration. In addition, studies
	have shown changes in other biological characteristics such as protease sensitivity and temperature sensitivity. An added benefit
	is that the conjugated molecules are less viscous in solution than comparable other technologies, providing the potential for
	easier injections and fewer injection site reactions. Furthermore, we believe that adding PSA to an existing marketed drug may
	allow for patent extension, thereby potentially creating a patent-protected next generation candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	current standard for certain biologic delivery agents is Polyethylene Glycol (&ldquo;PEG&rdquo;) which is attached similarly to
	therapeutics. The mode of action between PSA and PEG is similar, increasing the apparent size of the molecule and thereby increasing
	the circulating time of the drug in the blood. PEGylation is a proven technology that can offer advantages in terms of pharmacokinetics
	and pharmacodynamics for therapeutics over non-modified, first generation molecules. There are a number of PEG-modified molecules
	on the market, in clinical trials and under development. However, PEGylation is considered to have limitations, such as non-biodegradability
	and, at high doses, may thereby result in intra-cellular accumulation, potentially leading to vacuole formation in the cells.
	In contrast, because PSA is a chain of sialic acids, which are natural constituents of the human body, it is biodegradable into
	individual sialic acid units. In addition, PEG in many cases has been shown to be immunogenic when coupled to proteins and can
	activate the complement system. PEG has also demonstrated limitations on a few select molecules. PSA has to date been shown to
	be non-immunogenic. We believe PSA may provide the advantages of PEG without many of its disadvantages, offering a potential advance
	over PEG molecules.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Virexxa&reg;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Virexxa&reg;
	(sodium cridanimod) belongs to a class of low-molecular weight immunomodulators, which have been relevant in a wide range
	of therapeutic areas (antiviral, antibacterial, antitumor, and anti-inflammatory). Sodium cridanimod is approved for
	marketing in the Russian Federation, and numerous CIS countries for the treatment of certain infectious diseases. Sodium
	cridanimod has been authorized and marketed in the Russian Federation and CIS states for more than 17 years and approximately
	11,000,000 doses have been sold for non-cancer indications under certain brand names Neovir&reg; and Primavir&reg;. In
	addition there are 22 completed clinical trials conducted by others outside the U. S. that assessed the efficiency and safety
	of sodium cridanimod in certain non-cancer indications.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	decision to investigate Virexxa&reg; for the treatment of endometrial cancer was based in part on the history of sodium cridanimod
	in preclinical and clinical research conducted by others, as summarized below.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition to its immunomodulatory properties, Virexxa&reg; has been shown to increase the levels of progesterone receptor
	(&ldquo;PR&rdquo;) expression in the endometrial tumor tissue of patients who are PR deficient, and thus may have the
	potential to restore the sensitivity of non-responsive endometrial cancers to hormonal (e.g. progestin) therapy. At present,
	the clinical development program for Virexxa&reg; includes an ongoing FDA IND-enabled Phase II study for Virexxa&reg; in
	conjunction with progestin therapy in a population of patients with recurrent or persistent progesterone receptor negative
	(&ldquo;PrR-&ldquo;) endometrial cancer. Virexxa&reg; has been granted an Orphan Drug Designation by the FDA for use in
	conjunction with medroxyprogesterone in PrR- endometrial cancer.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Preclinical
	studies have shown that sodium cridanimod can increase interferon-alpha production by human immune cells
	and increase PR levels in endometrium. Furthermore, a Phase II clinical study conducted in patients with endometrial carcinoma
	has shown that sodium cridanimod significantly increases levels of PR expression in tumor tissue of patients who are PR deficient.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Virexxa&reg;
	may also represent therapeutic opportunities in other hormone-resistant tumor types, such as triple-negative breast cancer.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	OncoHist&trade;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OncoHist&trade;
	is based on research covered under our patent portfolio related to novel functions of histones. Histone H1 has strong anti-proliferative
	properties against cancer cells of different histological origin. This has been demonstrated extensively for hematologic malignancies,
	such as leukemias, lymphomas, and myelomas, and for tumors from other tissues. Susceptibility of cells to the cytotoxic effect
	of histones is determined by the ability of histone H1 to selectively destabilize the tumor cell membrane, which results in cell
	death.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A
	novel form of the molecule was developed by the Company and a patent filed for the protection of the new chemical entity, N-bis-met-histone
	1.3 (OncoHist&trade;) in use against cancer, providing patent protection at least until 2027. The activity of the new molecule
	was tested on 58 tumor cell lines derived from various tissues. Hematopoietic tumor cell lines were found to be among the most
	sensitive cell lines. The mechanism of action appears to be novel, involving the binding of OncoHist&trade; to the cell membrane,
	which is completely different from that of other therapeutic agents on the market for hematopoietic cancers. Confirmatory work
	on this mode of action with more detailed analyses is being completed by Dana-Farber Cancer Institute (&ldquo;Dana-Farber&rdquo;).
	Hematopoietic tumor lines resistant to current chemotherapeutic agents have shown sensitivity to OncoHist&trade;.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OncoHist&rsquo;s&trade;
	potency and potential to inhibit growth of cells from various histological origins were indicated through in-vitro testing against
	the U.S. National Cancer Institute 60 (&ldquo;NCI-60&rdquo;). OncoHist&trade; was awarded orphan drug designation (Orphan Medicinal
	Product Designation (&ldquo;OMPD&rdquo;)) for treatment of AML by the European Commission in December 2007 and by the FDA in October
	2008. OncoHist&trade; was awarded an additional OMPD status for Acute Lymphocytic Leukemia (&ldquo;ALL&rdquo;) by the EMA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A
	Phase I-II trial to evaluate the safety and tolerability of OncoHist&trade; was conducted in 2008 at Saarland University in Germany
	with 22 AML patients. Clinical effects were noted in seven patients with three partial remissions. Most notably, two patients
	who had received two treatment cycles each experienced stabilization of their disease for seven and 17 months, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A
	clinical safety trial with a planned 120 AML patients was in progress and being performed by SynBio in clinical centers in the
	Russian Federation. The aim of this trial was to examine the potential benefits of OncoHist&trade; in combination with standard
	HAM chemotherapy: high dose cytarabine with mitoxantrone. During execution of the SynBio AML trial, the Russian Ministry of Health
	issued changes in their standard of care for treating AML patients. High dose cytarabine chemotherapy was determined to offer
	no benefits in terms of efficacy as compared to lower dose therapy and was discontinued.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have completed preclinical toxicity studies using clinical material supplied to us by SynBio. We have had a pre-IND meeting with
	the FDA and came to agreement with the FDA on characterization, clinical criteria and the inclusion of an additional disease indication
	in the Phase I study. In addition, we are planning to establish a second source supplier of OncoHist&trade; material suitable
	for humans in Phase I/II(a) clinical trials under cGMP. We intend to commence clinical trials in the U.S. during the second half
	of 2017. Sponsored research at Dana Farber Cancer Institute is helping to elucidate the mechanism of action of OncoHist&trade;
	as well as characterize the response of AML tumor lines to OncoHist&trade;. Interim data has been presented at the American Society
	of Hematology meeting and publications are expected during second half 2016. Certain OncoHist&trade; clinical data, generated
	by SynBio, that is available to us for analysis has advanced our understanding of this drug candidate in a capital efficient manner.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Other
	Technologies
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	ImuXen
</I>
</B>
	&trade;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ImuXen&trade;
	is a patented platform technology based on the concept of simultaneous delivery of multiple Active Pharmaceutical Ingredients
	(&ldquo;APIs&rdquo;) as antigens within the same liposome. The liposomes are composed of lipids that encapsulate an aqueous core.
	The APIs can be trapped in the core, be associated with the lipids, or both. Proteins, peptides, nucleic acids, polysaccharides
	and live or inactivated infectious agents can all be used as an API with the same liposome. Both the size and the lipid composition
	can be controlled which affects the biological properties of the liposome. Manufacturing involves the passive entrapment of the
	vaccine APIs by freeze drying commercially available liposomes with the antigens of interest.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Having
	multiple APIs formulated with the same liposome allows simultaneous delivery of the antigens to the same antigen-presenting cell.
	This may allow a more efficient immune response to all the agents presented. In addition, it is possible that multiple vaccines
	can be delivered with a single injection. Relevant pre-clinical studies have indicated a reduction in the dose required, a reduction
	in the number of doses required and a faster immune response time. This efficient immune response also may allow for use of antigens
	that traditionally give a poor antibody response.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	technology is not currently the focus of clinical development for the Company. However, through a license agreement with Pharmsynthez,
	there is a novel multiple sclerosis vaccine that is in clinical development in Russia.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	A
	Phase I clinical trial to treat relapsing
	remitting multiple sclerosis and secondary progressive multiple sclerosis was completed by SynBio in the Russian Federation.
	Peptides corresponding to antigenic sections of basic myelin protein were encapsulated within liposomes to be used as the therapeutic
	agent (MyeloXen&trade;). As
	an integral part of the Company&rsquo;s strategy, we await later stage clinical data on MyeloXen&trade; to determine whether to
	pursue this candidate in U. S. clinical trials for potential out-licensing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Significant
	Co-Development Collaborations and Strategic Arrangements:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Baxalta
	Incorporated
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	August 2005, the Company entered into an exclusive research, development, license and supply agreement with Baxter Healthcare
	SA (&ldquo;Baxter SA&rdquo;) and Baxter Healthcare Corporation (together referred to as &ldquo;Baxter&rdquo;) to develop products
	with an extended half-life of certain proteins and molecules using the Company&rsquo;s patent protected PolyXen&trade; technology
	whereby polysialic acid (&ldquo;PSA&rdquo; &ndash; a chain of polysialic acids) is conjugated with Baxter&rsquo;s proprietary
	molecule(s) designed to create a longer-acting haemophilia drug, a polysialylated recombinant Factor VIII (&ldquo;rFVIII&rdquo;)
	protein than what is currently available on the market. Baxter also has rights that extend to treatments of the failure of blood
	to coagulate. Baxter commenced human clinical trials on this novel drug candidate during the first quarter of 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During
	June 2015, in connection with the separation of its biopharmaceuticals business to form Baxalta Incorporated, Baxter assigned
	all of its rights and obligations under its existing agreement with the Company to Baxalta.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	agreement has been amended several times since 2005, most recently in January 2014. The January 2014 amendment provides for increased
	future development, regulatory, sales and deadline extension receipts, restructured target deadlines and royalty receipts on potential
	net sales. The Company is entitled to up to $100 million in potential development, regulatory, sales and deadline extension receipts,
	which are contingent on the performance of Baxter achieving certain milestones. The Company is also entitled to royalties on potential
	net sales.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	connection with this amendment, Baxter SA also made a $10 million equity investment at a price of $0.935 per share, which is a
	post money market cap of approximately $140 million in the Company in exchange for 10,695,187 shares of the Company&rsquo;s common
	stock during January 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Through
	December 31, 2015, the Company and Baxter continued to engage in research and development activities. No amounts were recognized
	as revenue during the years ended December 31, 2015 and 2014. Since August 2005, the Company has received approximately $19 million
	from Baxter that includes milestone receipts, fees for services and a $10 million purchase of common stock of the Company in January
	2014. The Company received a non-refundable $2 million payment from Baxter in 2010 and granted Baxter warrants to purchase approximately
	4.6 million new shares of common stock of the Company in connection with the 2010 amendment to the Baxter Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Baxter
	has agreed to meet a number of clinical milestones with strict timelines under the 2014 amendment relating to: Clinical Trial
	Authorization (&ldquo;CTA&rdquo;)
<B>
</B>
	submission, Final Clinical Study Report
<B>
</B>
	and Biologics License Application (&ldquo;BLA&rdquo;)
	submission. Baxter submitted a CTA application to the UK Medicines and Healthcare Products Regulatory Agency in late 2015 and
	commenced human clinical trials during the first quarter of 2016 in connection with this collaboration. There are very limited
	provisions to further modify the Baxter Agreement. There can be no assurance if or when Baxter will actually achieve any of the
	remaining due diligence milestones.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Baxter
	is a related party of the Company, with a share ownership of approximately 8.0% of the total issued common stock as of December
	31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.1PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	SynBio
	LLC
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	August 2011 the Company entered into a stock subscription and collaborative development agreement with SynBio (the &ldquo;Co-Development
	Agreement&rdquo;) pursuant to which the Company granted SynBio an exclusive license to develop, market and commercialize certain
	drug candidates utilizing molecules based on the Company&rsquo;s PolyXen&trade; and OncoHist&trade; technologies in the Russian
	market and the Commonwealth of Independent States (the &ldquo;CIS&rdquo;) (including Armenia, Azerbaijan, Belarus, Kazakhstan,
	Kyrgyzstan, Republic of Moldova, Tajikistan, Turkmenistan and Uzbekistan), collectively the &ldquo;SynBio Market&rdquo;. In exchange
	for the Company granting to SynBio those certain license rights, SynBio granted an exclusive license to the Company to use any
	SynBio pre-clinical and clinical data generated by SynBio, at its own expense, in connection with those development efforts and
	to engage in the development and commercialization of drug candidates that may arise from the collaboration in any territory outside
	of Russia and the CIS based upon the Co-Development Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company hopes and expects to mitigate certain risks of drug development by reviewing human clinical data arising out of this collaboration
	with SynBio before the Company considers taking the particular drug candidate into FDA and EMA trials. Under the Co-Development
	Agreement, SynBio is responsible for progressing six new product candidates through human proof of concept trials in Russia as
	primary validation for the initiation of EMA/FDA clinical trials by the Company. The primary goal of the Co-Development Agreement
	is to research and develop drug candidates for planned commercialization using SynBio and the Company&rsquo;s combined respective
	expertise and technologies. Drug candidates must meet the success criteria as decided upon by a joint steering committee, which
	includes representation from both SynBio and the Company, where the Company has the right to appoint the Chair who has the casting
	vote. Once a potential drug candidate is selected, clinical trials will be separately conducted by each company in their respective
	territories with the goal to achieve regulatory approval of the products for commercial sale.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	SynBio
	is wholly responsible for funding and conducting their own research and clinical development activities in Russia as the Company
	is wholly responsible for funding and conducting their own research and clinical development activities in the US, Europe and
	elsewhere ex-Russia and the ex-CIS regions. There are no milestones or other research related payments provided for under the
	Co-Development Agreement other than fees for the provision of each party&rsquo;s respective research supplies based on their technology
	and royalties payable to the Company based on SynBio sales. For the years ended December 31, 2015 and 2014, the Company recognized
	no supply service revenues in connection with the Co-Development Agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Concurrent
	with entering into the Co-Development Agreement, the Company entered into a stock subscription agreement with SynBio pursuant
	to which the Company sold SynBio approximately 35.5 million shares of newly issued common stock for cash of approximately $18.6
	million.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	furtherance of our co-development clinical objectives, on December 31, 2014 the Company granted to SynBio certain warrants that
	contain vesting triggers based on the achievement by SynBio of certain clinical development objectives within specific timeframes.
	This grant consisted of a warrant to purchase 6,745,000 new shares of common stock at an exercise price of $0.77 per share (&ldquo;SynBio
	2014 Warrant&rdquo;). Simultaneously with the SynBio 2014 Warrant grant, the Company granted additional warrants to purchase 320,000
	aggregate new shares of common stock to SynBio and Pharmsynthez non-director designees under the same terms and conditions of
	the SynBio 2014 Warrant. Pharmsynthez is a related party of SynBio and a collaboration partner of the Company. As part of this
	transaction, the warrant granted to SynBio in 2011 was canceled and of no further force and effect. The SynBio 2014 Warrant expires
	on December 30, 2019 and no warrants were exercised during the years ended December 31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the Relationship Deed signed concurrent with the 2011 Co-Development Agreement and subscription, the Company granted SynBio
	(as Controlling Shareholder) the right to appoint two directors to the extent their shareholding is greater than 40% in the Company.
	The Relationship Deed of 2011 was replaced in January 2014 with a Director Appointment Agreement containing that same provision.
	Further undertakings therein state that, as long as the Controlling Shareholder holds more than 25% of the Company&rsquo;s common
	stock, all transactions and relationships between it and the Company will, (a) be at arm&rsquo;s length and on a normal commercial
	basis; (b) it will not seek to exercise any day-to-day operational or managerial control over the business of the Company, nor,
	(c) influence any director or non-executive director in any way in regard to the conduct of the Company&rsquo;s business. The
	agreement contains further provisions relating,
<I>
	inter alia
</I>
	, to: nominee board appointments, conflicts of interest, acting
	in good faith and terms of confidentiality.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	SynBio
	is a related party of the Company, with a share ownership of approximately 39.0% of the total issued common stock as of December
	31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Serum
	Institute of India Limited
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	the period from 2004 through 2011, the Company entered into and amended certain license and supply agreements with Serum Institute.
	The original license agreement with Serum Institute was a collaborative Development and Manufacturing Arrangement (&ldquo;DMA&rdquo;)
	to develop agreed upon potential commercial product candidates using the Company&rsquo;s PolyXen&trade; technology. Serum Institute
	then endeavored to further develop the potential commercial product candidates and eventually initiate pre-clinical and clinical
	trials at their own cost. The agreement was amended in 2011, resulting in the surrender of development rights for 14 potential
	commercial product candidates in 2012, which were vested to Serum Institute under the terms of the previous agreements, back to
	the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Following
	the 2011 amendment, Serum Institute retained an exclusive license to use the Company&rsquo;s PolyXen&trade; technology to research
	and develop one potential commercial product, Polysialylated Erythropoietin (&ldquo;PSA-EPO&rdquo;). Serum Institute will be responsible
	for conducting all pre-clinical and clinical trials required to achieve regulatory approvals within territories outside of certain
	predetermined territories assigned to the Company, which include the US, the European Economic Area, and Japan, among other territories,
	at Serum Institute&rsquo;s own expense. The royalty payment schedule based on net revenues on the future commercial sales of PSA-EPO
	under the DMA was also modified as a result of the 2011 amendment. Royalty payments are payable by Serum Institute to the Company
	for net sales to certain customers in the Serum Institute sales territory. Royalty payments are payable by the Company to Serum
	Institute for net sales received by the Company over the term of the license. No royalty revenue or expense was recognized by
	the Company related to the Serum Institute arrangement during the years ended December 31, 2015 and 2014. There are no milestone
	or other research-related payments due under the DMA. Through December 31, 2015, the Company and Serum Institute continued to
	engage in research and development activities with no resultant commercial products.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	furtherance of our co-development clinical objectives, on December 31, 2014 the Company granted to Serum Institute certain warrants
	that contain vesting triggers based on the achievement by Serum Institute of certain clinical development objectives within specific
	timeframes. This grant consisted of a warrant to purchase 3,200,000 new shares of common stock at an exercise price of $0.77 per
	share (&ldquo;Serum 2014 Warrant&rdquo;). Simultaneously with the Serum 2014 Warrant grant, the Company granted additional warrants
	to purchase 160,000 aggregate new shares of common stock to Serum Institute non-director designees under the same terms and conditions
	of the Serum 2014 Warrant. The Serum 2014 Warrant expires on December 30, 2019 and no warrants were exercised during the years
	ended December 31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition, the DMA allows for Serum Institute to nominate a non-executive director to the Board of Directors of the Company as
	long as Serum Institute or its subsidiaries holds at least 6% of the Company&rsquo;s common stock. Serum Institute is a related
	party of the Company, with a share ownership of approximately 8.5% of the total issued common stock as of December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	OJSC
	Pharmsynthez
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	November 2011, the Company entered into a collaborative research and development license agreement with OJSC Pharmsynthez (the
	&ldquo;Pharmsynthez Arrangement&rdquo;) pursuant to which the Company granted an exclusive license to Pharmsynthez to develop,
	commercialize and market six product candidates based on the Company&rsquo;s PolyXen&trade; and ImuXen&trade; technology anywhere
	within Russia and the CIS. In exchange, Pharmsynthez granted an exclusive license to the Company to use any pre-clinical and clinical
	data developed by Pharmsynthez, within the scope of the Pharmsynthez Arrangement, and to engage in further research, development
	and commercialization of drug candidates in any territory outside of Russia and the CIS at the Company&rsquo;s own expense.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	accordance with the terms of the Pharmsynthez Arrangement, the Company licensed certain PolyXen&trade; and ImuXen&trade; technology
	rights for use in Russia and the CIS as well as certain clinical and research data developed by the Company on the six product
	candidates to Pharmsynthez.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company hopes and expects to mitigate certain risks of drug development by reviewing human clinical data arising out of this collaboration
	with Pharmsynthez before the Company takes the particular drug candidate into FDA and EMA trials, a strategy designed to mitigate
	drug development risks. Under the agreement, Pharmsynthez is responsible for progressing six new drug candidates through human
	proof of concept trials in Russia as primary validation prior to the initiation of EMA/FDA clinical trials by the Company outside
	of Russia. The license agreement will operate alongside the current arrangements which the Company has entered into with SynBio,
	discussed above.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A
	joint steering committee where the Company has the right to appoint the Chair who has the casting vote was established to facilitate
	the communication of scientific data and to assist generally with each party&rsquo;s research decisions and to monitor research
	and development progress under the Pharmsynthez Arrangement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pharmsynthez
	is wholly responsible for funding and conducting their own research and clinical development activities in Russia. The Company
	is wholly responsible for funding and conducting its own research and clinical development activities in the US, Europe and the
	rest of the world outside of Russia and the ex-CIS regions. There are no milestones or other research related payments provided
	for under the Co-Development Agreement other than royalties.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	July 1, 2015, the Company entered into a SPA with Pharmsynthez providing for the issuance of a minimum of a $3 million SPA Note.
	The SPA also provides for the issuance of certain warrants up to the amount of the SPA Note. In July 2015, the Company issued
	the SPA Note for $3 million plus a Warrant in accordance with the terms of the SPA. The SPA Note carries a term of one year and
	is convertible, in whole or in part, at the option of Pharmsynthez into shares of common stock at a conversion price of $0.15.
	In the event that the SPA Note remains outstanding at May 11, 2016, Pharmsynthez shall be granted an additional warrant to purchase
	an additional number of shares of the Company&rsquo;s common stock equal to 50% of the number of shares issuable under the SPA
	Note. The Warrant has a five-year term and is exercisable commencing January 1, 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	November 13, 2015, the Company entered into an APA with Kevelt and Pharmsynthez. Pursuant to the APA, the Sellers
	will transfer to the Company certain intellectual property rights held by the Sellers with respect to Virexxa&reg;, and the
	Company will receive the worldwide rights to develop, market and license Virexxa&reg; for certain uses, except for excluded uses within the CIS, in exchange for 111.5 million shares of Company common stock and certain
	other consideration.&nbsp; Virexxa&reg; is a Phase II oncology drug candidate which is under investigation for the treatment
	of certain endometrial cancers.&nbsp; As part of this total consideration, the Company will also acquire Kevelt's U.S.
	Orphan Drug designation for the use of Virexxa&reg; in the&nbsp;treatment of progesterone receptor negative endometrial
	cancer in conjunction with progesterone therapy.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	APA also contains a financing component wherein the Company received from Pharmsynthez up to $3.5 million in bridge financing
	commitments and a commitment of an additional $6.5 million in financing as part of a planned capital raise
	and up-list to a national securities exchange.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	of March 30, 2016, the Company has received $3.5 million of the $3.5 million bridge financing. However, transfer of all of
	the Virexxa
<SUP>
	&reg;
</SUP>
	intellectual property and development rights and issuance of 100.5 million shares of the total
	111.5 million shares of the Company&rsquo;s common stock was not completed as of March 30, 2016. The Company expects these
	transfers, along with the balance of the transactions contemplated in the APA, to be consummated during the second quarter
	of 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: #FEFEFE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	SPA was amended in November 2015 concurrent with the execution of the APA in order to provide for the New Notes and the New Warrant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pharmsynthez
	is a related party of SynBio, which is related party of the Company. In addition, one of the Company&rsquo;s directors is also
	a director of SynBio and Pharmsynthez.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Tabular
	Summary of Drug Candidate Programs
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Xenetic
	Corporate Programs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 19%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Product
	Candidate
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Indication
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Clinical
	Developer
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Headquarters
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Program
	Name/Developmental Stage
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Virexxa
<SUP>
	&reg;
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Endometrial Cancer
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Xenetic
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	U.S.
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	VIR-EC-01
</B>
	:
	US FDA IND-enabled Phase II trial in progress
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ErepoXen&trade;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Anemia
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Xenetic
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	U.S.
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PSA-EPO-06
</B>
	:
	ICH Compliant Phase II in-process being conducted in Australia, South Africa and New Zealand. Cohort III in
	progress
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OncoHist&trade;
	AML
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Acute
	Myeloid Leukemia
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Xenetic
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	U.S.
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Onc-AML-01
</B>
	:
	Pre-clinical studies and pre-IND meeting with the FDA is complete. Negotiations with contract manufacture and clinical research
	organizations are in progress
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Xenetic
	Collaborative Partner Programs
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	(alphabetical
	by clinical developer)
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 19%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Product
	Candidate
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Indication
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Clinical
	Developer
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 14%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Headquarters
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 38%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Program
	Name/Developmental Stage
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Factor VIII
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Hemophilia
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Baxter
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	US
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PSA-FVIII
</B>
	:
	CTA for a Phase I/II clinical trial was approved.&nbsp;&nbsp;Clinical trial commenced in Q1 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PulmoXen&trade;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Cystic Fibrosis
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pharmsynthez
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Russia
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PMO-CF-01
</B>
	:
	Phase I completed. A Phase II clinical trial is expected to start Q4 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	MyeloXen&trade;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Multiple Sclerosis
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pharmsynthez
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Russia
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	IMU-MS-01
</B>
	:
	Phase I dose ranging study is complete
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ErepoXen&trade;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Anemia
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Serum Institute
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	India
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PSA-EPO-03
</B>
	:
	Phase II(a) intravenous and subcutaneous human clinical trials conducted in India are complete. The study report
	is expected in Q2 2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ErepoXen&trade;
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Anemia
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SynBio
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Russia
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	PSA-EPO-05
</B>
	:
	Russian Phase II(b)/III in progress
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OncoHist&trade; AML
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Acute Myeloid Leukemia
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SynBio
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Russia
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Onc-AML-02
</B>
	:
	Russian Phase II is on hold pending protocol revision due to a change in Russian Standard of Care requirements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OncoHist&trade; NHL
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Non-Hodgkins Lymphoma
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	SynBio
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Russia
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-RIGHT: 3PT; PADDING-LEFT: 3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Onc-NHL-01
</B>
	:
	Russian Phase II dose ranging studies are completed in Russia
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Most
	advanced product candidate in the Company pipeline: Virexxa&reg;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Virexxa&reg;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Virexxa&reg;
	(sodium cridanimod) belongs to a class of low-molecular weight immunomodulators, which have been relevant in a wide range of therapeutic
	areas (antiviral, antibacterial, antitumor, and anti-inflammatory). Sodium cridanimod is approved for marketing in the Russian
	Federation, and numerous CIS countries for the treatment of certain infectious diseases. Sodium cridanimod has been authorized
	and marketed in the Russian Federation and CIS states for more than 17 years and approximately 11,000,000 doses have been sold
	for non-cancer indications under certain brand names Neovir&reg; and Primavir&reg;. In
	addition there are 22 completed clinical trials conducted by others outside the U. S. that assessed the efficiency and safety
	of sodium cridanimod in certain non-cancer indications.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	decision to investigate Virexxa&reg; for the treatment of endometrial cancer was based in part on the history of sodium cridanimod
	in preclinical and clinical research conducted by others, as summarized below.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In
	addition to its immunomodulatory properties, Virexxa&reg; has been shown to increase the levels of progesterone receptor
	(&ldquo;PR&rdquo;) expression in the endometrial tumor tissue of patients who are PR deficient, and thus may have the
	potential to restore the sensitivity of non-responsive endometrial cancers to hormonal (e.g. progestin) therapy. At present,
	the clinical development program for Virexxa&reg; includes an ongoing FDA IND-enabled Phase II study for Virexxa&reg;
	in conjunction with progestin therapy in a population of patients with recurrent or persistent progesterone receptor
	negative (&ldquo;PrR-&rdquo;) endometrial cancer. Virexxa&reg; has been granted an Orphan Drug Designation by the FDA for use in conjunction with medroxyprogesterone in PrR- endometrial
	cancer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Preclinical
	studies have shown that sodium cridanimod can increase interferon-alpha production by human immune cells
	and increase PR levels in endometrium. Furthermore, a Phase II clinical study conducted in patients with endometrial carcinoma
	has shown that sodium cridanimod significantly increases levels of PR expression in tumor tissue of patients who are PR deficient.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Virexxa&reg;
	may also represent therapeutic opportunities in other hormone-resistant tumor types, such as triple-negative breast cancer.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Second
	most advanced product candidate in the Company pipeline: ErepoXen&trade;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s drug candidate that is currently the second most advanced in its clinical pipeline is ErepoXen&trade; (polysialylated
	erythropoietin (&ldquo;PSA-EPO&rdquo;)) which uses the Company&rsquo;s PolyXen&trade; technology for the treatment of anemia in
	Chronic Kidney Disease (&ldquo;CKD&rdquo;) patients. ErepoXen&trade; is in a Company-sponsored Phase II escalating repeat subcutaneous
	dose-ranging study in Australia and New Zealand for pre-dialysis CKD patients. This trial is designed to be compliant with the
	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (&ldquo;ICH&rdquo;).
	ErepoXen&trade; has also been a co-development project with our long-established strategic partner, Serum Institute, and has finished
	a Phase II(a) clinical trial in India for intravenous administration to patients on dialysis. In addition, ErepoXen&trade; is
	also in a 150 patient Phase II(b)/III clinical trial in Russia to directly compare ErepoXen&trade; to Aranesp. The Company expects
	SynBio to enter the commercialization and marketing stage of ErepoXen&trade; in the Russian and CIS markets, as the first market
	launch for a PSA candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s commercialization strategy for ErepoXen&trade;, being a potentially mainstream drug addressing a substantial global
	market, includes seeking an out-license arrangement for the continuing development of ErepoXen&trade; as either a Phase II(b)
	or Phase III candidate with a well-capitalized license partner more experienced at taking drug candidates through the latter stages
	of human clinical trials and better able to execute a global market launch. If successful, this strategy could:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD STYLE="WIDTH: 86%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	be the beginning of the monetization
	of the Company&rsquo;s IP investment to date in ErepoXen&trade; by way of an upfront license payment plus milestone payments
	as the product is advanced through the clinic; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	potentially
	reduce the timeline for incoming royalty revenues if ErepoXen&trade; is taken to market by an already leading provider with an
	established market presence.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	ErepoXen&trade; strategy, when implemented, should have the effect of decreasing demands on the Company&rsquo;s own financial
	and working capital resources, allowing those resources to be applied towards the in-house development and marketing of new orphan
	and rare disease candidates where the Company is better able to maintain financial and clinical control throughout the process
	from pre-clinical development, through IND filing, human clinical trials, and potentially market approval and product launch.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Next
	most advanced product candidate in the Company pipeline: OncoHist&trade;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company&rsquo;s next most advanced drug candidate is OncoHist&trade; AML. We have completed preclinical toxicity studies using
	clinical material supplied to us by SynBio. We have had a pre-IND meeting with the FDA and came to agreement with the FDA on characterization,
	clinical criteria and the inclusion of an additional disease indication in the Phase I study. In addition, we are planning to
	establish a second source supplier of OncoHist&trade; material suitable for humans in Phase I/II(a) clinical trials under cGMP.
	We hope to commence clinical trials in the U.S. during the second half of 2017. Sponsored research at Dana Farber Cancer Institute
	is helping to elucidate the mechanism of action of OncoHist&trade; as well as characterize the response of AML tumor lines to
	OncoHist&trade;. Interim data has been presented at the American Society of Hematology meeting and publications are expected during
	the second half of 2016. Certain OncoHist&trade; clinical data, generated by SynBio, that is available to us for analysis has
	advanced our understanding of this drug candidate in a capital efficient manner.
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Plans
	to commence clinical trials in the U.S. have been delayed due to insufficient working capital necessary to establish a source
	of cGMP material suitable for these trials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Other
	product candidates in the Company pipeline
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company believes certain additional orphan and non-orphan oncology drug candidates may be developed utilizing certain of our existing
	and future pre-clinical and clinical data. Specifically, we expect to be able to utilize the results from substantially all of
	our pre-clinical toxicity and certain other pre-clinical data generated in the development of OncoHist&trade; AML for several
	other blood cancer indications focused on orphan indications.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	also believe that the platform nature of our technologies should allow us to pursue additional drug candidates by leveraging certain
	existing and future scientific data to be developed under our PolyXen&trade;, OncoHist&trade; and Virexxa
<SUP>
	&reg;
</SUP>
	technology
	programs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Xenetic
	Corporate Programs
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	VIR-EC-01:
	Xenetic Virexxa&reg; Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	At
	present, the clinical development program for Virexxa&reg; (sodium cridanimod) includes an ongoing FDA IND-enabled Phase II study
	for Virexxa&reg; in conjunction with progestin therapy in a population of subjects with recurrent or persistent progesterone receptor
	negative (&ldquo;PrR-&ldquo;) recurrent or persistent endometrial cancer. This study is also active under the same IND in ex-U.S.
	sites in Belarus and Ukraine.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	study is an open-label, multicenter, single-arm Phase II study calling for a total of 58 subjects with documented evidence of
	PrR- endometrial cancer as determined by immunohistochemistry.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	primary objective of this study is to assess the antitumor activity of Virexxa&reg; in conjunction with progestin therapy as measured
	by objective response rate (partial/complete) in women with progesterone receptor negative recurrent or persistent endometrial
	carcinoma not amenable to surgical treatment, radiotherapy, or chemotherapy.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Secondary
	objectives of the study include (a) to assess progression free survival, time to response , time to progression, duration of overall
	survival and Overall Disease Control Rate for subjects receiving Virexxa&reg; and progestin therapy and (b) to evaluate the safety
	and tolerability of Virexxa&reg; in conjunction with progestin therapy, as measured by adverse events, laboratory safety parameters,
	and cardiac safety assessments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additional
	translational objectives include to determine the efficacy of Virexxa&reg; in combination with progestin on PrR levels in tumor
	tissue, to correlate changes of PrR- levels with efficacy parameters and to assess pharmacokinetic data for Virexxa&reg; and progestins
	after a single-dose and multiple-dose administration.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	PSA-EPO-06:
	Xenetic ErepoXen&trade; Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	is designed to be an ICH compliant Phase II open label clinical, sequential multiple dose finding study for subcutaneously administered
	PSA-EPO in CKD patients not on dialysis and not receiving erythropoiesis stimulating agents. It is being conducted in Australia,
	South Africa and New Zealand. Patients with hemoglobin levels between 8 and 10 grams per deciliter (&ldquo;g/dL&rdquo;) were given
	the drug candidate once every two weeks. If the hemoglobin level increases to between 10 and 12 g/dL, the patient is moved to
	once every four weeks administration. The patient&rsquo;s pharmacodynamic, pharmacokinetic and immunogenic parameters are followed
	for the duration of the trial. Dose levels in an escalating form will then be administered. Safety and other parameters will be
	examined at the end of each dosing cohort before moving onto the next dose level. The first two cohorts of patients have been
	completed. There were no Serious Adverse Events (&ldquo;SAEs&rdquo;) attributable to PSA-EPO reported thus far. The third cohort
	of patients at a higher dose level is in progress. The endpoint is to determine a dose of PSA-EPO that is safe and will move the
	patient&rsquo;s hemoglobin level into the 10 to 12 g/dL range.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	costs for this trial are being borne by the Company. Costs will be dependent on how many cohorts will be treated. The final results
	from the second cohort are expected to be reported during the first half of 2016. Clinical material was manufactured for the Company
	by Serum Institute. The trial is being run by Novotech Pty Limited (&ldquo;Novotech&rdquo;) of Australia.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	ONC-AML-01:
	Xenetic OncoHist&trade; Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company expects to submit an IND filing for Phase I/II(a) clinical trials for AML to the FDA and commence clinical trials, but
	not before the end of 2017. We expect this to be an open label increasing dose ranging study to assess the safety, tolerability
	and efficacy of OncoHist&trade; for adult patients with refractory or relapsed AML. This trial will be conducted in the US. Data
	from the previously completed work by Saarland University&rsquo;s Phase I clinical trial and the SynBio clinical trials will be
	used to aid in the design of the clinical protocol. We expect the Phase I/II(a) clinical trial material to be produced by a cGMP
	compliant manufacturing facility. Selection of the Clinical Research Organization (&ldquo;CRO&rdquo;) to run the trial is in progress.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	costs for the clinical trial are being borne by the Company. The Company will need to raise additional capital prior to commencing
	Phase I/II(a) clinical trials. The OncoHist&trade; technology was acquired as part of the Company&rsquo;s acquisition of SymbioTec
	GmbH (&ldquo;SymbioTec&rdquo;) in January 2012 and was valued at $9.6 million as of the acquisition date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Xenetic
	Collaborative Partner Programs
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under
	the terms of the relevant license agreements with the various parties, the Company provides neither capital nor human resources
	to the clinical developments of the various product candidates thus licensed for development by our collaborative partners whose
	sole responsibility is to meet the timelines associated with each program. &nbsp;&nbsp;We use the data generated from these jurisdictions
	as a means of understanding the clinical validity-human response of the drug before pursuing FDA and EMA trials, this having been
	a long-established development strategy for the Company as a means of maximizing the development potential of the Company&rsquo;s
	product pipeline while minimizing the capital exposure associated with such objective.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	that there has been a history of delays in the clinical programs being pursued by our partners in both Russia and India, based
	on the data that has been available to us, we have accomplished this objective with both OncoHist&trade; and ErepoXen&trade;,
	the two product candidates which are currently the primary focus of our efforts and upon which we are now devoting our capital
	and human resources.&nbsp; Accordingly, any program delays on these candidates outside the purview of the FDA or EMA&nbsp;will
	not have a negative impact on the Company pipeline.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	PSA-FVIII:
	Baxter Factor VIII Pre-Clinical Program
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PSA-recombinant
	Factor VIII has been developed as a long acting therapeutic to treat hemophilia A. Baxter is running this program, which is in
	the Clinical Trial phase. Baxter has agreed to meet strict due diligence time milestones based on: Clinical Trial Authorization
	submission in respect of Phase I/II clinical trials, Final Clinical Study Report
<B>
</B>
	Phase I/II and BLA submission all by fixed
	dates per the contract. The total cost of this program is being borne by Baxter. There can be no assurance if or when Baxter will
	actually achieve any of these due diligence milestones. Baxter filed a CTA for the program in Q4 2015 and commenced human clinical
	trials during the first quarter of 2016. The stated goal of Baxter is to have a significantly longer-acting FVIII to remain the
	world&rsquo;s leader in Hemophilia therapies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	PMO-CF-01:
	Pharmsynthez PulmoXen&trade; Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	is a Phase I(a) open label two dose safety study for inhaled PSA-DNase 1 in healthy volunteers and has been completed and reported
	on April 7, 2014. The study is being conducted in Russia. No adverse events were reported so far and lung function was reported
	to be normal. A clinical trial with CF patients is in start-up stage (regulatory applications). The total cost of the trial is
	being borne by Pharmsynthez. The trial is being run by a partner-sponsored CRO in Russia, Belarus and Ukraine.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	and when satisfactory human clinical data comes out of this collaboration, and provided that the Company is sufficiently confident
	that the drug candidate is well-tolerated and effective for this indication, the Company plans to pursue its own development program
	for this candidate. However, the Company would have to raise additional capital to pursue its own development of this drug candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	IMU-MS-01:
	Pharmsynthez MyeloXen&trade; Clinical Trial (Multiple Sclerosis)
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	was a Phase I open label clinical sequential dose finding study for subcutaneously administered MyeloXen&trade; (liposomes containing
	peptides for basic myelin protein) in healthy volunteers and patients. This was a proof-of-concept study to show the influence
	of MyeloXen&trade; on catalytic anti-MBP levels and activities. The study was conducted in Russia and is complete. The study report
	is under final review to be submitted to the Russian MoH. The total cost for the clinical trial was borne by Pharmsynthez. The
	clinical material was manufactured by Pharmsynthez. The clinical trial was run by a partner-sponsored CRO in Russia.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	and when satisfactory clinical patient data comes out of this collaboration that provides the Company a level of comfort that
	the drug candidate is well-tolerated and effective, the Company plans to pursue its own development program for this candidate.
	However, the Company would have to raise additional capital to pursue its own development of this drug candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	PSA-EPO-03:
	Serum Institute ErepoXen&trade; Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	is a Phase II(a) open label clinical, sequential single dose finding study for intravenously administered PSA-EPO for CKD patients
	who are on dialysis. This trial follows the successful completion of two subcutaneous PSA-EPO clinical trials in India. The first
	was a Phase I single dose range finding study for subcutaneously administered PSA-EPO in healthy volunteers. The second was a
	Phase II single dose range finding study for subcutaneously administered PSA-EPO in CKD patients not on dialysis. All trials are
	being conducted in India. All three cohorts of patients have been completed. There were no Serious Adverse Events (&ldquo;SAEs&rdquo;)
	attributable to PSA-EPO reported thus far. The final report on the trail is expected in Q1 2016. The endpoint of the trial is
	to determine the maximum tolerated single dose of PSA-EPO. The total cost of the clinical trial is being borne by Serum Institute
	and the clinical material was manufactured by Serum Institute. The clinical trial is being run by a partner-sponsored CRO in India.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	PSA-EPO-05:
	SynBio ErepoXen&trade; (Epolong) Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	is a Phase II(b)/III open label clinical, randomized, comparative, multiple dose study for subcutaneously administered ErepoXen&trade;
	in CKD patients not on dialysis and not receiving erythropoiesis stimulating agents. Patients are compared to a control arm with
	Aranesp&reg; (darbepoetin alfa). The study is being conducted in the Russian Federation by SynBio and is currently in progress.
</FONT>
	The total cost for this clinical trial is being borne by SynBio. The clinical material was manufactured by Serum Institute.
	The clinical trial is being run by a partner-sponsored CRO in Russia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	ONC-AML-02:
	SynBio Arahist-09 Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	was a Phase II open label two dose level, randomized comparative study to assess the safety, tolerability and efficacy of OncoHist&trade;
	in combination with HAM (high dose cytarabine chemotherapy) in adult patients with refractory or early relapsed AML. This study
	was conducted in Russia. Patients received one cycle of HAM regimen (one week) and one cycle of OncoHist&trade; regimen (three
	times per week for three weeks). The HAM regimen was based on the then current standard of care in Russia. This standard of care
	was changed by the Russian Ministry of Health and the study is on hold. The total cost of the trial was borne by SynBio. The clinical
	material for this OncoHist&trade; trial was manufactured at the Shemyakin Institute in Moscow for SynBio. The trial was run by
	a partner-sponsored CRO in Russia.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	ONC-NHL-01:
	SynBio Anahoret Clinical Trial
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	was a Phase II open label increasing dose ranging study to assess the safety, tolerability and efficacy of OncoHist&trade; as
	a single agent in treating NHL. This study was conducted in Russia. The trial is complete and the report submitted to the Russian
	MoH. It was shown that OncoHist&trade; was well tolerated in this trial. The total cost of the trial was borne by SynBio. The
	clinical OncoHist&trade; drug product was manufactured at the Shemyakin Institute in Moscow for SynBio. The trial was run by a
	partner-sponsored CRO in Russia.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	and when satisfactory clinical patient data comes out of this collaboration that provides the Company a level of comfort that
	the drug candidate is well-tolerated and effective, the Company plans pursue its own development program for this candidate. However,
	the Company would have to raise additional capital to pursue its own development of this drug candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Patents
	and Proprietary Rights
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has several drug product candidates under development, each protected by patent and pending patent applications in the
	United States and the rest of the world.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Xenetic
	has received patent protection for several therapeutics that have been linked to a polysialic acid.&nbsp; These include PSA-erythropoietin,
	PSA-insulin and PSA-insulin like protein, PSA-Factor VIII, PSA-DNAse I and PSA-granulocyte colony stimulating factor.&nbsp; Further
	Xenetic&rsquo;s portfolio includes patents cover methods to prepare proteins that are linked to a polysialic acid.&nbsp; These
	patents include coverage for linking a PSA to a protein in a high pH solution and through a process for producing an aldehyde
	derivative of a sialic acid through the opening and oxidation of a sialic acid unit.&nbsp; The linkage can be at the N-terminus.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Xenetic
	has received patent protection for the production of PSA and the removal of endotoxin during the purification process.&nbsp; The
	removal of endotoxin occurs through, for instance, the addition of a high pH solution to the PSA and through a process to separate
	a polydisperse ionically charged polysaccharide, such as PSA, into fractions of different average molecular weight through the
	use, for instance, of a column and elution buffers with different and constant ionic strength and/or pH, resulting in a fractionated
	polysaccharide that has a molecular weight polydispersity of 1.1 or lower.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Xenetic
	also has patents that cover its OncoHist&trade; product.&nbsp; These include recently allowed patents covering the OncoHist&trade;
	composition and claims for the use of OncoHist&trade; to treat cancer, including leukemia.&nbsp; The OncoHist&trade; portfolio
	also includes patents that cover the use of a histone protein as an antibiotic and to threat thrombocytopenia and further as an
	antimicrobial component of a personal care product.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s portfolio also includes in-licensed patents from Ploughshare Innovations, a licensing arm of the United Kingdom
	Department of Defense,&nbsp;in connection with MyeloXen&trade; technology. The Company has no current clinical development efforts
	ongoing at this time that fall within the bounds of the Ploughshare Innovations in-license. To the extent that such efforts are
	ongoing, such efforts are being undertaken by a collaborative partner, though the rights under the in-license (e.g. for the patents)
	lie with the Company and are subject to a sublicense provided to the collaborative partner. This includes a method used to entrap
	a water soluble drug within a liposome when the drug is mixed with a mono or disaccharide.&nbsp; This patent portfolio fits well
	with the Company&rsquo;s liposome patents and pending applications that include those that cover using liposomes with an entrapped
	complex of a DNA operatively encoding antigen to induce an immune response in a human or animal and methods to form liposomes.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company currently owns 201 US and international patents and over 90
	pending patent applications that cover various aspects of our technologies. We have filed patent applications, and plan
	to file additional patent applications, covering various aspects of our PolyXen&trade; technology platform covering polysialylation
	and advanced polymer conjugate technologies, as well as proprietary product candidates including ErepoXen&trade; and PulmoXen&trade;.
	Additionally, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of manufacturing
	polymers and polymer conjugates and methods of administering polymer conjugates. In addition, our patent portfolio contains patents
	and patent applications that encompass our OncoHist&trade; technology platform including use of histones for the treatment of
	different cancers. The OncoHist&trade; patent portfolio, acquired as part of our acquisition of SymbioTec GmbH in January 2012,
	includes OncoHist&trade;, a bis-Met histone. Our patent strategy is to file patent applications on innovations and improvements
	to cover a significant majority of the major pharmaceutical markets in the world. Generally, patents have a term of 20 years from
	the earliest priority date (assuming all maintenance fees are paid). In some instances, patent terms can be increased or decreased,
	depending on the laws and regulations of the country or jurisdiction that issued the patent.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully
	protect our trade secrets. Others may independently develop substantially equivalent confidential and proprietary information
	or otherwise gain access to, or disclose, our trade secrets. Thus, while we rely on trade secret protection and other unpatented
	proprietary rights for important proprietary technologies, any loss of such rights could harm our business, results of operations
	and financial condition.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	certain situations where we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies
	may be affected by limitations in our access to these proprietary drugs. Even if we believe we are free to work with a proprietary
	drug, we cannot guarantee that we will not be accused of, or be determined to be, infringing a third party&rsquo;s rights and
	be prohibited from working with the drug or found liable for damages. Any such restriction on access or liability for damages
	would have a material adverse effect on our business, results of operations and financial condition.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual
	issues. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for
	patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and
	costly. Additionally, issued patents can be subject to opposition or other proceedings that can result in the revocation of the
	patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant
	and/or broad coverage). Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a
	patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial
	delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of a products
	encompassed by our patent(s). We may have to participate in interference proceedings declared by the U.S. Patent and Trademark
	Office, which could result in a loss of the patent and/or substantial cost to us. Further, we understand that if any of our pending
	patent applications do not issue, or are deemed invalid following issuance, we may lose valuable IP protection.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	US
	and foreign patent rights and other proprietary rights exist that are owned by third parties and relate to pharmaceutical compositions
	and reagents, medical devices and equipment and methods for preparation, packaging and delivery of pharmaceutical compositions.
	We cannot predict with any certainty which, if any, of these rights will be considered relevant to our technology by authorities
	in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or
	may be asserted against us by third parties. We could incur substantial costs in defending ourselves and our partners against
	any such claims. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could
	effectively block our ability to develop or commercialize some or all of our products in the US and in other countries and could
	result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain
	one or more licenses from third parties. There can be no assurance that we can obtain a license to any technology that we determine
	we require on reasonable terms, if at all, or that we could develop or otherwise obtain alternative technology. The failure to
	obtain licenses, if required, may have a material adverse effect on our business, results of operations and financial condition.
	Further, we may not be able to obtain IP licenses related to the development of our drug candidates on a commercially reasonable
	basis, if at all.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	It
	is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors
	who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting
	relationships with us. These agreements provide that all confidential information developed or made known to the individual during
	the course of the individual&rsquo;s relationship with us is to be kept confidential and not disclosed to third parties except
	in specific circumstances. The agreements provide that all inventions conceived by an employee shall be our property. There can
	be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets
	in the event of unauthorized use or disclosure of such information.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Manufacturing
	and Supply
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company does not maintain the capability to manufacture its own material necessary to support its drug candidate development programs
	nor does it intend to acquire such capability as part of its present business strategy. The Company currently has agreements in
	place with Serum Institute whereby Serum Institute produces clinical materials for use in the development of drug candidates involving
	our PolyXen&trade; technology. The Company is currently dependent on SynBio for clinical materials with respect to its OncoHist&trade;
	AML research programs. The Company is investigating second source alternative suppliers for its clinical materials. There can
	be no assurance that it will be successful or that if a second source is secured that it would be available on commercially reasonable
	terms or in a timely fashion should any disruption in supply from Serum Institute or SynBio occur.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Government
	Regulation
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	General
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	development, testing, manufacture, labeling, marketing, and promotion of any drug, including all of our drug candidates, are subject
	to extensive regulation in the US by the FDA under the Federal Food, Drug and Cosmetic Act and by other federal, state, local
	and foreign government laws and regulations including in the UK, Germany, Russia and other countries in which we conduct business.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	The
	NDA Review Process
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	steps ordinarily required before a new drug, that is subject to NDA approval, may be marketed in the US include pre-clinical laboratory
	tests, further relevant testing, formulation studies, the submission to the FDA of an IND filing (which must become effective
	before clinical testing may commence) and adequate and well controlled clinical trials on human subjects to establish the safety
	and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements
	typically takes several years and the actual time required may vary substantially based upon the type, complexity and novelty
	of the product, disease or condition for which the new drug is indicated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Government
	regulation may delay or prevent marketing of potential products for a considerable period of time and requires substantial time,
	effort and financial resources on the part of a manufacturer. Success in early stage clinical trials does not assure success in
	later stage clinical trials. Data obtained from clinical activities is not always conclusive and may be susceptible to varying
	interpretations that could delay, limit, or prevent regulatory approval. Even if a product receives regulatory approval, later
	discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal
	of the product from the market.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pre-clinical
	tests include laboratory evaluation of product chemistry and formulation, as well as additional relevant trials to assess the
	potential safety and efficacy of the product. The conduct of the pre-clinical tests and formulation of compounds for testing must
	comply with federal regulations and requirements. The results of pre-clinical testing are submitted to the FDA as part of an IND.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A
	30 day waiting period after the filing of each IND is required prior to the commencement of clinical testing in humans. If the
	FDA has not commented on or questioned the IND within this 30 day period, clinical trials may begin. If the FDA has comments or
	questions, the questions must be answered to the satisfaction of the FDA before initial clinical testing can begin. In addition
	the FDA may, at any time, impose a clinical hold on ongoing clinical trials. If the FDA imposes a clinical hold, clinical trials
	cannot commence or recommence without FDA authorization and then only under terms authorized by the FDA. In some instances, the
	IND process can result in substantial delay and expense.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Clinical
	trials typically involve the administration of the IND to volunteers or patients under the supervision of a qualified investigator.
	Clinical trials must be conducted in compliance with federal regulations and requirements, under protocols detailing the objectives
	of the trial and the parameters to be used in monitoring safety and effectiveness. Each protocol involving testing on US subjects
	must be submitted to the FDA as part of the IND. The study protocol and informed consent information for patients in clinical
	trials must also be approved by the Institutional Review Board at each institution where the trials will be conducted.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Clinical
	trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap.
	In Phase I, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism,
	pharmacokinetics and pharmacological actions and safety, including side effects associated with increasing doses. Phase II usually
	involves trials in limited patient populations to determine dosage tolerance and optimum dosage, identify possible adverse effects
	and safety risks, and provide preliminary support for the efficacy of the drug in the indication being studied. If a compound
	demonstrates evidence of effectiveness and an acceptable safety profile in Phase II evaluations, Phase III trials are undertaken
	to further evaluate clinical efficacy and to further test for safety within an expanded patient population, typically at geographically
	dispersed clinical trial sites. It is possible that Phase I, Phase II, or Phase III testing of product candidates may not be completed
	successfully within any specified time period, if at all.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	After
	successful completion of the required clinical testing, generally an NDA is prepared and submitted to the FDA. FDA approval of
	the NDA is required before marketing of the product may begin in the US. The NDA must include the results of extensive clinical
	and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls. The
	cost of preparing and submitting an NDA is substantial. Under federal law, the submission of an NDA is additionally subject to
	a substantial application user fee (unless eligible for a waiver or reduction), which currently range from $1,084,550 to $2,169,100,
	and the manufacturer and/or sponsor under an approved NDA are also subject to annual product and establishment user fees, currently
	exceeding $104,000 per product and $554,000 per establishment. These fees are typically increased annually.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency's
	threshold determination that the NDA is sufficiently complete to permit substantive review. Once the submission is accepted for
	filing, the FDA begins an in-depth review of the NDA. Under federal law, the FDA has agreed to certain performance goals in the
	review of NDAs. The user fee goal for review of most non-priority applications is ten months. However, the review process is often
	significantly extended by FDA requests for additional information or clarification of information already provided in the submission.
	The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy
	to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation
	as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	FDA evaluations of the NDA and the manufacturing facilities and procedures, which typically involves an FDA on-site inspection,
	are favorable, the FDA may issue an approval letter or, in some cases, an approvable letter followed by an approval letter. An
	approvable letter generally contains a statement of specific conditions that must be met in order to secure final approval of
	the NDA. If and when those conditions have been met to the FDA's satisfaction, the FDA will typically issue an approval letter.
	An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications
	in an approved label. If the FDA's evaluation of the NDA submission or manufacturing facilities is not favorable, the FDA may
	refuse to approve the NDA or issue a not approvable letter. The not approvable letter outlines the deficiencies in the submission
	and often requires additional testing or information in order for the FDA to reconsider the application. Even with submission
	of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for
	approval. With limited exceptions, the FDA may withhold approval of an NDA regardless of prior advice it may have provided or
	commitments it may have made to the sponsor. As a condition of NDA approval, the FDA may require post-approval testing and surveillance
	to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions. Such labeling restrictions
	can materially impact the potential market and profitability of the drug. Once granted, product approvals can still be withdrawn
	if compliance with regulatory standards is not maintained or problems are identified following initial marketing.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Once
	the NDA is approved, a product will be subject to certain post-approval requirements, including requirements for adverse event
	reporting and submission of periodic reports. Persons responsible for manufacture or distribution are subject to FDA inspections
	to assess compliance with applicable statutory and regulatory requirements. The Food and Drug Administration Amendments Act of
	2007 also provides the FDA enhanced post-marketing authority, including the authority to require post-marketing studies and clinical
	trials, labeling changes based on new safety information, and compliance with risk evaluations and mitigation strategies approved
	by the FDA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additionally,
	the FDA also strictly regulates the promotional claims that may be made about drug products. The FDA requires substantiation of
	any claims of superiority of one product over another including, in many cases, requirements that such claims be proven by adequate
	and well controlled head-to-head clinical trials. To the extent that market acceptance of the Company&rsquo;s products may depend
	on their superiority over existing therapies, any restriction imposed by FDA on the Company&rsquo;s ability to advertise or otherwise
	promote claims of superiority, or requirements to conduct additional expensive clinical trials to provide proof of such claims,
	could negatively affect the sales of the Company's products and/or its costs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Orphan
	Drug Act
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Orphan Drug Act provides incentives to manufacturers to develop and market drugs for rare diseases and conditions affecting fewer
	than 200,000 persons in the US at the time of application for Orphan Drug Designation. The first developer to receive FDA marketing
	approval for an orphan drug is entitled to a seven year exclusive marketing period in the US for that product. However, a drug
	that the FDA considers to be clinically superior to, or different from, another approved orphan drug, even though for the same
	indication, may also obtain approval in the US during the seven year exclusive marketing period. In addition, holders of exclusivity
	for orphan drugs are expected to assure the availability of sufficient quantities of their orphan drugs to meet the needs of patients.
	Failure to do so could result in the withdrawal of marketing exclusivity for the drug.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Legislation
	similar to the Orphan Drug Act has been enacted in other countries outside the US, including the European Union (&ldquo;EU&rdquo;).
	The orphan legislation in the EU is available for therapies addressing chronic debilitating or life threatening conditions that
	affect five or fewer out of 10,000 persons or are financially not viable to develop. The market exclusivity period is for ten
	years, although that period can be reduced to six years if, at the end of the fifth year, available evidence establishes that
	the product is sufficiently profitable not to justify maintenance of market exclusivity. The market exclusivity may be extended
	to 12 years if sponsors complete a pediatric investigation plan agreed upon with the relevant committee of the EMA.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Pediatric
	Information
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under
	the Pediatric Research Equity Act of 2007 (&ldquo;PREA&rdquo;), NDAs or BLAs or supplements to NDAs or BLAs must contain data
	to assess the safety and effectiveness of the drug for the claimed indication(s) in all relevant pediatric sub-populations and
	to support dosing and administration for each pediatric sub-population for which the drug is safe and effective. The FDA may grant
	deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any
	drug for an indication for which orphan drug designation has been granted. The Best Pharmaceuticals for Children Act (&ldquo;BPCA&rdquo;),
	provides sponsors of NDAs with an additional six month period of market exclusivity for all unexpired patent or non-patent exclusivity
	on all forms of the drug containing the active moiety if the sponsor submits results of pediatric studies specifically requested
	by the FDA under BPCA within required timeframes. The Biologics Price Competition and Innovation Act provides sponsors of BLAs
	an additional six month extension for all unexpired non-patent market exclusivity on all forms of the biologic containing the
	active moiety pursuant to the BPCA if the conditions under the BPCA are met.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Foreign
	Regulation
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition to regulations in the U.S., we are subject to a variety of foreign regulatory requirements governing human clinical trials
	and marketing approval for drugs. The foreign regulatory approval process includes all of the risks associated with FDA approval
	set forth above, as well as additional country specific regulations. Whether or not we obtain FDA approval for a product, we must
	obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials
	or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer
	or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing,
	pricing and reimbursement vary greatly from country to country.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Environmental
	Regulation
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition to being subject to extensive regulation by the FDA, the Company must also comply with environmental regulation insofar
	as such regulation applies to the Company or its drug candidates. Our costs of compliance with environmental regulation as applied
	to similar pharmaceutical companies are minimal, since we do not currently, nor do we intend to, engage in the production of any
	of our drug candidates. The Company currently uses unaffiliated manufacturers to produce all of its drug candidate material and
	receive final material from such manufacturer, without any involvement on our part in the manufacturing process at any stage of
	the process.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Although
	we believe that our safety procedures for using, handling, storing and disposing of our product candidate materials comply with
	the environmental standards required by state and federal laws and regulations, we cannot completely eliminate the risk of accidental
	contamination or injury from these materials. We do not carry a specific insurance policy to mitigate this risk to us or to the
	environment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Employees
	&amp; Consultants
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	At
	March 30, 2016 the Company employed seven full time and three part time persons. The Company is not a party to any collective
	bargaining agreement with its employees; nor are any of its employees a member of any labor unions. The Company is subject to
	certain statutory and contractual obligations in instances where it terminates U.K. based employees. These obligations, which
	are ordinary and customary in the U.K., generally range from one to six months wages for terminated employees and would not be
	expected to represent a material adverse effect to the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To
	complement our own expert professional staff, we utilize specialists in regulatory affairs, pharmacovigilance, process engineering,
	manufacturing, quality assurance, clinical development and business development. These individuals include scientific advisors
	as well as independent consultants.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Competition
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are engaged in a rapidly evolving field. If our drug candidate development reaches the level of commercialization and marketing,
	we expect to compete primarily with established pharmaceutical companies such as Amgen Inc., Bristol-Myers Squibb Company, F.
	Hoffmann-La Roche Ltd, Nektar Therapeutics and others. We also expect to compete with established pharmaceutical companies as
	well as academic institutions and other smaller pharmaceutical companies during the drug development stage of our progress. Competition
	is intense and expected to increase.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	large and rapidly growing market for new drug therapies for use in humans is likely to attract new entrants. Numerous biotechnology
	and pharmaceutical companies are focused on developing new drug therapies and many of these companies have greater financial and
	other resources and development capabilities than we do. Our competitors also have greater collective experience in undertaking
	pre-clinical and clinical testing of products, obtaining regulatory approvals and manufacturing and marketing prescription pharmaceutical
	products. Accordingly, certain of these competitors may succeed in obtaining approval for drug products and therapies more rapidly
	than us.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition to competing with universities and other research institutions in the development of drug products, therapies, technologies
	and processes, we may compete with other companies in acquiring rights to products or technologies from universities. There can
	be no assurance that our products or product candidates will be more effective or achieve greater market acceptance than competitive
	products, or that these companies will not succeed in developing products and technologies that are more effective than those
	being developed for us or that would render our products and technologies less competitive or obsolete.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Available
	Information
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	website address is www.xeneticbio.com. The information in, or that can be accessed through, our website is not part of this Annual
	Report on Form 10-K. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments
	to those reports are available, free of charge, on or through our website as soon as practicable after we electronically file
	such forms, or furnish them to, the SEC. The public may read and copy any materials we file with the SEC at the SEC&rsquo;s Public
	Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operations of the Public Reference Room can be
	obtained by calling 1-800-SEC-0330. The SEC maintains an internet site that contains reports, proxy and information statements
	and other information regarding our filings at www.sec.gov.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition to disclosing current information pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and for reports
	of information required to be disclosed by Regulation FD through our SEC filings, we also intend to disclose such current information
	through our investor relations website, press releases, public conference calls, webcasts and through various social media channels,
	including Facebook, Twitter, LinkedIn, Google+ and Chairman&rsquo;s Blog Profile.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Directors
	and Executive Officers
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Set
	forth below is the name, age, position and brief account of the business experience of each of our executive officers and directors
	as of March 30, 2016:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 33%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Age
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 57%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Position
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Michael Scott Maguire
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	52
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	President, Chief Executive Officer and Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Dmitry Genkin
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	47
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Firdaus Jal Dastoor FCS
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	63
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Darlene Deptula-Hicks
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	58
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Roman Knyazev
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	35
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dr. Roger
	Kornberg
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	68
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Michael
	Scott Maguire
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Mr.&nbsp;Maguire
	has been President, Chief Executive Officer and Director of the Company since his appointment in 2004. His background is in life
	science and healthcare investment banking and he has advised many US and European companies on capital raisings and commercial
	development over his 26 year career. Mr.&nbsp;Maguire began his banking career with Merrill Lynch in 1987 in New York, and after
	receiving his MBA from the Babson Graduate School in 1993, he joined the healthcare division of W.R. Grace National Medical Care
	(&ldquo;NMC&rdquo;) where he helped develop the international healthcare division. During his time in charge of international
	business development, he helped double NMC&rsquo;s international revenues through Mergers and Acquisitions. In 1996 he co-founded
	the Arthur Andersen global healthcare corporate finance practice based in London, a practice that he built to include a staff
	of 36 across the US and Europe, elevating to the role of managing director. Mr.&nbsp;Maguire is currently a director of Healthcare
	Capital Partners Limited, a healthcare corporate finance and proprietary investment boutique he co-founded in 2002 and a non-executive
	director of Renal Services (UK) Limited, a company focused on dialysis service provision in the U.K. Based on Mr.&nbsp;Maguire&rsquo;s
	experience within the biotechnology sector and his executive experience, specifically his experience as an executive officer at
	other companies, as well as his service on other boards of directors, the Board believes Mr.&nbsp;Maguire has the appropriate
	set of skills to serve as a member of our Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Dr.
	Dmitry Genkin
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dr.
	Genkin was appointed as a Director of the Company in September 2015. Dr. Genkin has the Russian equivalent of an MD in Internal
	Therapy and studied drug delivery under Professor Gregoriadis at The School of Pharmacy, University of London in 1992 and the
	Department of Clinical Pharmacology at Karolinska Hospital, Stockholm from 1992 until 1993. Since 1993, Dr. Genkin has headed
	a number of Russia's largest pharmaceutical companies including Pharmavit, which had 27% of the Russian pharmaceutical market.
	In 1998, he was awarded the silver medal by the Russian Natural Science Academy. Dr. Genkin is currently a partner and director
	of FDS Pharma and Chairman of Pharmsynthez, which is listed on the Moscow stock exchange. Based on Dr. Genkin&rsquo;s experience
	in the field of life sciences and biotechnology, the Board believes Dr. Genkin has the appropriate set of skills to serve as a
	member of our Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Firdaus
	Jal Dastoor, FCS
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Mr.&nbsp;Dastoor
	was appointed as a Director of the Company in January 2014 pursuant to terms included in the Company&rsquo;s acquisition of Xenetic
	UK. Mr.&nbsp;Dastoor was appointed non-executive Director of Xenetic UK in July 2007. He has been a Fellow Member of The Institute
	of Company Secretaries of India since 2008 and began his career as a company secretary. He was Company Secretary of the Poonawalla
	Group until 1994. He then took on assignments involved in business development strategies and operations. Mr.&nbsp;Dastoor is
	on the board of several companies operating in the field of engineering products, life sciences and biotech, international trade,
	financial services and quality standards certifications. Currently, he is a Group Director of the Poonawalla Group of Companies
	in charge of Finance and Corporate Affairs. Based on Mr.&nbsp;Dastoor&rsquo;s experience in the field of life sciences and biotechnology,
	finance and business development, the Board believes Mr.&nbsp;Dastoor has the appropriate set of skills to serve as a member of
	our Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Darlene
	Deptula-Hicks
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ms.&nbsp;Deptula-Hicks
	was appointed to the Board of Directors of the Company in April 2014. Ms.&nbsp;Deptula-Hicks is a strategic senior financial executive
	with extensive experience in both public and private companies, including experience in fund raising, mergers and acquisitions,
	public and private offerings and with operational management focused in life sciences. Since September 2015, Ms. Deptula-Hicks
	is the Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS).&nbsp; In November 2014,
	Ms. Deptula-Hicks was engaged as a financial consultant at Pieris Pharmaceuticals, Inc. pursuant to a consulting agreement with
	the financial advisory firm of Danforth Advisors, LLC.&nbsp;&nbsp; Prior to that and since June 2012, Ms.&nbsp;Deptula-Hicks served
	as Executive Vice President and Chief Financial Officer of Microline Surgical, Inc. From 2006 to 2011, Ms.&nbsp;Deptula-Hicks
	was the Executive Vice President, Chief Financial Officer, Treasurer and Secretary of ICAD, Inc.&nbsp; She received her Bachelor
	of Science in Accounting from Southern New Hampshire University and her MBA from Rivier College. Based upon her extensive financial
	experience including experience in fund raising, mergers, public companies and life sciences, the Board believes Ms.&nbsp;Deptula-Hicks
	has the appropriate set of skills to serve as a member of our Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Roman
	Knyazev
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Mr.
	Knyazev was appointed to the Board of Directors of the Company in April 2014.&nbsp; Mr. Knyazev has been an Investment director
	for Rusnano Moscow since 2009 and is currently on the board of several biotechnology companies. In his current role, he provides
	technical expertise, asset valuation, financial modelling and business valuation as well as develops and presents investment strategies
	and project financing to clients. In 2003, he began his career as the Chief Financial Officer of Biotech Pharma Moscow where he
	gained experience in both the financial and management sector. Mr. Knyazev led the development and implementation of management
	accounting and budgeting processes as well as facilitated internal audits of regional branches. Mr. Knyazev is a Kauffman Fellow,
	Class 17, which is a Silicon Valley-based two year leadership program for venture capitalists and innovators of all kinds. Based
	on Mr.&nbsp;Knyazev&rsquo;s experience in clinical stage biotechnology companies, the Board believes Mr.&nbsp;Knyazev has the
	appropriate set of skills to serve as a member of our Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Dr.
	Roger Kornberg
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dr.
	Kornberg was appointed to the Board of Directors of the Company in February 2016. Dr. Kornberg is a member of the U.S. National
	Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned
	his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972.&nbsp;He
	became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological
	chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford
	Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular
	basis of Eukaryotic Transcription, the process by which DNA is copied to RNA.&nbsp;Dr. Kornberg is also the recipient of several
	awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002
	Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences. Based
	on Dr. Kornberg&rsquo;s experience in the field of molecular biology, the Board believes Dr.&nbsp;Kornberg has the appropriate
	set of skills to serve as a member of our Board.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	1A &ndash; RISK FACTORS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are not required to provide the information required by this Item because we are a smaller reporting company.
</FONT>
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	1B &ndash; UNRESOLVED STAFF COMMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	2 &ndash; PROPERTIES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company occupies a facility consisting of approximately 4,000 square feet in the Ledgemont Technology Center in Lexington, Massachusetts.
	The premises are divided into approximately 50% laboratory and 50% office space and are leased by the Company&rsquo;s subsidiary,
	Xenetic Bioscience, Incorporated. The lease provides for an initial term of 61 months which commenced in January 2014 with an
	extension option of one additional five-year term. We believe that this space is adequate for the Company&rsquo;s current needs
	and that, if additional space is required, it can be obtained at commercially reasonable terms either within the Ledgemont Technology
	Center or nearby.
</FONT>
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	3 &ndash; LEGAL PROCEEDINGS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	4 &ndash; MINE SAFETY DISCLOSURES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Not
	applicable.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PART
	II
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	5 &ndash; MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	common stock is quoted under the symbol &ldquo;XBIO&rdquo; on the OTCQB operated by the OTC Markets Group, Inc. The criteria for
	listing on the OTCQB include that we remain current in our SEC reporting. Our reporting is presently current, and since inception,
	we have filed our SEC reports on time.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Only
	a limited market exists for our securities. There is no assurance that a regular trading market will develop, or if developed,
	that it will be sustained. Therefore, a shareholder may be unable to resell his securities in our company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table sets forth the range of high and low prices for our common stock for each of the periods indicated as reported
	by the OTCQB. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily
	represent actual transactions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 72%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year
	ended December 31, 2014
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	High
	Price
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Low
	Price
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1st Quarter ended March 31, 2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9.50
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.31
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2nd Quarter ended June 30, 2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.00
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.30
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3rd Quarter ended September 30, 2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.99
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.51
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4th Quarter ended December 31, 2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.68
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.18
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year
	Ended December 31, 2015
</B>
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1st Quarter Ended March 31, 2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.25
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.20
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2nd Quarter Ended June 30, 2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.24
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.18
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3rd Quarter Ended September 30, 2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.47
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.20
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4th Quarter
	Ended December 31, 2015
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.92
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	0.33
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	March 15, 2016 the last sales price per share of our common stock was $0.29.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Penny
	Stock
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are
	generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities
	exchanges or quoted on the NASDAQ system, provided that the current price and volume information with respect to transactions
	in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, prior to a transaction
	in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of
	the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description
	of the broker&rsquo;s or dealer&rsquo;s duties to the customer and of the rights and remedies available to the customer with respect
	to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description
	of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;
	(d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure
	document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including
	language, type size and format, as the SEC shall require by rule or regulation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations
	for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; and (c) the number of shares
	to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for
	such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer&rsquo;s account.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the
	broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive
	the purchaser&rsquo;s written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions
	involving penny stocks, and a signed and dated copy of a written suitability statement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These
	disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may
	have difficulty selling our securities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Holders
	of Record
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	of March 15, 2016 there were 426 holders of common stock of the Company of record.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Dividends
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	are no restrictions in our articles of incorporation or bylaws that prevent us from declaring dividends. The Nevada Revised Statutes,
	however, do prohibit us from declaring dividends where after giving effect to the distribution of the dividend:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We would not be able to pay our debts
	as they become due in the usual course of business; or
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Our total assets would
	be less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of shareholders who have
	preferential rights superior to those receiving the distribution.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="TEXT-ALIGN: JUSTIFY; FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has never previously declared or paid any cash dividends on its common stock. We currently intend to retain earnings and
	profits, if any, to support our business strategy and do not intend to pay any cash dividends within the foreseeable future. Any
	future determination to pay cash dividends will be at the sole discretion of the Company&rsquo;s Board of Directors and will depend
	upon the financial condition of the Company, its operating results, capital requirements, general business conditions and any
	other factors that the Board of Directors deems relevant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Recent
	Sales of Unregistered Securities
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Issuances
	of Unregistered Shares of Common Stock
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	December
	2015
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	December 2015, the Company issued 500,000 shares of the Company&rsquo;s common stock to non-employee consultants in exchange for
	services provided to the Company. The Company recorded $221,000 as the aggregate amount of consideration received by the Company
	for the associated services.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	shares were not registered under the Securities Act, or the securities laws of any state, and were offered and sold in reliance
	on the exemption from registration afforded by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act and corresponding
	provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	November
	2015
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	November 2015, in consideration of the assignment of certain intellectual property rights by Dr. Dmitry Genkin and Kirill Surkhov
	(together &ldquo;the Assignors&rdquo;) to Lipoxen Technologies Limited, the Company issued 11,000,000 shares of the Company&rsquo;s
	common stock to the Assignors pursuant to the terms of the APA. The Company recorded $3.74 million as the aggregate amount of
	consideration received by the Company for these certain intellectual property rights.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	issuance was made by the Company pursuant to an exemption from the registration either (a) under the Securities Act generally,
	in that the transactions are between an issuer and sophisticated investors and do not involve any public offering within the meaning
	of Section 4(a)(2) or (b) under Regulation S promulgated under the Securities Act in that offers, sales and issuances are not
	made to persons in the United States and no directed selling efforts are made in the United States.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	August
	2015
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	August 2015, the Company issued 527,535 shares of the Company&rsquo;s common stock to non-employee consultants in exchange for
	services provided to the Company. The Company recorded $196,341 as the aggregate amount of consideration received by the Company
	for the associated services.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	shares were not registered under the Securities Act, or the securities laws of any state, and were offered and sold in reliance
	on the exemption from registration afforded by Section 4(a)(2) and Regulation D (Rule 506) under the Securities Act and corresponding
	provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Issuances
	of Common Stock Warrants
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Pharmsynthez
	Common Stock Warrant Issuances
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	July 2015, the Company issued a $3 million 10% Senior Secured Collateralized Convertible Promissory Note (the &ldquo;Note&rdquo;)
	plus a warrant to purchase 10 million shares of common stock to OJSC Pharmsythez. The net proceeds of approximately $3 million
	were used for general working capital needs of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	Note was issued in a private placement by the Company pursuant to an exemption from the registration either (a) under the Securities
	Act generally, in that the transactions are between an issuer and sophisticated investors and do not involve any public offering
	within the meaning of Section 4(a)(2) or (b) under Regulation S promulgated under the Securities Act in that offers, sales and
	issuances are not made to persons in the United States and no directed selling efforts are made in the United States.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	SynBio
	LLC Common Stock Warrant Issuance
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	December 31, 2014, the Company issued a warrant to purchase 6,745,000 shares of the Company&rsquo;s common stock, par value $0.01,
	to SynBio in furtherance of our co-development clinical objectives. The exercise price for the purchase of the warrant is $0.77
	per share with a term of five years from the grant date. Simultaneously, warrants to purchase 320,000 shares of the Company&rsquo;s
	common stock, par value $0.01, were issued to SynBio and Pharmsynthez non-director designees under the same terms and conditions
	of the SynBio warrant. Pharmsynthez is a related party of SynBio, which is an affiliate of the Company. These warrants contain
	vesting triggers based on the achievement by SynBio of specific clinical development objectives.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Serum
	Institute of India Limited Common Stock Warrant Issuance
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	December 31, 2014, the Company issued a warrant to purchase 3,200,000 shares of the Company&rsquo;s common stock, par value $0.01,
	to Serum Institute in furtherance of our co-development clinical objectives. The exercise price for the purchase of the warrant
	is $0.77 per share with a term of five years from the grant date. Simultaneously, warrants to purchase 160,000 shares of the Company&rsquo;s
	common stock, par value $0.01, were issued to Serum Institute non-director designees under the same terms and conditions of the
	Serum Institute warrant. These warrants contain vesting triggers based on the achievement by Serum Institute of specific clinical
	development objectives. Serum Institute is a related party of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Non-Employee
	Director Common Stock Warrant Issuance
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	December 31, 2014, the Company issued a warrant to purchase 1,600,000 shares of the Company&rsquo;s common stock, par value $0.01,
	to a non-employee director for services provided to the Company. The exercise price for the purchase of the warrant is $0.77 per
	share with a term of five years from the grant date. This warrant was fully vested on the date of grant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These
	warrants are issued by the Company pursuant to an exemption from the registration either (a) under the Securities Act generally,
	in that the transactions are between an issuer and sophisticated investors and do not involve any public offering within the meaning
	of Section 4(a)(2) or (b) under Regulation S promulgated under the Securities Act in that offers, sales and issuances are not
	made to persons in the United States and no directed selling efforts are made in the United States.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	FDS
	Pharma ASS Intellectual Property Assignment and Share Issuance
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	December 31, 2014, in consideration of the assignment of certain intellectual property rights by Dr. Dmitry Genkin and FDS Pharma
	ASS to Lipoxen Technologies Limited, the Company issued to FDS Pharma ASS 3,244,784 shares of the Company&rsquo;s common stock,
	par value $0.01 per share. FDS Pharma ASS is related party of SynBio, which is an affiliate of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These
	shares were issued in a private placement and were not registered under the Securities Act, or the securities laws of any state,
	and were offered and issued in reliance on the exemption from registration afforded by Regulation D under the Securities Act and
	corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering. FDS
	Pharma ASS is an &ldquo;Accredited Investor&rdquo; as such term is defined in Regulation D promulgated under the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Baxter
	SA Purchase Agreement &ndash; Unregistered Shares Sold in January 2014
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	January 29, 2014, the Company entered into a Stock Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Baxter SA, pursuant
	to which the Company sold to Baxter SA 10,695,187 shares of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;Shares&rdquo;)
	for $10 million (the &ldquo;Purchase Price&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the Purchase Agreement, Baxter SA agreed that until the earlier of (i) three months after the effective date of the listing
	of the Company&rsquo;s common stock on the NASDAQ Stock Market; or (ii) January 29, 2015, Baxter SA would not assign, transfer,
	sell or dispose of the Shares to any party other than a wholly owned subsidiary. In addition, Baxter SA agreed that until the
	12 month anniversary of the Lock-Up Expiration Date, it would not sell or offer to sell any shares of common stock of the Company
	in an amount that would exceed 15% of the daily trading volume of the Company&rsquo;s common stock on the principal market or
	exchange on which the Company&rsquo;s shares of common stock are traded, and in no event would Baxter SA sell or offer to sell
	more than 15% of the Shares in any one month period. During 2015, Baxter agreed in writing to a further lock-up period expiring
	in June 2016 and certain other related restrictions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Shares were sold in a private placement and were not registered under the Securities Act, or the securities laws of any state,
	and were offered and sold in reliance on the exemption from registration afforded by Section 4(a)(2) and Regulation D (Rule 506)
	under the Securities Act and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving
	any public offering. Baxter SA is an &ldquo;Accredited Investor&rdquo; as such term is defined in Regulation D promulgated under
	the Securities Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Repurchases
	of Equity Securities of the Issuer
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During
	2015 and 2014, we did not repurchase any of our outstanding securities.
</FONT>
</P>
</EFX_MARKET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	6 &ndash; SELECTED FINANCIAL DATA
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are not required to provide the information required by this Item because we are a smaller reporting company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	7 &ndash; MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	BUSINESS
	OVERVIEW
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company is a clinical stage biopharmaceutical company that is focused on the research and development of certain pharmaceutical
	products for use in humans that incorporate the use of its patented and proprietary platform technologies that we believe will
	enable the creation of next-generation biologic drugs and novel oncology therapeutics with an emphasis primarily on orphan indications.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	hold more than 201 United States (&ldquo;U.S.&rdquo;) and international patents
	in addition to certain proprietary rights to four core technologies that are designed to treat a variety of indications with potential
	use advantages over competing products, in addition we have approximately 90 pending
	patents. In June 2014, the U.S. Patent and Trademark Office (the &ldquo;USPTO&rdquo;) has granted the Company U.S. Patent No.
	8,735,557, entitled &quot;Activated Sialic Acid Derivatives for Protein Derivatization and Conjugation,&quot; which contains claims
	that cover the compound, ErepoXen&trade;, and Xenetic's broader polysialic acid technologies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company&rsquo;s core technologies are summarized below:
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="WIDTH: 13%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 87%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	PolyXen&trade;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	An
	enabling technology that utilizes Polysialic Acid (&ldquo;PSA&rdquo;), a biopolymer, consisting of a chain of sialic acids,
	which is a natural constituent of the human body. PSA is designed to extend the half-life in circulation in the human body
	for a variety of existing drug molecules and, thereby, to create potentially superior next generation drug candidates.
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Virexxa&reg;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Virexxa&reg;,
	sodium cridanimod, belongs to a class of low-molecular weight synthetic interferon inducers. In addition to its immunomodulatory
	properties, Virexxa&reg; has been shown to increase levels of &nbsp;progesterone receptor expression in tumor tissue of patients
	who are progesterone receptor deficient, and thus may restore sensitivity of non-responsive endometrial cancers to hormonal
	(e.g. progestin) therapy. Based on preclinical observations, Virexxa&reg; may also be therapeutically relevant in other hormone-resistant
	cancers, such as triple-negative breast cancer.&nbsp;&nbsp;Virexxa&reg; has been granted an Orphan Drug Designation by the
	USFDA for use in conjunction with medroxyprogesterone in progesterone receptor negative endometrial cancer.
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OncoHist&trade;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	novel therapeutic platform that utilizes the properties of the human histone H1.3 (&ldquo;H1.3&rdquo;) for the development
	of drug candidates for the treatment of a broad range of cancer indications. OncoHist&trade;, unlike many competing oncology
	therapies, is based on a molecule occurring naturally in the human body, in the cell nucleus, and is therefore expected to
	be less toxic and immunogenic than other oncology therapies.
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ImuXen&trade;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	novel liposomal co-entrapment encapsulation technology designed to create new vaccines and improve the use and efficacy of
	certain existing vaccines for use in the human body. The technology is based on the co-entrapment of the nominated antigen(s)
	in a liposomal vesicle, a design that is intended to maximize both cell and immune system mediated responses.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	of the Company&rsquo;s current drug candidates are in the development stage and none has yet received regulatory approval for
	marketing in the U.S. by the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) or by any applicable agencies in other
	countries.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Critical
	Accounting Estimates
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	preparation of our financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions
	that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of
	expenses during the reporting period. On an ongoing basis, we evaluate our estimates that are based on historical experience and
	on various assumptions that we believe to be reasonable under the circumstances. The result of these evaluations forms the basis
	for making judgments about the carrying values of assets and liabilities and the reported amount of expenses that are not readily
	apparent from other sources. Because future events and their effects cannot be determined with certainty, actual results could
	differ from our assumptions and estimates, and such differences could be material.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Management
	believes that the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported
	financial results, and they require management&rsquo;s most difficult subjective or complex judgments, resulting from the need
	to make estimates about the effect of matters that are inherently uncertain. The following narrative describes these critical
	accounting estimates, the judgments and assumptions and the effect if actual results differ from these assumptions.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Revenue
	Recognition
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	derive our revenue from our license and collaboration arrangements with pharmaceutical and biotechnology partners, some of which
	include royalty agreements based on potential net sales of approved commercial pharmaceutical products. Revenue from our collaborative
	partners are generally paid directly by the partners and are recognized on the accrual basis when all the following criteria are
	met: (i) persuasive evidence of an arrangement exists, (ii) delivery (or passage of title) has occurred or services have been
	rendered, (iii) the seller's price to the buyer is fixed or determinable, and (iv) collectability is reasonably assured.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	terms of our license agreements include delivery of an IP license to a collaboration partner. We may be compensated under license
	arrangements through a combination of non-refundable upfront receipts, development and regulatory objective receipts and royalty
	receipts on future product sales by partners. We make our best estimate of the period over which we expect to fulfil our performance
	obligations, which may include technology transfer assistance, research activities, clinical development activities, and manufacturing
	activities from development through the commercialization of the product. Given the uncertainties of these collaboration arrangements,
	significant judgment is required to determine the duration of the performance period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-refundable
	upfront license fees received, whereby our continued performance or future obligations are considered inconsequential or perfunctory
	to the relevant licensed technology, are recognized as revenue upon delivery of the technology in accordance with U.S. GAAP. This
	determination requires significant judgment to assess the nature of any continuing obligations. Reimbursements for research and
	development services completed by us related to the collaboration agreements are recognized in operations as revenue on a gross
	basis.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	expect to receive royalty receipts in the future as products are sold. We expect to recognize royalty revenue in the period of
	sale, based on the underlying contract terms, provided that the reported sales are reliably measurable and we have no remaining
	performance obligations, assuming all other revenue recognition criteria are met.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	license and collaboration agreements with certain collaboration partners could also provide for future receipts to us based solely
	upon the performance of the respective collaboration partner in consideration of milestone extensions or upon the achievement
	of specified sales volumes of approved drugs. For such receipts, we expect to recognize the receipts as revenue when earned under
	the applicable contract terms on a performance basis or ratably over the term of the agreement. These receipts may also be recognized
	as revenue when our continued performance or future obligations are considered inconsequential or perfunctory.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Embedded
	Derivatives Related to Debt Instruments
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.45PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	our financing arrangements, we issue debt instruments that may include features that meet the criteria of embedded derivatives
	requiring bifurcation. The fair value of each embedded derivative is valued independently using a &ldquo;with-and-without&rdquo;
	method.&nbsp; The &ldquo;with-and-without&rdquo; methodology involves valuing the whole instrument on an as-is basis and then
	valuing the instrument without the individual embedded derivative. The difference between the entire instrument with all of the
	embedded derivatives compared to the instrument without the individual embedded derivative is the fair value of that individual
	derivative. The embedded derivatives are settled when the underlying debt instrument is settled. Therefore, there are three possible
	settlement mechanisms: the debt instrument can be converted into equity, repaid early, or held to maturity.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	connection with our July 2015 financing, we developed a set of potential outcomes resulting in the settlement of the SPA Note
	consisting of a future qualifying capital raise with conversion, default of the SPA Note, the SPA Note being converted to equity
	and the SPA Note being held to maturity. &nbsp;These were included in a valuation model utilizing Monte Carlo Simulations to develop
	the fair value of the embedded derivatives, which included a simulation of the Company&rsquo;s stock price with consideration
	provided for the expected volatility of the Company, the expected life of the host instrument, and risk free rate.&nbsp; The assumptions
	used in calculating the fair value represents our best estimates and involves inherent uncertainties and the application of our
	judgment.&nbsp; As a result, the use of alternate assumptions would result in outcomes that could be materially different. Additionally,
	the Company is required to update its assumptions and estimates at each valuation date. Based on updated circumstances, factors
	and knowledge of the Company at future valuation dates, then applicable assumptions and estimates could result in material changes
	in the estimated fair value of the embedded derivatives.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Share-based
	Payments
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Share-based
	payments includes grants of options to employees and non-employees to purchase shares of common stock, grants of Joint Share Ownership
	Plan (&ldquo;JSOP&rdquo;) awards to employees, as well as agreements to issue common stock in exchange for services provided by
	non-employees. Currently, we utilize one option plan, the Xenetic Biosciences, Inc. Equity Incentive Plan pursuant to which we
	may grant options to purchase shares of common stock to employees and non-employees. Prior to the acquisition of Xenetic UK in
	January 2014, the Company had two option plans, the Lipoxen plc Unapproved Share Option Plan and the Xenetic Biosciences plc 2007
	Share Option Scheme. Both of these plans were converted subsequent to year end to reflect the new shares of common stock issued
	related to the Acquisition. As part of the conversion, option holders under both plans have the right to subscribe for a number
	of shares of common stock in exchange for the cancellation and surrender by the option holder in a manner similar to which the
	shareholders prior to the Acquisition were given the right to acquire shares of common stock in the new company according to the
	terms of the Acquisition.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	measure share-based payments to employees in accordance with Financial Accounting Standards Board Accounting Standards Codification
	(&ldquo;ASC&rdquo;) Topic 718,
<I>
	Compensation &ndash; Stock Compensation
</I>
	and to non-employees in accordance with ASC Topic
	505
<I>
	, Equity
</I>
	. Stock option compensation expenses are based on the estimated fair value of the underlying option calculated
	using the Black-Scholes option pricing model, which requires the input of subjective assumptions and judgments, including estimating
	share price volatility and expected term of the awards. Our shares do not have a sufficient trading history for us to adequately
	assess the fair value of the stock option grants. Therefore, for all share-based payments, we determine the expected volatility
	based on a weighted-average of the historical volatility of a peer group of comparable publicly traded companies with product
	candidates in similar stages of development to our product candidates in conjunction with our historical volatility. We intend
	to consistently apply this methodology of using a peer group of comparable companies until the historical volatility of our own
	share price is relevant to measure expected volatility for future equity based awards. For employee stock options issued in 2014
	that qualify as &ldquo;plain vanilla&rdquo; stock options in accordance with Staff Accounting Bulletin No. 110 (&ldquo;SAB 110&rdquo;)
	issued by the SEC, the expected term is estimated using the simplified method, as defined in SAB 110. The Company has a limited
	history of stock option exercises, which does not provide a reasonable basis for the Company to estimate the expected term of
	employee stock options. For all other employee stock options, we estimate the expected life using judgment based on the anticipated
	research and development milestones of the Company&rsquo;s clinical projects and behavior of the Company&rsquo;s employees. The
	expected life of non-employee options is the contractual life of the option. The assumptions used in calculating the fair value
	of the stock option grants represent our best estimates and involve inherent uncertainties and the application of our judgment.
	As a result, if factors change and we use different assumptions, share-based payments expense could be materially different in
	the future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For
	employee options that vest based solely on service conditions, the fair value measurement date is generally on the date of grant
	and the related compensation expense, less expense for expected forfeitures, is recognized on a straight-line basis over the requisite
	vesting period of the awards. For non-employee options, the fair value measurement date is the earlier of the date the performance
	of services is complete or the date the performance commitment has been reached. We generally determine that the fair value of
	the stock options is more reliably measurable than the fair value of the services received. Compensation expense related to stock
	options granted to non-employees that vest based solely on service conditions is subject to re-measurement at each reporting period
	until the options vest and is recognized on a straight-line basis over the estimated vesting period of the awards.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those
	estimates. During 2015 and 2014, we applied a forfeiture rate of 0% as we have not historically experienced forfeitures. Upon
	exercise, stock options are redeemed for newly issued shares of common stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	fair value of common stock awards issued in exchange for services provided by non-employees is generally determined by using the
	fair value of the services provided, as this provides the most reliable measure of the fair value of the awards. Share-based payments
	expense is recognized as services are rendered on a straight-line basis. The assumptions used in calculating the fair value of
	the common stock awards represent our best estimates and involve inherent uncertainties and the application of our judgment. As
	a result, if factors change and we use different assumptions, share-based payments expense related to the common stock awards
	could be materially different in the future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under
	the JSOP, shares of the Company are jointly purchased at fair market value by the participating executives and the trustees of
	the JSOP trust, with shares held in the JSOP trust. For U.S. GAAP purposes the awards are valued as employee options. The JSOP
	trust holds the shares of the JSOP until such time as the JSOP shares are vested and the participating executives exercise their
	rights under the JSOP. The JSOP trust is granted an interest bearing loan by the Company in order to fund the purchase of its
	interest in the JSOP shares. The loan held by the trust is eliminated on consolidation in the financial statements of the Company.
	The Company funded portion of the share purchase price is deemed to be held in treasury until such time as they are transferred
	to the employee and is recorded as a reduction in equity.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	exercise price of the JSOP &ldquo;option&rdquo; is deemed to be the market value of the shares at the date of issue. The awards
	vest based on certain market conditions, which require each tranche of shares to meet specific market share price hurdles, or
	change in control conditions, as defined by the plan. Under the JSOP and subject to the vesting of the participants&rsquo; interest,
	participating executives will, when the JSOP shares are sold, be entitled to a share of the proceeds of sale equal to the growth
	in market value of the JSOP shares versus the exercise price, less simple interest on the original share purchase price, net of
	executives&rsquo; cash contribution at inception, as agreed for each grant (the &ldquo;Carry Charge&rdquo;). The balance of the
	proceeds will remain to the benefit of the JSOP trust and be applied to the repayment of the loan originally made by the Company
	to the JSOP trust. Any funds remaining in the JSOP trust after settlement of the loan and any expenses of the JSOP trust are for
	the benefit of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	measure the fair value of JSOP awards using Monte Carlo simulations, which requires estimates based on the Company&rsquo;s judgment,
	as well as other assumptions. These estimates include the expected term of each tranche of the JSOP awards, which the Company
	determines to be the initial life of the awards, and expected volatility, which is based on a weighted average of the historical
	volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to
	the Company&rsquo;s product candidates in conjunction with the historical volatility of Xenetic Biosciences plc&rsquo;s shares
	when traded on the U.K. AIM market. The Company has applied an expected dividend yield of 0% as the Company has not historically
	declared a dividend and does not anticipate declaring a dividend during the expected life of the awards. The risk-free rate is
	based upon the US Treasury yield curve in effect at the time of grant, with a term that approximates the expected life of the
	awards. The compensation expense is recorded over the expected life of the option, regardless of whether the awards vest. Having
	established the full value of the JSOP awards using the Monte Carlo simulation outlined above, a deduction is made in respect
	of the anticipated Carry Charge in order that the expense recorded in the financial statements only represents the participating
	executives&rsquo; net interest in the awards. The assumptions used in calculating the fair value of the JSOP awards represent
	our best estimates and involve inherent uncertainties and the application of our judgment. As a result, if factors change and
	we use different assumptions, share-based payments expense related to the JSOP awards could be materially different in the future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	exercise of the JSOP awards by the executives the Carry Charge due to the Company will be recognized as additional paid-in capital,
	arising from the sale of treasury stock.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Warrants
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	connection with certain financing, consulting and collaboration arrangements, we issue warrants to purchase shares of the Company&rsquo;s
	common stock. Outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and
	are classified as equity awards. We measure the fair value of the awards using the Black-Scholes option pricing model, which requires
	the input of subjective assumptions and judgments, including estimating the expected term of the awards and the share price volatility,
	at each reporting period until the measurement date is reached. The expected term is deemed to be the contractual life of the
	warrant and we determine the expected volatility based on a weighted-average of the historical volatility of a peer group of comparable
	publicly traded companies with product candidates in similar stages of development to our product candidates in conjunction with
	our historical volatility.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	other warrants are recorded at fair value as compensation expense on a straight-line basis over the requisite service period or
	at the date of issuance, if there is not a service period or if service has already been rendered. For warrants that contain vesting
	triggers based on the achievement of certain objectives, the Company applies judgment to estimate the probability and timing of
	the achievement of those objectives. These estimates involve inherent uncertainties, and as a result, if the probability or timing
	of the achievement of those objectives change, expense related warrants could be materially different in the future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Warrants
	issued to collaboration partners in conjunction with the issuance of common stock are recorded at fair value as a reduction in
	additional paid-in capital of the common stock issued.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Goodwill
	and Indefinite-lived Intangible Assets
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Goodwill
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Goodwill
	is not amortized but is reviewed for impairment annually as of October 1, or when events or changes in the business environment
	indicate that all, or a portion, of the carrying value of the reporting unit may no longer be recoverable. Under this method,
	we compare the fair value of our reporting unit to its carrying value. If the fair value is less than the carrying amount, a more
	detailed analysis is performed to determine if goodwill is impaired. An impairment loss, if any, is measured as the excess of
	the carrying value of goodwill over the fair value of goodwill. We also have the option to first assess qualitative factors to
	determine whether the existence of events or circumstances leads us to determine that it is more likely than not (that is, a likelihood
	of more than 50%) that goodwill is impaired. If we choose to first assess qualitative factors and it is determined that it is
	not more likely than not goodwill is impaired, we are not required to take further action to test for impairment. We also have
	the option to bypass the qualitative assessment and perform only the quantitative impairment test, which we may choose to do in
	some periods but not in others. As the option to perform the qualitative assessment is not a permanent election, we reassess this
	option during each annual impairment review.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	determine our reporting unit by identifying the components of our operating segment with similar economic characteristics based
	on quantitative and qualitative factors that have discrete financial information available. We determined that we have one reporting
	unit as of October 1, 2015 and 2014, the dates of our annual impairment reviews. Based on our annual impairment reviews, we used
	the quantitative method and determined no adjustment to the carrying value of goodwill would be necessary as the fair value of
	our reporting unit significantly exceeded its respective carrying value as of October 1, 2015 and 2014, respectively. If the fair
	value of our reporting unit were to be reduced by one-half, the fair value would still significantly exceed the carrying value
	of the reporting unit at October 1, 2015. There can be no assurance that future events will not result in an impairment of goodwill.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Indefinite-lived
	Intangible Assets
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	indefinite-lived intangible assets consist of acquired IPR&amp;D. IPR&amp;D intangible assets are considered indefinite-lived
	intangible assets until completion or abandonment of the associated research and development efforts. IPR&amp;D is not amortized
	but is reviewed for impairment annually as of October 1, or when events or changes in the business environment indicate the carrying
	value may be impaired. If the fair value of the intangible asset is less than the carrying amount, we perform a quantitative test
	to determine the fair value. The impairment loss, if any, is measured as the excess of the carrying value of the intangible asset
	over its fair value. We also have the option to first assess qualitative factors to determine whether the existence of events
	or circumstances leads us to determine that it is more likely than not (that is, a likelihood of more than 50%) that our indefinite-lived
	intangible asset is impaired. If we choose to first assess qualitative factors and it is determined that it is not more likely
	than not our indefinite-lived intangible asset is impaired, we are not required to take further action to test for impairment.
	We also have the option to bypass the qualitative assessment and perform only the quantitative impairment test, which we may choose
	to do in some periods but not in others. As the option to perform the qualitative assessment is not a permanent election, we reassess
	this option during each annual impairment review. During 2015 and 2014, we used the quantitative method and determined the fair
	value of the indefinite-lived intangible asset exceeded its carrying value as of October 1, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Significant
	judgments are inherent in the calculation of fair value. With the assistance of an independent third party, we calculated the
	fair value of our IPR&amp;D by using the Multi-Period Excess Earnings Method (the &ldquo;MPEEM&rdquo;) which is a form of the
	income approach. Under the MPEEM, the fair value of an intangible asset is equal to the present value of the asset&rsquo;s incremental
	after-tax cash flows (excess earnings) remaining after deducting the market rates of return on the estimated value of contributory
	assets (contributory charge) over its remaining useful life. This method requires us to make long-term projections of the amount
	and timing of income and expenses related to development and commercialization of the acquired intangible asset and assumptions
	regarding the rate of return on contributory assets, the weighted average cost of capital and the discount rate for estimated
	future after-tax cash flows. Specifically, this method took into account our estimates of future incremental milestone payments
	that may be achieved upon completion of clinical trial stages, regulatory approval and sales goals upon commercialization, as
	well as our expected royalty income based on sales upon commercialization. Projected expenses are based on our forecasted spend
	required to complete the development of our IPR&amp;D, which will require the Company to raise further capital to fund the development.
	Our projections are estimates subject to change based on several factors including the results of clinical trials and delays in
	regulatory approval. The discount rate used is commensurate with the uncertainties associated with the economic estimates described
	above and reflects the stage of development, the time and resources needed to complete the development of the product and the
	risks of advancement through regulatory approval processes.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Key
	assumptions utilized in the fair valuation of our indefinite-lived intangible asset OncoHist&trade; are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Discount rate &ndash; 47.5%
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Weighted average cost of capital &ndash;
	16.0%
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Estimated aggregate milestone receipts
	&ndash; approximately $300 million
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT CALIBRI, HELVETICA, SANS-SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Royalty rates &ndash;
	10% of net sales
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	While
	we believe reasonable estimates and appropriate assumptions were utilized to calculate the fair value of OncoHist&trade;, it is
	possible a material change could occur. Use of different estimates and judgments could yield materially different results in our
	analysis and could result in materially different asset values or expense.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	can be no assurance that we will be able to successfully develop and complete the acquired IPR&amp;D program and profitably commercialize
	the underlying product candidates before our competitors develop and commercialize similar products, or at all. Moreover, if the
	acquired IPR&amp;D program fails or is abandoned during development, then we may not realize the value we have estimated and recorded
	in our financial statements on the acquisition date, and we may also not recover the research and development investment made
	since the acquisition date to further develop that program. If such circumstances were to occur, our future operating results
	could be materially adversely impacted.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	did not record an impairment charge as a result of our goodwill or indefinite-lived intangible asset impairment tests in 2015
	or 2014. We will continue to closely monitor the performance of our indefinite-lived intangible asset and reporting unit. If the
	business experiences adverse changes in our key assumptions and judgments, we will perform an interim goodwill and/or indefinite-lived
	intangible asset impairment analysis. There can be no assurance that future events will not result in an impairment of our goodwill
	or indefinite-lived intangible asset. As a result of the going concern uncertainty discussed under
<I>
	Liquidity and Capital Resources
</I>
	below, the recoverability and classification of the Company&rsquo;s intangible assets and goodwill could be adversely affected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	RESULTS
	OF OPERATIONS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	comparison of our historical results of operations for the year ended December 31, 2015 to the year ended December 31, 2014 is
	as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Description
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Increase
	(Decrease)
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Percentage
	Change
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Operating costs and expenses:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;Research and development
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3,434,016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,323,896
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2,889,880
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	45.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;General and administrative
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,388,000
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,600,870
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(212,870
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Loss from operations
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(9,822,016
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(12,924,766
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(3,102,750
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	24.0
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other income (expense):
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;Change in fair value of derivative liability
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2,125,117)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,125,117
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	100.0
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;Loss on disposal of subsidiaries
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1,069,675)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1,069,675
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	100.0
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;Other expense
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(295,033)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(326,916)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(31,883
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	9.8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;Interest income
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,694
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	18,959
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(17,265
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	91.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;Interest expense
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(266,999
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(4,706
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	262,293
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5,573.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2,685,455)
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1,382,338)
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,303,117
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	94.3
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Net loss
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(12,507,471
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(14,307,104
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1,799,633
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12.6
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Revenue
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company recorded no revenues for the years ended December 31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Cost
	of Revenue
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company incurred no cost of revenue for the years ended December 31, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Research
	and Development
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company engages in independent research and development (&ldquo;R&amp;D&rdquo;) in connection with its various technologies. Overall,
	corporate R&amp;D expenses for the year ended December 31, 2015 decreased by approximately $2.89 million, or 45.7% to $3.43 million
	from $6.32 million in 2014. The table below sets forth the R&amp;D costs incurred by the Company, by category of expense, for
	the years ended December 31, 2015 and 2014:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="4" STYLE="BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Year
	ended December 31,
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 72%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Category
	of Expense
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 13%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Outside services and Contract Research Organizations
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,794,523
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5,107,990
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Share-based expense
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	886,805
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	141,634
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Salaries and wages
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	491,623
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	729,082
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Rents
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	89,354
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	78,076
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lab consumables
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	23,711
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	26,280
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Other
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	148,000
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	240,834
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total
	research and development expense
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3,434,016
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	6,323,896
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Research
	and Development by Subsidiary Location
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	decrease in R&amp;D expenses in the U.S. during 2015 was primarily due to the planned deferral of IND-enabling preclinical work
	conducted in connection with the OncoHist&trade; program due to working capital constraints. The costs of conducting the ongoing
	ErepoXen&trade; human clinical trials in Australia, which are borne by the U.K. subsidiary Lipoxen, were relatively unchanged
	during 2015 as compared to 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Research
	and Development by Category of Expense
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.5PT; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Outside
	Services and Contract Research Organization Costs
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.5PT; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	significant decrease in outside services and contract research organization costs of approximately $3.31 million, or 64.9% for
	the year ended December 31, 2015 is primarily due to the planned deferral of IND-enabling preclinical work conducted in connection
	with the OncoHist&trade; program due to working capital constraints. The costs of conducting the ongoing ErepoXen&trade; human
	clinical trials were relatively unchanged as the trials proceeded as planned, with costs of approximately $1.07 million and $1.12
	in 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Share-based
	Expense
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Share-based
	expense increased approximately $745,000 or 526.12% to $886,805 for the year ended December 31, 2015 from $141,634 for the prior
	year. The fluctuation is primarily due to the normal expensing of the fair value of stock option awards granted to R&amp;D personnel
	in September 2015 and December 2014. The December 2014 grants did not have a significant impact on the 2014 shared-based payments
	expense.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Salaries
	and Wages
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Salaries
	and wages decreased by approximately $237,000 or 32.6% to $491,623 for the year ended December 31, 2014 from $729,082 for the
	prior year. The decrease is due to the planned overall reduction in the number of scientific personnel following the closing of
	the U.K. lab facility. The layoffs of three U.K.-based scientific personnel at various points during 2014 were only partially
	offset by the hiring of two new scientists in the U.S. during the same year. The decrease is also partially related to certain
	non-recurring layoff costs incurred in 2014. There were no new R&amp;D personnel hired in 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.5PT; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Rents
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.5PT; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
</I>
	Rent
	expense allocated to research and development increased approximately $11,000, or 14.1% to $89,354 from $78,076 for the year ended
	December 31, 2015 over the comparable period in 2014. During each period, the Company operated the same research and development
	facility, which shares its space with general and administrative employees. While the overall rent expense for this facility did
	not change during these periods, the expense allocated to research and development increased during the year ended December 31,
	2015 due to a change in the Company&rsquo;s method of allocation.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Lab
	Consumables
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 170.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	slight decrease of approximately $2,000 in lab consumables expense is due to normal fluctuations in the amount of those supplies
	required for in-house research activities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Other
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 170.1PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other
	expenses decreased approximately $93,000, or 38.5%, to $148,000 for the year ended December 31, 2015 from $240,834 for the prior
	year. The decrease in other expense results from the net aggregate change of all miscellaneous costs, including an approximately
	$36,000 decrease in computer and equipment costs, approximately $30,000 decrease in recruiting costs and approximately $30,000
	decrease in general travel costs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	General
	and Administrative
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	General
	and administrative (&ldquo;G&amp;A&rdquo;) expenses decreased by approximately $213,000, or 3.2%, to $6,388,000 for the year ended
	December 31, 2015 from $6,600,870 for the prior year. Although the total level of general and administrative costs did not change
	significantly, there were significant changes of certain expenses as follows. Stock compensation expense increased approximately
	$1.04 million due to the normal expensing of the fair value of stock option awards granted to G&amp;A personnel in September 2015
	and December 2014. This increase was offset by a decrease in consulting, accounting and legal professional service costs of approximately
	$810,000 due to certain non-recurring costs during 2014 related to the Company&rsquo;s transition to the U.S. as a U.S. public
	company and short term cost reduction initiatives. In addition, travel expenses and rent and utilities costs in 2015 decreased
	approximately $202,000 and $115,000, respectively, due to the closure of the U.K. office in March 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	other general and administrative expenses resulted in a net decrease of approximately $121,000 for the year ended December 31,
	2015 over the comparable period in 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Change
	in Fair Value of Derivative Liability
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	loss of approximately $2.1 million is recognized on the change in fair value of the Company&rsquo;s compound derivative instrument
	during the year ended December 31, 2015. This change is primarily driven by the change in our stock price from period to period.
	The Company did not have debt instruments with embedded derivatives outstanding during the comparable period in 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Loss
	on Disposal of Subsidiaries
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	loss on disposal of subsidiaries is related to one transaction, the Hive Out Agreement, during the year ended December 31, 2014.
	There were no disposals of subsidiaries during the year ended December 31, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Other
	Income (Expense)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other
	expense decreased approximately $32,000, or 9.8% to $295,033 for the year ended December 31, 2015 from $326,916 in 2014. This
	decrease is primarily related to decreased foreign currency transaction expenses following the change in functional currency of
	the Company&rsquo;s foreign subsidiaries to the U.S. dollar in April 2015. This was offset by an approximately $60,000 loss recorded
	on the issuance of debt in July 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Interest
	Income
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest
	income decreased by approximately $17,000, or 91% to approximately $2,000 for the year ended December 31, 2015 from approximately
	$19,000 in 2014. The decrease is proportional to the decrease in average cash balances held by the Company during the period from
	January 1, 2014 to December 31, 2015 and is not due to any change in investment strategies.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Interest
	Expense
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest
	expense increased by approximately $262,000, or 5,574%, to approximately $267,000 for the year ended December 31, 2015 from approximately
	$5,000 in 2014. The increase in interest expense is primarily due to interest charges associated with the SPA Note. There was
	not a similar promissory note in the comparable period in 2014. The Company also recognized interest expense related to a financing
	arrangement with the landlord of the Company&rsquo;s office and laboratory lease in the U.S., which commenced in January 2014.
</FONT>
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Liquidity
	and Capital Resources
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	At
	December 31, 2015 and 2014 we had working capital deficits of approximately $3.2 million and $78,000, respectively. At December
	31, 2015, we had approximately $0.13 million in cash and $3.3 million in accounts payable and accrued expenses. At December 31,
	2014 we had cash and accounts payable and accrued expenses of $2.5 million and $2.3 million, respectively. Our working capital
	has been reduced in 2015 due to our net loss of $12.5 million that includes $5.3 million net cash used in operating activities
	comprised of approximately $1.8 million in consulting, legal and other professional service fees, approximately $1.5 million in
	salaries and wages, including scientific staff, approximately $1.3 million in program-specific clinical development costs and
	approximately $232,000 in rent and utilities expenses. The $1.8 million in consulting, legal and other professional service fees
	cash outflows in 2015 includes $0.9 million of costs that were incurred during 2014 but paid in 2015. The $1.3 million applied
	to external research and development and clinical program costs primarily related to our ErepoXen&trade; drug candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have historically relied upon equity financing to fund our operations. Since 2005, we have raised approximately $47 million in
	equity financing, including $10 million from the sale of shares to Baxter in January 2014, as well as received $10 million from
	revenue producing activities in the years prior to 2014. Approximately 90% of that revenue is from a single customer, Baxter,
	in connection with milestone receipts and fees for services. We expect the majority of our funding through equity or equity linked
	instruments to continue as a trend for the foreseeable future.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	July 1, 2015, the Company entered into the SPA with Pharmsynthez for the issuance of the SPA Note, which provided net proceeds
	of approximately $3 million in July 2015 for the general working capital needs of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	November 2015 we entered into the APA which included the 1
<SUP>
	st
</SUP>
	amendment to the SPA (the &ldquo;Amended SPA&rdquo;) wherein
	Pharmsynthez agreed to purchase from the Company up to $3.5 million of additional 10% Convertible Promissory Notes (the &ldquo;APA
	Notes&rdquo;). The APA contains a total financing commitment from Pharmsynthez in the amount of $10 million. The APA Notes represent
	bridge financing to be drawn down from this $10 million. As of March 30, 2016, the Company has received net proceeds of $3.5 million
	from the APA Notes, leaving a balance of $6.5 million in funding commitment from Pharmsynthez.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	of March 30, 2016 the Company will be required to raise additional working capital in order to meet its financial obligations
	for the next 12 months.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pharmsynthez,
	as part of the APA, has agreed to invest $6.5 million (the &ldquo;Additional Investment&rdquo;) as part of our planned total capital
	raise and planned up-list to a national securities exchange (the &ldquo;Capital Raise&rdquo;). The $6.5
	million would be a draw down from Pharmsynthez&rsquo;s $10 million total financing commitment. The total amount of financing contemplated
	in the APA is $18.5 million consisting of $3.5 million in the APA Notes (which has been drawn down as of March 30, 2016), $6.5
	million in the Additional Investment and a minimum of $8.5 million in other public offering proceeds. The Company believes this
	total financing will be sufficient for the Company to meet its financial obligations and to continue its planned operations for
	the next 12 months.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	the event that the Company is unable to cause a listing of its securities on a national securities exchange, after March 31, 2016,
	Pharmsynthez shall loan to the Company the Additional Investment on essentially similar terms as the APA Notes. This outcome would
	require the Company to seek additional financing and/or defer certain research and development activities in order to meet its
	financial obligations over the next 12 months.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company is optimistic that it will be successful in obtaining the financing contemplated in the APA; however, there can be no
	assurance that it will be able to do so or, if it is able to, that it can do so under commercially reasonable terms. Further,
	Pharmsynthez&rsquo;s $6.5 million commitment is an important factor in the Capital Raise. If Pharmsynthez becomes unable or unwilling
	to fulfill its $6.5 million commitment, the completion of the Capital Raise will be adversely affected. These financial statements
	have been prepared on a going concern basis; however, if we are unable to complete the Capital Raise for any reason, there will
	be substantial doubt about our ability to continue as a going concern.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Until
	we reach commercialization of our technology or receive significant and regular cash flows from our current collaborations or
	from planned out-licensing of our technology, we expect the trend of accessing capital markets to finance our working capital
	needs to continue.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	only significant cash receipts that we could expect from our current collaborations would be from Baxalta. Due to the uncertainties
	and risks inherent in the clinical development process, we are unable to predict precisely when those receipts may occur, if ever.
	We do not expect any significant receipts to become due within the next 12 months; however, there can be no assurance that future
	receipts will ever become due because they are contingent on positive outcomes from Baxalta&rsquo;s clinical development efforts
	in connection with the Factor VIII drug candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have commenced the process of seeking out-license arrangements for our ErepoXen&trade; technology but are currently unable to
	reliably predict when that process may result in an agreement. Due to the uncertainties inherent in the clinical research process
	and unknown future market conditions, there can be no assurance our ErepoXen&trade; technology will lead to any future income.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Cash
	Flows Used in Operating Activities
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash
	flows used in operating activities for the year ended December 31, 2015 totaled approximately $5.3 million. The $5.3 million includes
	net operating cash uses of approximately $1.78 million in consulting, legal and other professional service fees, approximately
	$1.54 million in salaries and wages, including scientific staff, approximately $1.25 million in program-specific clinical development
	costs and approximately $232,000 in rent and utilities expenses.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash
	flows used in operating activities for the year ended December 31, 2014 totaled approximately $12.3 million. The $12.3 million
	includes net operating cash uses of approximately $7.00 million in consulting, legal and other professional service fees, approximately
	$3.01 million in salaries and wages, including scientific staff, and approximately $1.80 million in program-specific clinical
	development costs.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Cash
	Flows from Investing Activities
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash
	flows used in investing activities for the year ended December 31, 2015 included approximately $2,000 from the purchase of assets
	consisting of laboratory equipment, offset by approximately $8,000 derived from the disposition of certain property and equipment
	during the year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash
	flows used in investing activities for the year ended December 31, 2014 included approximately $58,000 from the purchase of assets
	consisting of office furniture and fixtures and laboratory equipment, partially offset by approximately $5,500 derived from the
	disposition of certain property and equipment during the year.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Cash
	Flow from Financing Activities
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For
	the year ended December 31, 2015, we raised $3.0 million and $0.1 million with the issuances of the SPA Note and a short-term
	promissory note, respectively. From the proceeds of the SPA Note, we repaid our $0.1 million short-term promissory note.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For
	the year ended December 31, 2014 we received $10 million in proceeds in exchange for the issuance of approximately 10.7 million
	shares of common stock to Baxter and we received approximately $102,000 in proceeds in connection with the exercise of stock options
	by the CEO of the company. The proceeds were applied toward our working capital needs during the year. During the year, we repaid
	approximately $286,000 on our loan to an affiliate of the Company.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Off
	Balance Sheet Arrangements
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has no off balance sheet financing arrangements. The Company has two facility lease obligations and written employment
	agreements with three key employees.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Recent
	Accounting Pronouncements
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	March 2016, Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-06,
<I>
	Derivatives and Hedging (Topic 815)
</I>
	(&ldquo;ASU 2016-06&rdquo;). ASU 2016-06 clarifies the requirements for assessing whether
	contingent call or put options that can accelerate the payment of principal on debt instruments are clearly and closely related
	to their debt hosts. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim
	periods within those annual periods. Early application is permitted. The Company is currently evaluating the impact of this new
	standard.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	February 2016, FASB issued ASU 2016-02,
<I>
	Leases (Topic 842)
</I>
	(&ldquo;ASU 2016-02&rdquo;). ASU 2016-02 will require lessees
	to recognize a lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement
	date. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within
	those annual periods. Early application is permitted. The Company is currently evaluating the impact of this new standard.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	November 2015, FASB issued ASU 2015-17,
<I>
	Income Taxes (Topic 740)
</I>
	(&ldquo;ASU 2015-17&rdquo;). ASU 2015-17 simplifies the
	presentation of deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a
	classified statement of financial position. This guidance is effective for annual reporting periods beginning after December 15,
	2016, including interim periods within those annual periods, with early adoption permitted. The Company early adopted ASU 2015-17
	for the year ended December 31, 2015 on a prospective basis, as permitted. There was no impact of early adoption of ASU 2015-17
	on the Company&rsquo;s consolidated financial statements previously reported.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	April 2015, FASB issued ASU 2015-03,
<I>
	Interest &ndash; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation
	of Debt Issuance Costs
</I>
	(&ldquo;ASU 2015-03&rdquo;). ASU 2015-03 requires that debt issuance costs related to a recognized
	debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent
	with debt discounts. This guidance is effective for annual reporting periods beginning after December 15, 2015, and interim periods
	within fiscal years beginning after December 15, 2016, with early adoption permitted. The Company early adopted ASU 2015-03 in
	July 2015, as permitted. There was no impact of early adoption of ASU 2015-03 on the Company&rsquo;s consolidated financial statements
	previously reported.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	August 2014, the FASB issued ASU 2014-15,
<I>
	Presentation of Financial Statements &ndash; Going Concern
</I>
<I>
	(Subtopic 205-40)
</I>
	(&ldquo;ASU 2014-15&rdquo;). ASU 2014-15 defines management&rsquo;s responsibility to evaluate whether there is substantial
	doubt about an organization&rsquo;s ability to continue as a going concern and provides guidance on the related footnote disclosures.
	This guidance is effective for annual reporting periods beginning after December 15, 2016, and interim periods within annual periods
	beginning after December 15, 2016. Early application is permitted. The Company is currently evaluating the impact of this new
	standard.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	May 2014, the FASB issued ASU 2014-09,
<I>
	Revenue from Contracts with Customers (Topic 606)
</I>
	(&ldquo;ASU 2014-09&rdquo;). ASU
	2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 605,
<I>
	Revenue
	Recognition
</I>
	, and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue
	to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity
	expects to be entitled to in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-15,
<I>
	Revenue from
	Contracts with Customers (Topic 606): Deferral of the Effective Date
</I>
	, which defers the effective date of ASU 2014-09 for all
	entities by one year. This guidance is currently effective for annual reporting periods beginning after December&nbsp;15, 2017,
	including interim periods within that reporting period, under either full or modified retrospective approach. Early application
	is permitted as of annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact
	of this new standard on its revenue recognition policy.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has considered other recent accounting pronouncements and concluded that they are either not applicable to the business,
	or that no material effect is expected on the consolidated financial statements as a result of future adoption.
</FONT>
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	7A &ndash; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0 0PT 24.5PT; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are not required to provide the information required by this Item because we are a smaller reporting company.
</FONT>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET_RISK>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 8%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item 8
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 92%; FONT-WEIGHT: BOLD">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 90%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Report of Independent Registered Public Accounting
	Firm (Marcum LLP)
</P>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	F-1
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Report of Independent Registered Public Accounting Firm (Ernst &amp; Young LLP)
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-2
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Balance Sheets as of December 31, 2015 and 2014
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-3
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Comprehensive Loss for the years ended December 31, 2015 and 2014
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-4
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Cash Flows for the years ended December 31, 2015 and 2014
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-5
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Changes in Stockholders&rsquo; Equity for the years ended December 31, 2015 and 2014
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-6
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Notes to the Consolidated Financial Statements
</FONT>
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	F-7
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	REPORT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.5PT">
	The Board
	of Directors and Shareholders of Xenetic Biosciences, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	We have audited the
	accompanying consolidated balance sheet of Xenetic Biosciences, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2015, and the
	related consolidated statements of comprehensive loss, changes in stockholders&rsquo; equity, and cash flows for the year ended
	December 31, 2015. Our audit also includes the financial statement schedule. These consolidated financial statements and schedule
	are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these consolidated financial
	statements based on our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	We conducted our audit
	in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
	plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
	We were not engaged to perform an audit of the Company&rsquo;s internal control over financial reporting. Our audit included consideration
	of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
	but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
	Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
	disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
	and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In our opinion, the
	consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position
	of Xenetic Biosciences, Inc. at December 31, 2015, and the consolidated results of its operations and its cash flows for the year
	ended December 31, 2015, in conformity with accounting principles generally accepted in the United States of America. Also, in
	our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a
	whole, presents fairly, in all material respects, the information set forth therein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The
	accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
	in Note 1 to the financial statements, the Company has had recurring net losses and continues to experience negative cash
	flows from operations. These conditions raise substantial doubt about its ability to continue as a going concern.
	Management&rsquo;s plans regarding those matters also are described in Note 1. The financial statements do not include any
	adjustments that might result from the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-INDENT: -11.5PT">
	/s/ Marcum LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-INDENT: -11.5PT">
	Boston, MA
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-INDENT: -11.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	March 30, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	REPORT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.5PT">
	The Board
	of Directors and Shareholders of Xenetic Biosciences, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -11.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	We have
	audited the accompanying consolidated balance sheet of Xenetic Biosciences, Inc. (the &ldquo;Company&rdquo;) as of December
	31, 2014, and the related consolidated statements of comprehensive loss, changes in stockholders&rsquo; equity, and cash
	flows for the year ended December 31, 2014. Our audit also includes the financial statement schedule. These financial
	statements and schedule are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion
	on these financial statements based on our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	We conducted our audit
	in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
	plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.
	We were not engaged to perform an audit of the Company&rsquo;s internal control over financial reporting. Our audit included consideration
	of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
	but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
	Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
	disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
	and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In our opinion,
	the financial statements referred to above present fairly, in all material respects, the consolidated financial position of
	Xenetic Biosciences, Inc. at December 31, 2014, and the consolidated results of its operations and its cash flows for the year ended December 31, 2014, in conformity with US generally accepted accounting principles. Also, in
	our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as
	a whole, presents fairly, in all material respects, the information set forth therein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The accompanying consolidated
	financial statements have been prepared assuming that the Company will continue as a going concern. As disclosed in Note 1 to the
	Financial Statements, the Company&rsquo;s recurring losses from operations and its requirement to raise funds to continue operations
	beyond April 2015, raise substantial doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard
	to these matters are also described in Note 1.&nbsp;The 2014 consolidated financial statements do not include any adjustments to
	reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities
	that may result from the outcome of this uncertainty.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-INDENT: -11.5PT">
	/s/ Ernst &amp; Young LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-INDENT: -11.5PT">
	Reading, United Kingdom
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 11.5PT; TEXT-INDENT: -11.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	April 15, 2015
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	XENETIC BIOSCIENCES, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED BALANCE SHEETS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 70%; PADDING-LEFT: 10PT">
	Cash
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	132,229
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	2,507,401
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,510
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	66,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Prepayment on acquisition
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,744,517
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Prepaid expenses and other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	247,298
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	204,012
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Total current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,190,554
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,777,413
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property and equipment, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	62,021
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	119,449
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Goodwill
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,283,379
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,465,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Indefinite-lived intangible assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,243,128
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,754,857
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other assets
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	129,306
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	199,270
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total assets
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	16,908,388
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	16,316,146
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	LIABILITIES AND STOCKHOLDERS' EQUITY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,788,521
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	852,760
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,487,046
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,409,691
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Hybrid debt instrument, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,652,749
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Other current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,098
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41,472
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Loans due to related parties
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	395,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	395,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Total current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,342,414
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,698,923
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,918,518
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,080,097
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	38,791
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	56,383
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,299,723
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	5,835,403
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Commitments and contingent liabilities (Note 14)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Stockholders' equity:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Common stock, $0.001 par value; 1,500,000,000 and 215,456,000 shares authorized as of December 31, 2015 and December 31, 2014, respectively; 162,013,011 and 149,985,476 shares issued as of December 31, 2015 and December 31, 2014, respectively; 151,324,817 and 139,297,282 shares outstanding as of December 31, 2015 and December 31, 2014, respectively
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	162,013
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	149,986
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Additional paid in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	99,605,997
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90,660,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accumulated deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(88,131,899
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(75,624,428
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accumulated other comprehensive income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	253,734
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	575,676
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Treasury stock
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,281,180
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,281,180
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Total stockholders' equity
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,608,665
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	10,480,743
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total liabilities and stockholders' equity
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	16,908,388
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	16,316,146
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	accompanying notes are an integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	XENETIC BIOSCIENCES, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE
	LOSS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	YEAR ENDED DECEMBER 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Operating costs and expenses:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(3,434,016
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(6,323,896
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	General and administrative
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,388,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(6,600,870
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Loss from operations
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(9,822,016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(12,924,766
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other income (expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Change in fair value of derivative liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,125,117
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Loss on disposal of subsidiaries
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,069,675
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Other expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(295,033
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(326,916
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Interest income
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,694
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,959
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Interest expense
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(266,999
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(4,706
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,685,455
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,382,338
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12,507,471
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(14,307,104
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other comprehensive loss from foreign currency translation adjustment
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(321,942
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(324,578
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT">
	Total comprehensive loss
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(12,829,413
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(14,631,682
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net loss per share of common stock, basic and diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.09
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(0.11
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Weighted-average shares of common stock outstanding, basic and diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	140,397,488
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	135,896,022
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<BR CLEAR="ALL">
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	XENETIC BIOSCIENCES, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	YEAR ENDED DECEMBER 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	CASH FLOWS FROM OPERATING ACTIVITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(12,507,471
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(14,307,104
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Depreciation and amortization
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	56,115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	88,689
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Amortization of hybrid debt instrument discount
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	108,527
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Non-cash interest expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	153,791
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,594,113
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,513,238
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Warrant expense for services
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	933,195
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	239,889
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Change in fair value of derivative liability
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,125,117
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Loss on issuance of hybrid debt instrument
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	59,612
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Hybrid debt instrument issuance costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(30,933
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Loss on disposal of subsidiaries
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,069,675
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Fee paid on disposal of subsidiaries
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(430,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Foreign currency translation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	369,947
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(353,952
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Other non-cash transactions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(127,875
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Other receivables, prepayments and other assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	21,227
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(24,468
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Accounts payable, accrued expenses and other liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	943,909
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(479,015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash used in operating activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,300,726
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(12,683,048
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	CASH FLOWS FROM INVESTING ACTIVITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Purchases of property and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,663
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(57,669
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Disposition of property and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,882
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5,487
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Cash acquired from acquisition
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43,502
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Cash transferred in connection with Hive Out Agreement
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(43,502
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash provided by (used in) investing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	6,219
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(52,182
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	CASH FLOWS FROM FINANCING ACTIVITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Proceeds from issuance of debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Payments on debt
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(100,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Proceeds from issuance of common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Proceeds from exercise of stock options
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	101,933
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Payments on loan from related party
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(286,124
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	3,000,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	9,815,809
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Effect of exchange rate change on cash
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(80,665
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	587,336
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net change in cash, excluding restricted cash
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,375,172
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,332,085
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Cash at beginning of period
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,507,401
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,839,486
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Cash at end of period
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	132,229
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,507,401
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	SUPPLEMENTAL CASH FLOW INFORMATION:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash paid for interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	592
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,706
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_CASH_FLOW>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
	SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Interest paid in common stock
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	75,935
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Non-cash issuance of common stock in connection with pending asset acquisition
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,744,517
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Non-cash issuance of warrants in
	connection with debt
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,626,344
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Non-cash recording of derivative
	liability in connection with debt
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,419,105
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Equity consideration transferred in the acquisition
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,750,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Repurchase and cancellation of common stock in disposal of subsidiaries
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(3,750,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	accompanying notes are an integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	XENETIC BIOSCIENCES, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF CHANGES IN
	STOCKHOLDERS&rsquo; EQUITY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="5" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Common
	Stock
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Additional
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Accumulated Other Comprehensive
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Total
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Number
	of Shares
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Par Value ($0.001)
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Paid in
<BR>
	Capital
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Accumulated Deficit
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Income
<BR>
	(Loss)
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Treasury Stock
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Stockholders' Equity
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 5PT; TEXT-INDENT: -5PT; WIDTH: 18%">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance
	as of January 1, 2014
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	130,575,516
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	130,576
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	75,175,039
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(58,306,999
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	900,254
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(5,281,180
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	12,617,690
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Exercise of stock options
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,984,080
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,984
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	99,949
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	101,933
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of common stock
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	13,939,971
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	13,940
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	10,797,256
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	10,811,196
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of warrants
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	239,889
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	239,889
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Deemed issuance of shares in reverse merger
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	13,500,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	13,500
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	3,736,500
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	3,750,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Repurchase and cancellation of shares in Hive
	Out Agreement
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(10,000,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(10,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(90,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(3,010,325
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(3,110,325
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Repurchase and cancellation of shares in Acquisition
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(14,091
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(14
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	14
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Share-based payments
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	702,042
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	702,042
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Net loss
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(14,307,104
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(14,307,104
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Foreign currency translation
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(324,578
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(324,578
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 5PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance
	as of December 31, 2014
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	149,985,476
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	149,986
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	90,660,689
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(75,624,428
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	575,676
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(5,281,180
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	10,480,743
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of common stock
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,027,535
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,027
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	336,313
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	337,340
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of common stock in connection with
	pending asset acquisition
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	11,000,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	11,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	3,733,517
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	3,744,517
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of warrants
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	933,195
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	933,195
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Issuance of warrants in connection with debt
	(net of issuance costs of $16,769)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,609,575
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,609,575
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Settlement of accrued interest in common stock
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	75,935
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	75,935
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Share-based payments
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,256,773
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	2,256,773
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Net loss
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(12,507,471
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(12,507,471
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Foreign currency translation
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(321,942
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&ndash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(321,942
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.5PT; PADDING-LEFT: 5PT; TEXT-INDENT: -5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Balance
	as of December 31, 2015
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	162,013,011
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	162,013
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	99,605,997
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(88,131,899
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	253,734
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	(5,281,180
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	6,608,665
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	accompanying notes are an integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	XENETIC BIOSCIENCES, INC.
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	1.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	The Company
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Background
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Xenetic Biosciences,
	Inc. (the &ldquo;Company&rdquo;), incorporated in the state of Nevada and based in Lexington, Massachusetts, is a clinical stage
	biopharmaceutical company that is focused on the discovery, development and planned commercialization of a new generation of human
	drug therapies for the treatment of a variety of conditions including anemia, refractory Acute Myeloid Leukemia, Cystic Fibrosis
	and certain other cancers based upon its proprietary and patented drug delivery platform systems and drug development collaborations
	with major third party pharmaceutical companies around the world.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company&rsquo;s
	core technologies include PolyXen&trade; a platform for creating next generation biologic drugs by extending the efficacy, safety
	and half-life of existing biologic drugs, OncoHist&trade;, for the development of novel oncology drug therapies focused on orphan
	indications in humans, and ImuXen&trade;, for the development of vaccines that can simultaneously deliver multiple active pharmaceutical
	ingredients. The Company is also developing a broad pipeline of drug candidates for next generation biologics and novel oncology
	therapeutics in a number of orphan disease indications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Going Concern and Management&rsquo;s
	Plan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	While these consolidated
	financial statements have been prepared on a going concern basis, if the Company does not successfully raise additional working
	capital, there can be no assurance that the Company will be able to continue its operations and these conditions raise substantial
	doubt about its ability to continue as a going concern.&nbsp; The accompanying consolidated financial statements do not include
	any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of
	liabilities that may result should the Company be unable to continue as a going concern.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In March 2016, the
	Company engaged an investment banking firm to assist with a proposed sale of the Company&rsquo;s
	securities. The Company is optimistic that it will be successful in obtaining financing, however there can be no assurance that
	it will be able to do so or, if it is able to, that is can do so under commercially reasonable terms. In the event the Company
	is unsuccessful in this proposed sale, the Company will plan to rely upon proceeds from the sale of up to $6.5 million in securities
	to OJSC Pharmsynthez (&ldquo;Pharmsynthez&rdquo;) as provided for in the AS Kevelt Asset Purchase Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	AS Kevelt Asset Purchase
	Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In November
	2015, the Company entered into an Asset Purchase Agreement (the &ldquo;APA&rdquo;) with AS Kevelt, an Estonian company
	(&ldquo;Kevelt&rdquo;), and Pharmsynthez, parent of Kevelt (together referred to as the &ldquo;Sellers&rdquo;). Pursuant to
	the APA, Kevelt will transfer to the Company certain intellectual property rights held by the Sellers with respect to
	the immunomodulatory product candidate Virexxa&reg; held by Kevelt and the Sellers will grant the Company the worldwide right
	to develop, market and license Virexxa&reg; for certain uses, except for excluded uses in Russia, the Commonwealth
	of Independent States and certain other countries. In consideration, the Company will issue to Pharmsynthez 100.5 million
	shares of its common stock. The APA also provides for the Company&rsquo;s issuance of 10% Senior Secured Convertible
	Promissory Notes of up to $3.5 million to Pharmsynthez (the &ldquo;APA Notes&rdquo;) and certain warrants to purchase a
	number of shares equal to the issuable shares of the Company&rsquo;s stock upon conversion of the APA Notes. There is also a
	provision in the APA for the contingent sale of up to $6.5 million of the Company&rsquo;s common stock in the event of a
	qualifying capital raise. Also as part of the APA, Dr. Dmitry Genkin and Kirill Surkhov, shareholders
	and founders of Pharmsynthez, will assign a U.S. provisional patent application to the Company in exchange for 11 million
	shares of the Company&rsquo;s common stock. The Company issued 11 million shares in November 2015 as a prepayment toward
	completing the APA transaction, recording $3.74 million as the proportional fair value of the total consideration to be
	recorded upon the completion of the APA transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In connection with
	the APA, certain terms in the Securities Purchase Agreement (the &ldquo;SPA&rdquo;) with Pharmsynthez issued in July 2015 were
	modified. See Note 8,
<I>
	Hybrid Debt Instrument
</I>
	, for further discussion of the SPA. As of December 31, 2015, the APA was not
	yet consummated and is contingent upon the parties meeting their respective closing conditions as set forth in the APA. The APA
	transaction is expected to be completed during 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	2014 Business Combination
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	On January&nbsp;23,
	2014, the Company consummated a reverse merger (the &ldquo;Acquisition&rdquo;) pursuant to a written plan of reorganization, in
	which the Company merged with Xenetic Biosciences (UK) Limited (formerly Xenetic Biosciences plc) (&ldquo;Xenetic UK&rdquo;), a
	company incorporated in England and Wales under the Companies Act of 1985, such that Xenetic UK became a wholly owned subsidiary
	of the Company. Upon completion of the Acquisition, the Company acquired all issued and outstanding shares of capital stock of
	Xenetic UK. As a result, 132,545,504 shares of the Company&rsquo;s common stock were newly issued and, immediately following the
	Acquisition, there were 136,045,504 shares of common stock issued and outstanding. At that time, because former Xenetic UK shareholders
	owned approximately 97% of the combined company on a fully diluted basis and all members of the combined company&rsquo;s executive
	management were from Xenetic UK, Xenetic UK was deemed to be the acquiring company for accounting purposes and the transaction
	was accounted for as a reverse acquisition in accordance with accounting principles generally accepted in the United States (&ldquo;US
	GAAP&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Prior to the Acquisition,
	the Company changed its name from General Sales and Leasing, Inc. to Xenetic Biosciences, Inc. As used in these consolidated financial
	statements, unless otherwise indicated, all references herein to &ldquo;Xenetic&rdquo;, the &ldquo;Company&rdquo;, &ldquo;we&rdquo;
	or &ldquo;us&rdquo; refer to Xenetic Biosciences, Inc. and its wholly owned subsidiaries.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	2.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Summary of Significant Accounting Policies
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Preparation of Financial
	Statements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	These
	consolidated financial statements have been prepared on the assumption that the Company will be able to realize its assets
	and discharge its liabilities in the normal course of business. This assumption is presently in question and contingent upon
	the Company&rsquo;s ability to raise additional working capital. The financial statements do not include any adjustments
	relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that
	might be necessary should the Company be unable to continue as a going concern.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Certain
	prior period amounts have been reclassified to conform to the presentation for the current period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.45PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Principles of Consolidation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The financial statements
	of the Company include the accounts of Xenetic UK and its wholly owned subsidiaries: Lipoxen Technologies Limited (&ldquo;Lipoxen&rdquo;),
	Xenetic Bioscience, Incorporated, and SymbioTec GmbH (&ldquo;SymbioTec&rdquo;). All material intercompany balances and transactions
	have been eliminated on consolidation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Use of Estimates
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The consolidated
	financial statements and accompanying notes are prepared in accordance with U.S. generally accepted accounting principles
	(&ldquo;U.S. GAAP&rdquo;). The preparation of the financial statements in accordance with US GAAP requires management to
	make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts
	of revenue and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes
	may differ materially from management&rsquo;s estimates, judgments and assumptions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Change in Accounting
	Principle
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the second
	quarter of 2015, the Company elected to apply pushdown accounting to the Company&rsquo;s acquisition of SymbioTec that occurred
	in 2012. Pushdown accounting refers to the use of the acquirer&rsquo;s basis in the preparation of the acquiree&rsquo;s separate
	financial statements as the new basis of accounting for the acquiree. Application of pushdown accounting is treated as a change
	in accounting principle and was applied retrospectively to the Company&rsquo;s consolidated financial statements. This
	change resulted in no impact to the consolidated financial statements for the year ended December 31, 2015 or 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Functional Currency Change
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Effective April 1,
	2015, the functional currency of the Company&rsquo;s foreign subsidiaries changed from the British Pound Sterling to the United
	States (&ldquo;U.S.&rdquo;) dollar. The changes in the economic facts and circumstances that caused the functional currency to
	change to that of the parent company include: the closing of the Company&rsquo;s last office outside of the U.S. during the first
	quarter of 2015, a shift of financial dependence of the subsidiaries to the parent and the growth of the Company&rsquo;s operations
	in U.S. dollar-denominated expenses. The Company translated assets and liabilities of these foreign subsidiaries at the exchange
	rate in effect at the balance sheet date and included accumulated net translation adjustments in equity as a component of accumulated
	other comprehensive loss. The change in functional currency is applied on a prospective basis. Therefore, any gains and losses
	that were previously recorded in accumulated other comprehensive loss remain unchanged through March 31, 2015. Foreign currency
	transaction gains and losses are the result of exchange rate changes on transactions denominated in currencies other than the
	functional currency. The remeasurement of those foreign currency transactions is included in determining net income or loss for
	the period of exchange.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Foreign
	Currency Translation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company&rsquo;s
	reporting currency is U.S. dollars. During the years ended December 31, 2015 and 2014, the Company had operations in the U.S.,
	United Kingdom (&ldquo;U.K.&rdquo;) and Germany. Assets and liabilities of foreign operations were translated to U.S. dollars at
	the exchange rate in effect at the balance sheet date and revenue and expenses at the average exchange rate for the period. Gains
	and losses from the translation of the consolidated financial statements of foreign subsidiaries into U.S. dollars were included
	in stockholders&rsquo; equity as a component of other comprehensive income. The Company did not record tax provisions or benefits
	for the net changes in foreign currency translation adjustments, as the Company intends to permanently reinvest undistributed earnings
	in its foreign subsidiaries. Following the change in the functional currency of the Company&rsquo;s foreign subsidiaries to the
	U.S. dollar on April 1, 2015, it is no longer necessary to record gains and losses from the translation of the consolidated financial
	statements of foreign subsidiaries from a foreign functional currency into the reporting currency.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Realized
	and unrealized gains and losses resulting from foreign currency transactions arising from exchange rate fluctuations on
	balances denominated in currencies other than the functional currencies, are recognized in &ldquo;Other (expense)
	income&rdquo; in the consolidated statements of comprehensive loss. Monetary assets and liabilities that are denominated in a
	currency other than the functional currency are re-measured to the functional currency using the exchange rate at the balance
	sheet date and gains or losses are recorded within the &ldquo;Other income (expense)&rdquo; section of the consolidated
	statements of comprehensive loss.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Correction of Identified
	Errors
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the second
	quarter of 2015, the Company identified an error in the consolidated financial statements related to the accounting for foreign
	currency matters. One of the Company&rsquo;s subsidiary&rsquo;s functional currency had been incorrectly designated as the Euro
	instead of British Pound Sterling during the period January 1, 2013 through March 31, 2015. As a result, certain applicable financial
	results of this entity were being translated to the reporting currency when they should have been first remeasured into the functional
	currency. In addition, the Company identified an error in the consolidated financial statements related to the pushdown accounting
	of that subsidiary. The new basis of accounting of the acquired entity formed as a result of the acquisition was not first remeasured
	into the functional currency before being translated to the reporting currency.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The correction of
	the errors identified above resulted in the recognition of foreign currency net gains and foreign currency translation net losses.
	We concluded that these adjustments were not material to the Company&rsquo;s financial position or results of operations for any
	of the prior periods presented. Therefore, we recognized the cumulative impact during the three months ended June 30, 2015, which
	resulted in a net gain in other income (expenses) in the consolidated statement of comprehensive loss of $0.24 million for the
	year ended December 31, 2015 and a cumulative impact in accumulated other comprehensive income in the consolidated balance sheet
	of $0.31 million as of June 30, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Fair Value of
	Financial Instruments
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	ASC Topic 820
<I>
	Fair
	Value Measurement
</I>
	defines fair value as the price that would be received to sell an asset or be paid to transfer a liability
	in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy,
	which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon
	the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in
	active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
	Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources
	with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there
	is little, if any, market activity for the asset or liability at the measurement date. See Note 9,
<I>
	Fair Value Measurements
</I>
	,
	for discussion of the Company&rsquo;s fair value measurements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Cash, Cash Equivalents
	and Investments
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company considers
	all highly liquid investments with maturities of 90 days or less from the date of purchase to be cash equivalents. Investments
	with original maturities of greater than 90 days from the date of purchase but less than one year from the balance sheet date are
	classified as short-term investments, while investments with maturities of one year or beyond from the balance sheet date are classified
	as long-term investments. Management determines the appropriate classification of its cash equivalents and investment securities
	at the time of purchase and re-evaluates such determination as of each balance sheet date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Restricted Cash
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	As
	of December 31, 2015 and 2014, restricted cash represents a certificate of deposit that matures annually, and secures the Company&rsquo;s
	outstanding letter of credit of $66,000 for the operating lease for office and laboratory space in Lexington, Massachusetts. The
	letter of credit is required to be maintained
</FONT>
	through
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	the term of the lease, which
	expires in January 2019.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Concentration
	of Credit Risk
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Financial instruments
	that subject the Company to concentrations of credit risk include cash and cash equivalents. The Company maintains cash and cash
	equivalents with various major financial institutions. The Company performs periodic evaluations of the relative credit standing
	of these financial institutions and limits the amount of credit exposure with any one institution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Property and Equipment
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company records
	property and equipment at cost less accumulated depreciation. Expenditures for major renewals and improvements which extend the
	life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating
	expense as incurred. The Company calculates depreciation using the straight-line method over the estimated useful lives of the
	assets:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 29%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	Asset Classification
</TD>
<TD STYLE="WIDTH: 2%; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Estimated Useful Life
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Laboratory equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	3 years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Office and computer equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	3 years
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Leasehold improvements
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	5 years or the remaining term of the lease, if shorter
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Furniture and fixtures
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	5 years
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company eliminates
	the cost of assets retired or otherwise disposed of, along with the corresponding accumulated depreciation, from the related accounts,
	and the resulting gain or loss is reflected in the results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Indefinite-Lived Intangible
	Assets
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Acquired indefinite-lived
	intangible assets consist of In-Process Research and Development (&ldquo;IPR&amp;D&rdquo;) related to the Company&rsquo;s business
	combination with SymbioTec, which was recorded at fair value on the acquisition date. IPR&amp;D intangible assets are considered
	indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. Substantial
	additional research and development may be required before the Company&rsquo;s IPR&amp;D reaches technological feasibility. Upon
	completion of the IPR&amp;D project, the IPR&amp;D assets will be amortized over their estimated useful lives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In accordance with
	ASC Topic 350,
<I>
	Intangibles - Goodwill and Other
</I>
	(&ldquo;ASC 350&rdquo;), the Company assesses intangible assets with indefinite
	lives for impairment at least annually as of October&nbsp;1, or when events or changes in the business environment indicate the
	carrying value may not be fully recoverable. T
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	he
</FONT>
	Company also has the option to first
	assess qualitative factors to determine whether the existence of events or
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	circumstances
	leads to the determination that it is more likely than not (that is, a likelihood of more than 50%) that the acquired IPR&amp;D
	is impaired. If the Company chooses to first assess the qualitative factors and it is determined that it is not more likely than
	not acquired IPR&amp;D is impaired, the Company is not required to take further action to test for impairment. The Company also
	has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which the Company may choose
	to perform in some periods but not in others.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	No impairment was
	recorded during the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Goodwill
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Goodwill is comprised
	of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable
	intangible assets acquired. Goodwill is not amortized, but in accordance with ASC 350, the Company assesses goodwill for impairment
	at least annually, or when events or changes in the business environment indicate the carrying value may not be fully recoverable.
	The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances
	leads to the determination that it is more likely than not (that is, a likelihood of more than 50%) that goodwill is impaired.
	If the Company chooses to first assess qualitative factors and it is determined that it is not more likely than not goodwill is
	impaired, the Company is not required to take further action to test for impairment. The Company also has the option to bypass
	the qualitative assessment and perform only the quantitative impairment test, which the Company may choose to do in some periods
	but not in others. The Company performs its annual impairment review as of October&nbsp;1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	No impairment was
	recorded during the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Impairment
	of Long-Lived Assets
</I>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In accordance with
	ASC Topic 360
<I>
	Property, Plant and Equipment
</I>
	, the Company reviews long-lived assets to be held and used, including property
	and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset
	group may not be fully recoverable. No such impairments were recorded during the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	Evaluation
	of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group
	and its eventual disposition. Impairment, if any, is calculated as the amount by which an asset&rsquo;s carrying value exceeds
	its fair value, typically using discounted cash flows to determine fair value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Embedded Derivatives
	Related to Debt Instruments
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.45PT">
	Embedded derivatives
	that are required to be bifurcated from their host contract are evaluated and valued separately from the host contract (i.e., the
	debt instrument). Features of the Company&rsquo;s debt instrument that meet the definition of a derivative and the criteria for
	separate accounting include the conversion feature and certain put options. Embedded derivatives are valued individually and recorded
	as a compound derivative. The compound derivative is presented together with the host debt instrument and the related debt discount
	on a combined basis. Changes in the estimated fair value of the bifurcated embedded derivatives are reported as gains and losses
	in the consolidated statement of comprehensive loss each reporting period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Revenue Recognition
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company enters
	into supply, license and collaboration arrangements with pharmaceutical and biotechnology partners, some of which include royalty
	agreements based on potential net sales of approved commercial pharmaceutical products. The Company recognizes revenue in accordance
	with the authoritative guidance, ASC Topic 605,
<I>
	Revenue Recognition
</I>
	. The Company recognizes revenue when all of the following
	criteria are met: (i)&nbsp;persuasive evidence of an arrangement exists, (ii)&nbsp;delivery (or passage of title) has occurred
	or services have been rendered, (iii)&nbsp;the seller&rsquo;s price to the buyer is fixed or determinable, and (iv)&nbsp;collectability
	is reasonably assured.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The terms of the Company&rsquo;s
	license agreements include delivery of an Intellectual Property (&ldquo;IP&rdquo;) license to a collaboration partner. The Company
	may be compensated under license arrangements through a combination of non-refundable upfront payments, development and regulatory
	objective payments and royalty payments on future product sales by partners. Non-refundable upfront payments and development and
	regulatory objective payments received by the Company in license and collaboration arrangements that include future obligations,
	such as supply obligations, are recognized ratably over the Company&rsquo;s expected performance period under each respective arrangement.
	The Company makes its best estimate of the period over which the Company expects to fulfil the Company&rsquo;s performance obligations,
	which may include technology transfer assistance, research activities, clinical development activities, and manufacturing activities
	from development through the commercialization of the product. Given the uncertainties of these collaboration arrangements, significant
	judgment is required to determine the duration of the performance period. Non-refundable upfront license fees received, whereby
	continued performance or future obligations are considered inconsequential or perfunctory to the relevant licensed technology,
	are recognized as revenue upon delivery of the technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company expects
	to recognize royalty revenue in the period of sale, based on the underlying contract terms, provided that the reported sales are
	reliably measurable and the Company has no remaining performance obligations, assuming all other revenue recognition criteria are
	met.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Reimbursements for
	research and development services completed by the Company related to the collaboration agreements are recognized in operations
	as revenue on a gross basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company&rsquo;s
	license and collaboration agreements with certain collaboration partners could also provide for future payments to the Company
	based solely upon the performance of the respective collaboration partner in consideration of deadline extensions or upon the achievement
	of specified sales volumes of approved drugs. For such payments, the Company expects to recognize the payments as revenue when
	earned under the applicable contract terms on a performance basis or ratably over the term of the agreement. These payments may
	also be recognized as revenue when continued performance or future obligations by the Company are considered inconsequential or
	perfunctory.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Research and
	Development Expenses
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Research and development
	expenses consist of expenses incurred in performing research and development activities, including compensation and benefits, facilities
	expenses, overhead expenses, clinical trial and related clinical manufacturing expenses, fees paid to clinical research organizations
	and clinical manufacturing organizations and other outside expenses. The Company expenses research and development costs as incurred.
	The Company expenses upfront, non-refundable payments made for research and development services as obligations are incurred. The
	value ascribed to intangible assets acquired but which have not met capitalization criteria is expensed as research and development
	at the time of acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Share-based Payments
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<I>
	Stock options
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company grants
	share-based payments in the form of options to employees and non-employees, Joint Share Ownership Plan (&ldquo;JSOP&rdquo;) awards
	to employees, as well as agreements to issue common stock in exchange for services provided by non-employees. The Company measures
	share-based payments to employees in accordance with ASC Topic 718,
<I>
	Compensation &ndash; Stock Compensation
</I>
	and to non-employees
	in accordance with ASC Topic 505,
<I>
	Equity
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Stock option compensation
	expenses are based on the fair value of the option calculated using the Black-Scholes option pricing model. Determining the appropriate
	fair value model and related assumptions requires judgment, including estimating share price volatility and expected terms of the
	awards. The expected volatility rates are estimated based on the actual volatility of the Company and of comparable public companies
	over the expected term. The expected terms represent the time that options are expected to be outstanding. The Company estimates
	forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates.
	The Company has not paid dividends and does not anticipate paying cash dividends in the foreseeable future and, accordingly, uses
	an expected dividend yield of zero. The risk-free interest rate is based on the rate of US Treasury securities with maturities
	consistent with the estimated expected term of the awards. Upon exercise, stock options are redeemed for newly issued shares of
	common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	For employee options
	that vest based solely on service conditions, the fair value measurement date is generally on the date of grant and the related
	compensation expense, less expense for expected forfeitures, is recognized on a straight-line basis over the requisite vesting
	period of the awards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	For non-employee options,
	the fair value measurement date is the earlier of the date the performance of services is complete or the date the performance
	commitment has been reached. The Company generally determines that the fair value of the stock options is more reliably measurable
	than the fair value of the services received. Compensation expense related to stock options granted to non-employees that vest
	based solely on service conditions is subject to re-measurement at each reporting period until the options vest and is recognized
	on a straight-line basis over the requisite vesting period of the awards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<I>
	Common stock awards
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company grants
	common stock awards to non-employees in exchange for services provided. The Company generally measures the fair value of these
	awards using the fair value of the services provided as it is a more reliable measure of the fair value of the awards. The fair
	value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards
	is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the
	settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner
	and charged to the same account as if such settlements had been made in cash.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<I>
	Joint Share Ownership Plan
	awards
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company measures
	the fair value of JSOP awards using Monte Carlo simulations based on the terms of the plan, which includes vesting conditions based
	on the achievement of certain market conditions in the form of share price hurdles. Determination of the appropriate fair value
	model and related assumptions requires judgment, including estimating share price volatility and the expected term of the awards.
	Accordingly, the Company recognizes compensation expense related to its JSOP awards using a graded vesting model.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Warrants
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	connection with certain financing, consulting and collaboration arrangements, the Company issues warrants to purchase shares
	of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by
	the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes
	option pricing model as of the measurement date. Warrants issued to collaboration partners in conjunction with the issuance
	of common stock are initally recorded at fair value as a reduction in additional paid-in capital of the common stock
	issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	All other warrants are recorded at fair
	value as expense over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted
	in connection with ongoing arrangements are more fully described in Note 11,
<I>
	Stockholders&rsquo; Equity
</I>
	.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Income Taxes
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company accounts
	for income taxes using the liability method in accordance with ASC Topic 740,
<I>
	Income Taxes
</I>
	. Under this method, deferred
	tax assets and liabilities are determined based on temporary differences resulting from the different treatment of items for tax
	and financial reporting purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to
	taxable income in the years in which those temporary differences are expected to reverse. Additionally, the Company must assess
	the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The Company evaluates the recoverability
	of its deferred tax assets on a quarterly basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Basic and Diluted Net
	Loss per Share
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company computes
	basic net loss per share by dividing net loss attributable to common stockholders by the weighted-average number of shares of common
	stock outstanding during the period. The Company computes diluted net loss per share after giving consideration to the dilutive
	effect of stock options that are outstanding during the period, except where such non-participating securities would be anti-dilutive.
	The Company&rsquo;s JSOP awards, prior to exercise, are considered treasury shares by the Company and thus do not impact the Company&rsquo;s
	net loss per share calculation. As of December 31, 2015 and 2014, there were 10,688,194 JSOP awards issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Basic and
	diluted net loss per share are the same for the years ended December 31, 2015 and 2014 as the Company was in a net loss
	position. Potentially dilutive non-participating securities have not been included in the calculations of diluted net loss
	per share, as their inclusion would be anti-dilutive. As of December 31, 2015 and 2014, approximately 12.03 million and 11.87
	million potentially dilutive securities were deemed anti-dilutive.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Segment Information
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Operating segments
	are identified as components of an enterprise about which separate discrete financial information is available for evaluation
	by the chief operating decision maker, who is the Company&rsquo;s Chief Executive Officer, in making decisions on how to allocate
	resources and assess performance. The Company views its operations and manages its business in one operating segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<B>
<I>
</I>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Operating Leases
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	Company leases an administrative and laboratory facility under an operating lease. Lease agreements may include rent holidays,
	rent escalation clauses and tenant improvement allowances. The Company recognizes scheduled rent increases on a straight-line basis
	over the lease term beginning with the date the Company takes possession of the leased space.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
<B>
<I>
	Acquisitions
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company has a
	history of engaging in acquisition transactions that require the Company to evaluate whether the transaction meets the criteria
	of a business combination and, in some cases, whether it meets the definition of a reverse merger. For those acquisitions that
	meet the criteria for a reverse merger, the Company evaluates the entities involved to distinguish the appropriate accounting acquirer
	and acquiree according to ASC 805. If the transaction does not meet the business combination requirements, the transaction is accounted
	for as an asset acquisition or recapitalization and no goodwill is recognized. If the acquisition meets the definition of a business
	combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities
	assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated
	fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically
	determined by using either estimates of replacement costs or discounted cash flow valuation methods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	When determining the
	fair value of tangible assets acquired, the Company estimates the cost to replace the asset with a new asset, taking into consideration
	such factors as age, condition and the economic useful life of the asset. When determining the fair value of intangible assets
	acquired, the Company uses judgment to estimate the applicable discount rate, growth rates and the timing and amount of future
	cash flows. The fair value of assets acquired and liabilities assumed is typically determined using the assistance of an independent
	third party specialist.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Business combination
	related costs are expensed in the period in which the costs are incurred and the services are received. Asset acquisition related
	costs are generally capitalized as a component of cost of the assets acquired.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Recent Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In March 2016, Financial
	Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-06,
<I>
	Derivatives
	and Hedging (Topic 815)
</I>
	(&ldquo;ASU 2016-06&rdquo;). ASU 2016-06 clarifies the requirements for assessing whether contingent
	call or put options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt
	hosts. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within
	those annual periods. Early application is permitted. The Company is currently evaluating the impact of this new standard.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In February 2016,
	FASB issued ASU 2016-02,
<I>
	Leases (Topic 842)
</I>
	(&ldquo;ASU 2016-02&rdquo;). ASU 2016-02 will require lessees to recognize a
	lease liability and a right-of-use asset for all leases, with the exception of short-term leases, at the commencement date. This
	guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual
	periods. Early application is permitted. The Company is currently evaluating the impact of this new standard.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In November 2015,
	FASB issued ASU 2015-17,
<I>
	Income Taxes (Topic 740)
</I>
	(&ldquo;ASU 2015-17&rdquo;). ASU 2015-17 simplifies the presentation of
	deferred income taxes by requiring that deferred tax assets and liabilities be classified as non-current in a classified statement
	of financial position. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim
	periods within those annual periods, with early adoption permitted. The Company early adopted ASU 2015-17 for the year ended December
	31, 2015 on a prospective basis, as permitted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In April 2015, FASB
	issued ASU 2015-03,
<I>
	Interest &ndash; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance
	Costs
</I>
	(&ldquo;ASU 2015-03&rdquo;). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be
	presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts.
	This guidance is effective for annual reporting periods beginning after December 15, 2015, and interim periods within fiscal years
	beginning after December 15, 2016, with early adoption permitted. The Company early adopted ASU 2015-03 in July 2015, as permitted.
	There was no impact of early adoption of ASU 2015-03 on the Company&rsquo;s consolidated financial statements previously reported.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In August 2014, the
	FASB issued ASU 2014-15,
<I>
	Presentation of Financial Statements &ndash; Going Concern
</I>
<I>
	(Subtopic 205-40)
</I>
	(&ldquo;ASU
	2014-15&rdquo;). ASU 2014-15 defines management&rsquo;s responsibility to evaluate whether there is substantial doubt about an
	organization&rsquo;s ability to continue as a going concern and provides guidance on the related footnote disclosures. This guidance
	is effective for annual reporting periods beginning after December 15, 2016, and interim periods within annual periods beginning
	after December 15, 2016. Early application is permitted. The Company is currently evaluating the impact of this new standard.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	In May 2014, the FASB
	issued ASU 2014-09,
<I>
	Revenue from Contracts with Customers (Topic 606)
</I>
	(&ldquo;ASU 2014-09&rdquo;). ASU 2014-09 supersedes
	the revenue recognition requirements in Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 605,
<I>
	Revenue Recognition
</I>
	,
	and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the
	transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to
	be entitled to in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-15,
<I>
	Revenue from Contracts
	with Customers (Topic 606): Deferral of the Effective Date
</I>
	, which defers the effective date of ASU 2014-09 for all entities
	by one year. This guidance is currently effective for annual reporting periods beginning after December&nbsp;15, 2017, including
	interim periods within that reporting period, under either full or modified retrospective approach. Early application is permitted
	as of annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard
	on its revenue recognition policy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company has considered
	other recent accounting pronouncements and concluded that they are either not applicable to the business, or that no material effect
	is expected on the consolidated financial statements as a result of future adoption.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 22.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	3.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Acquisitions
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	2014 Business
	Combination
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	On January&nbsp;23,
	2014, the Company completed the Acquisition transaction with Xenetic UK which resulted in the Company acquiring all of the issued
	and outstanding common stock of Xenetic UK. The Acquisition was accounted for as a reverse acquisition under the acquisition method
	of accounting per ASC 805, with Xenetic UK treated as the accounting acquirer and the Company treated as the &ldquo;acquired&rdquo;
	company for financial reporting purposes. This was determined based on the following facts: (i)&nbsp;after the reverse merger,
	former shareholders of Xenetic UK held a majority of the voting interest of the combined company; (ii)&nbsp;former Board of Directors
	of Xenetic UK possess majority control of the Board of Directors of the combined company; and (iii)&nbsp;members of the management
	of Xenetic UK are responsible for the management of the combined company. As such, the financial statements of Xenetic UK are treated
	as the historical financial statements of the combined company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The fair value of
	the consideration transferred in the reverse merger was $3.75 million. This was calculated as the number of shares of common stock
	that Xenetic UK would have had to issue in order for&nbsp;the Company&rsquo;s shareholders to hold the same equity interest in
	the combined entity immediately following the acquisition (approximately 9.2%), multiplied by the estimated fair value of the Company&rsquo;s
	common stock on the acquisition date (&pound;0.06 per share). The estimated fair value of the&nbsp;Company&rsquo;s common stock
	was based on the price of the Company&rsquo;s stock on the acquisition date, which was actively traded on the Alternative Investments
	Market of the London Stock Exchange in the United Kingdom. In addition, Xenetic UK incurred approximately $3 million of transaction
	costs related to the reverse merger. The Company recognized approximately $0.5 million of transaction costs related to the reverse
	merger in general and administrative expenses on the consolidated statement of comprehensive loss during the year ended December
	31, 2014. No transaction costs related to the reverse merger were recognized during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	As of December 31,
	2014, the Company finalized the purchase accounting for the Acquisition. Management determined the purchase price allocations based
	on estimates of the fair values of all assets acquired and liabilities assumed. The Company believe that such information provides
	a reasonable basis for estimating the fair values of assets acquired and liabilities assumed. The fair values of the acquired assets
	and liabilities assumed are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 65%">
	Cash
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	43,502
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accounts receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	145
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,643
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	331,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accounts payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(354,079
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(36,146
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Long-term debt
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(372,813
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total identifiable net assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(379,248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Goodwill
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,129,248
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,750,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Following the Acquisition,
	an Agreement of Conveyance, Transfer and Assignment of Subsidiaries and Assumption of Obligations (the &ldquo;Hive Out Agreement&rdquo;)
	was executed, whereupon 10,000,000 outstanding shares of common stock held by Oxbridge Technology Partners SA (&ldquo;Oxbridge&rdquo;)
	were returned to the Company and recorded as treasury shares and were subsequently canceled. In exchange, Oxbridge acquired all
	issued and outstanding shares of both of the Company&rsquo;s former operating subsidiaries, Shift It Media Co. and General Aircraft,
	Inc. (the &ldquo;Disposed Subsidiaries&rdquo;), including all assets and liabilities connected with the businesses transferred.
	In addition, the Company disposed of the associated goodwill. The Hive Out Agreement also required a payment to Oxbridge of $430,000,
	which was paid by the Company shortly after the Acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company recorded
	this divestiture as a separate transaction from the Acquisition that results in the disposal of two of the Company&rsquo;s subsidiaries.
	The Disposed Subsidiaries did not record any operations in the combined entity following the Acquisition before they were disposed
	and these financial statements do not reflect the historical financial statements of the Disposed Subsidiaries as they were previously
	owned by the accounting acquiree. Accordingly, there are no balances to be recorded as discontinued operations on the statement
	of comprehensive loss. As a result of the divestiture of the Disposed Subsidiaries, the Company recorded a loss on disposal of
	subsidiaries of $1,069,675 during the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Due to the nature
	of the Acquisition and related Hive Out Agreement, the transaction did not result in any adjustments with a continuing impact on
	the Company&rsquo;s results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	2015 Asset Purchase
	Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In November
	2015, the Company entered into the APA with Kevelt and Pharmsynthez, parent of Kevelt. Pursuant to the APA, the Sellers will
	transfer to the Company certain intellectual property rights held by the Sellers with respect to the immunomodulatory product
	candidate Virexxa&reg; held by Kevelt and the Sellers will grant the Company the worldwide right to develop, market and
	license Virexxa&reg; for certain uses except for excluded uses in Russia, the Commonwealth of Independent States
	and certain other countries. In consideration, the Company will issue to Pharmsynthez 100.5 million shares of the
	Company&rsquo;s common stock. Also as part of the APA, Dr. Dmitry Genkin and Kirill Surkhov, shareholders and founders of
	Pharmsynthez, will assign a U.S. provisional patent application to the Company in exchange for 11 million shares of the
	Company&rsquo;s common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During December 2015,
	the 11 million shares were issued to Dr. Genkin and Mr. Surkhov under the terms of the APA. However, as of December 31, 2015, the
	APA transaction was not yet consummated and is contingent upon the parties meeting their respective closing conditions as set forth
	in the APA. As a result, the Company recorded approximately $3.74 million, the fair value of the proportional consideration provided,
	as a prepayment within current assets on the consolidated balance sheet as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The APA also provides
	for the Company&rsquo;s issuance of 10% Senior Secured Convertible Promissory Notes of up to $3.5 million to Pharmsynthez and certain
	warrants to purchase shares of the Company&rsquo;s common stock. In connection with the APA, certain terms in the SPA with Pharmsynthez
	issued in July 2015 were modified. See Note 8,
<I>
	Hybrid Debt Instrument
</I>
	, for discussion of the SPA and Note 11,
<I>
	Stockholders&rsquo;
	Equity
</I>
	, for discussion of the warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	There is also a provision
	in the APA for the contingent sale of up to $6.5 million of the Company&rsquo;s common stock in the event of a qualifying capital
	raise.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The APA transaction
	is expected to be completed during 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	4.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Significant Strategic Drug Development Collaborations - Related Parties
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Baxalta Incorporated
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In August 2005, the
	Company entered into an exclusive research, development, license and supply agreement with Baxter Healthcare SA (&ldquo;Baxter
	SA&rdquo;) and Baxter Healthcare Corporation (together referred to as &ldquo;Baxter&rdquo;) to develop products with an extended
	half-life of certain proteins and molecules using the Company&rsquo;s patent protected PolyXen&trade; technology whereby polysialic
	acid (&ldquo;PSA&rdquo; &ndash; a chain of polysialic acids) is conjugated with Baxter&rsquo;s proprietary molecule(s) to create
	a new generation of drugs to treat the failure of blood to coagulate in the therapeutic treatment of blood and bleeding disorders,
	such as hemophilia. The lead candidate in this collaboration is a longer-acting form of a recombinant Factor VIII (&ldquo;rFVIII&rdquo;)
	protein. During June 2015, in connection with the separation of its biopharmaceuticals business to form Baxalta Incorporated (&ldquo;Baxalta&rdquo;),
	Baxter assigned all of its rights and obligations under its existing agreement with the Company to Baxalta.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	This agreement has
	been amended several times since 2005, most recently in January 2014. The January 2014 amendment provides for increased future
	development, regulatory, sales and deadline extension receipts, restructured target deadlines and royalty receipts on potential
	net sales. The Company is entitled to up to $100 million in potential development, regulatory, sales and deadline extension receipts,
	which are contingent on the performance of Baxalta achieving certain milestones. The Company is also entitled to royalties on potential
	net sales varying by country of sale. The Company&rsquo;s right to receive these royalties in any particular country will expire
	upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in
	that particular country. In connection with this amendment, Baxter SA also made a $10 million equity investment in the Company
	in exchange for 10,695,187 shares of the Company&rsquo;s common stock during January 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Through December 31,
	2015, the Company and Baxalta continued to engage in research and development activities with no resultant commercial products.
	The Company did not recognize revenue in connection with this collaboration during the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Baxalta is a related
	party of the Company, with a share ownership of approximately 8.0% and 8.7% of the total issued common stock of the Company as
	of December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	SynBio LLC
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In August, 2011, SynBio
	LLC (&ldquo;SynBio&rdquo;) and the Company entered into a stock subscription and collaborative development of pharmaceutical products
	agreement (the &ldquo;Co-Development Agreement&rdquo;). The Company granted an exclusive license to SynBio to develop pharmaceutical
	products using certain molecule(s) based on SynBio&rsquo;s technology and the Company&rsquo;s proprietary technology (PolyXen&trade;,
	OncoHist&trade; and ImuXen&trade;) that prolongs the active life and/or improves the pharmacokinetics of certain therapeutic proteins
	and peptides (as well as conventional drugs). In return, SynBio granted an exclusive license to the Company to use the pre-clinical
	and clinical data generated by SynBio in certain agreed products and engage in the development of commercial candidates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	SynBio and the Company
	are each responsible for funding their own research activities. There are no milestone or other research-related payments due under
	the agreement other than fees for the supply of each company&rsquo;s respective research supplies based on their technology, which,
	when provided, are due to mutual convenience and not representative of an ongoing or recurring obligation to supply research supplies.
	Most recently, similar to the Company&rsquo;s agreement with Baxalta, Serum Institute of India Limited (&ldquo;Serum Institute&rdquo;)
	has agreed to directly provide the research supplies to SynBio, where the Company is not liable for any failure to supply the research
	supplies as a result of any act or fault of Serum Institute&rsquo;s. Upon successful commercialization of any resultant products,
	the Company is entitled to receive royalties on sales in certain territories and pay royalties to SynBio for sales outside those
	certain territories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Through December 31,
	2015, the Company and SynBio continued to engage in research and development activities with no resultant commercial products.
	The Company did not recognize revenue in connection with the Co-Development Agreement during the years ended December 31, 2015
	and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	SynBio is an affiliate
	of the Company, with a share ownership of approximately 39.0% and 41.6% of the total issued common stock of the Company as of December
	31, 2015 and 2014, respectively. On December 31, 2014, the Company granted SynBio a warrant to purchase 6,745,000 shares of common
	stock in connection with ongoing collaborative activities. See Note 9,
<I>
	Stockholders&rsquo; Equity
</I>
	, for further information
	on the warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Serum Institute of India
	Limited
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In the period from
	2004 through 2011, the Company entered into and amended certain license and supply agreements with Serum Institute. The original
	license agreement with Serum Institute was a collaborative Development and Manufacturing Arrangement (&ldquo;DMA&rdquo;) to develop
	agreed upon potential commercial product candidates using the Company&rsquo;s PolyXen
<SUP>
	&trade;
</SUP>
	technology. Serum Institute
	then endeavored to further develop the potential commercial product candidates and eventually initiate pre-clinical and clinical
	trials at their own cost. The agreement was amended in 2011, resulting in the surrender of development rights for 14 potential
	commercial product candidates in 2012, which were vested to Serum Institute under the terms of the previous agreements, back to
	the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Following the 2011
	amendment, Serum Institute retained an exclusive license to use the Company&rsquo;s PolyXen&trade; technology to research and develop
	one potential commercial product, Polysialylated Erythropoietin (&ldquo;PSA-EPO&rdquo;). Serum Institute will be responsible for
	conducting all pre-clinical and clinical trials required to achieve regulatory approvals within the certain predetermined territories
	at Serum Institute&rsquo;s own expense. The royalty payment schedule based on net revenues on the future commercial sales of PSA-EPO
	under the DMA was also modified as a result of the 2011 amendment. Royalty payments are payable by Serum Institute to the Company
	for net sales to certain customers in the Serum Institute sales territory. Royalty payments are payable by the Company to Serum
	Institute for net sales received by the Company over the term of the license. There are no milestone or other research-related
	payments due under the DMA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Through December 31,
	2015, the Company and Serum Institute continued to engage in research and development activities with no resultant commercial products.
	No royalty revenue or expense was recognized by the Company related to the Serum Institute arrangement during the years ended December
	31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Serum Institute is
	a related party of the Company, with a share ownership of approximately 8.5% and 9.2% of the total issued common stock of the Company
	as of December 31, 2015 and 2014, respectively. On December 31, 2014, the Company granted Serum Institute a warrant to purchase
	3,200,000 shares of common stock in connection with ongoing collaborative activities. See Note 9,
<I>
	Stockholders&rsquo; Equity
</I>
	,
	for further information on the warrant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<B>
<I>
	OJSC
	Pharmsynthez
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In November 2011,
	the Company entered into a collaborative research and development license agreement with OJSC Pharmsynthez (the &ldquo;Pharmsynthez
	Arrangement&rdquo;) pursuant to which the Company granted an exclusive license to Pharmsynthez to develop, commercialize and market
	six product candidates based on the Company&rsquo;s PolyXen&trade; and ImuXen&trade; technology in certain territories. In exchange,
	Pharmsynthez granted an exclusive license to the Company to use any pre-clinical and clinical data developed by Pharmsynthez, within
	the scope of the Pharmsynthez Arrangement, and to engage in further research, development and commercialization of drug candidates
	outside of certain territories at the Company&rsquo;s own expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In July 2015, the
	Company entered into the SPA with Pharmsynthez providing for the issuance of certain promissory notes and certain warrants to purchase
	shares of the Company&rsquo;s common stock. See Note 8,
<I>
	Hybrid Debt Instrument
</I>
	, for discussion of the SPA and Note 11,
<I>
	Stockholders&rsquo;
	Equity
</I>
	, for discussion of the warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In November 2015,
	the Company entered into the APA with the Sellers. Pursuant to the APA, Kevelt will transfer to the Company certain intellectual
	property rights with respect to the immunomodulatory product candidate Virexxa&reg; held by Kevelt. See Note 3,
<I>
	Acquisitions
</I>
	,
	for further discussion of the APA. The APA also provides for the Company&rsquo;s issuance of certain promissory notes and certain
	warrants to purchase shares of the Company&rsquo;s common stock. See Note 11,
<I>
	Stockholders&rsquo; Equity
</I>
	, for discussion
	of the warrants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Pharmsynthez is a
	related party of SynBio, which is an affiliate of the Company. In addition, one of the Company&rsquo;s directors is also a director
	of SynBio and Pharmsynthez.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	5.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Property and Equipment, net
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Property and equipment,
	net consists of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31,
<BR>
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT">
	Laboratory equipment
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	249,969
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	254,150
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Office and computer equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	35,190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	189,459
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Leasehold improvements
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	26,841
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	92,354
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Furniture and fixtures
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	20,263
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	50,150
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Property and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	332,263
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	586,113
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Less accumulated depreciation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(270,242
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(466,664
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Property and equipment &ndash; net
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	62,021
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	119,449
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In connection with
	the closing of the London office in March 2015, the Company disposed of approximately $247,000 of depreciated fixed assets with
	a net book value of approximately $6,000 for cash proceeds of approximately $8,000, resulting in a gain of approximately $2,000.
	Depreciation expense was $48,750 and $83,863 for the years ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	6.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Goodwill and Indefinite-Lived Intangible Assets
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.5PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<I>
	Goodwill
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	A
	reconciliation of the change in the carrying value of goodwill is as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 65%">
	Balance as of January 1, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	3,665,199
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Acquired from acquisitions
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,129,248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Disposed with Hive Out Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,129,248
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Foreign currency translation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(200,042
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	Balance as of December&nbsp;31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,465,157
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Foreign currency translation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(181,778
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance as of December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	3,283,379
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The goodwill acquired
	from the Acquisition was disposed in connection with the Hive Out Agreement. See Footnote 3,
<I>
	Acquisitions
</I>
	, for further discussion
	on the Acquisition and the Hive Out Agreement. As of October 1, 2015 and 2014, the dates of the Company&rsquo;s annual impairment
	review, the fair value of the Company&rsquo;s goodwill balance significantly exceeded its carrying value.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<I>
	Indefinite-Lived
	Intangible Assets
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	Company&rsquo;s acquired indefinite-lived intangible asset, OncoHist&trade;, is IPR&amp;D relating to the Company&rsquo;s business
	combination with SymbioTec in 2012. The carrying value of OncoHist&trade; was $9.24 million
	and $9.75 million as of December 31, 2015 and 2014, respectively. No impairment was recorded during the years ended December 31,
	2015 and 2014. The changes in the carrying value reflected herein are solely comprised of the effects of changes in foreign currency.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	OncoHist&trade;
	is not yet commercialized and has not yet begun to be amortized as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	7.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Accrued Expenses
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Accrued expenses consist
	of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December&nbsp;31,
<BR>
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT">
	Accrued payroll and benefits
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	625,289
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	67,120
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accrued professional fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	413,945
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	574,186
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accrued research costs
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	145,026
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	573,879
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accrued interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	77,857
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	224,929
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	194,506
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,487,046
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,409,691
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	8.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Hybrid Debt Instrument
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Securities
	Purchase Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	On July 1, 2015, the
	Company entered into the SPA with Pharmsynthez providing for the issuance of a minimum of a $3 million 10% Senior Secured Collateralized
	Convertible Promissory Note (the &ldquo;SPA Note&rdquo;). The SPA also provides for the issuance of certain warrants up to the
	amount of the SPA Note. See Note 11,
<I>
	Stockholders&rsquo; Equity
</I>
	, for discussion of the accounting treatment of the warrants.
	The convertible debt and its embedded debt-like features have been recorded on the face of the consolidated balance sheet within
	current liabilities as an aggregate hybrid debt instrument with a balance of $3.7 million as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	On July 1, 2015, the
	Company issued the SPA Note for $3 million plus a warrant to purchase 10 million shares of common stock in accordance with the
	terms of the SPA. In the event the SPA Note remains outstanding at April 1, 2016, Pharmsynthez will be granted an additional warrant
	to purchase $10 million shares of common stock. The SPA Note carries a term of one year and is convertible, in whole or in part,
	at the option of Pharmsynthez into shares of common stock at a conversion price of $0.15. The SPA Note bears interest at the rate
	of 10% annually, payable quarterly in cash or, at the Company&rsquo;s option, in shares of common stock at the lessor of $0.15
	or the then applicable conversion price. At any point after six months following the issuance of the SPA Note, but before the maturity
	date of the SPA Note, the Company has the option of prepayment of the SPA Note and any accrued interest. If the Company exercises
	the prepayment option, the Company is obligated to pay the outstanding principal amount of the SPA Note and accrued interest multiplied
	by 115%. If the SPA Note is converted or redeemed, prior to the maturity date, the Company will pay cash to Pharmsynthez equal
	to the interest that would have accrued from the conversion or redemption date to the maturity date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Upon a qualifying
	capital raise in which the Company obtains financing of $7 million or greater (&ldquo;Capital Raise&rdquo;), Pharmsynthez has the
	option to either redeem the SPA Note for cash at the balance of principal plus accrued interest multiplied by 115% or convert the
	principal plus accrued interest multiplied by 115% into common stock at the effective conversion price. In the event of default,
	as defined under the terms of the SPA Note, all obligations will be immediately due and payable and the interest rate will increase
	to 18% annually. The Company determined these two features represent contingent put options for Pharmsynthez.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company concluded
	the two contingent put option features related to a Capital Raise and event of default, the SPA Note conversion feature and the
	ability for interest to be paid in shares of common stock feature each meet the definition of a derivative under ASC Topic 815,
<I>
	Derivatives and Hedging
</I>
	(&ldquo;ASC 815&rdquo;), and require bifurcation and accounting as embedded derivatives. The four
	embedded derivatives, which were bifurcated and individually fair valued by the Company, have been recorded as a compound derivative
	within the Hybrid Debt Instrument. The Company calculated the fair values of each individual embedded derivative by taking the
	difference between the fair value of the SPA Note with each embedded derivative and the fair value of the SPA Note without the
	individual embedded derivative. The Company calculated the fair values using the discounted present value of each embedded derivative
	value as determined by Monte Carlo Simulations. The key valuation assumptions used consist of the Company&rsquo;s stock price,
	the risk free interest rate and expected volatility. The embedded derivatives were recorded within the Hybrid Debt Instrument as
	a compound derivative liability at an estimated fair value of $1.4 million at issuance and created an offsetting debt discount
	on the consolidated balance sheet that will be amortized over the life of the SPA Note using the effective interest rate method.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The fair value of
	the compound derivative is remeasured at each report date until settled, with changes in fair value recognized in the consolidated
	statement of comprehensive loss as a gain or loss on derivative. The fair value of the compound derivative increased $2.1 million
	since issuance to $3.5 million as of December 31, 2015. This change was recognized as a loss in Other Expense in the consolidated
	statement of comprehensive loss for the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The key assumptions
	used to calculate the estimated fair value of the compound derivative liability at issuance and as of December 31, 2015 are as
	follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	July 1, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 46%">
	Company stock price
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: RIGHT">
	0.51
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: RIGHT">
	0.22
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Expected volatility (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	115
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Risk-free interest rate (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The offset to debt
	arising from the recording of the compound derivative liability, the warrants and the associated issuance costs exceeded the debt
	proceeds by approximately $60,000. This amount was recorded as a loss in Other Expense in the consolidated statement of comprehensive
	loss for the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Interest expense related
	to the SPA Note of approximately $154,000 was recognized in Interest Expense in the consolidated statement of comprehensive loss
	for the year ended December 31, 2015. Of this amount, approximately $78,000 is recorded as accrued interest on the hybrid debt
	instrument and approximately $76,000 was settled in shares of issuable common stock as of December 31, 2015, as provided in the
	APA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company also evaluated
	the provision in the SPA Note that increases the annual interest rate in the event of default and concluded that the initial value
	of this contingent feature is immaterial to the consolidated financial statements as of December 31, 2015. The Company will evaluate
	the value of this contingent feature at each reporting period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Asset Purchase
	Agreement
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In November 2015,
	the Company entered into the APA with Kevelt and Pharmsynthez providing for the issuance of 10% Senior Secured Convertible Promissory
	Notes of up to $3.5 million to Pharmsynthez (the &ldquo;APA Notes&rdquo;) and warrants to purchase a number of shares of the Company&rsquo;s
	common stock equal to 50% of the number of shares issuable under the APA Notes. In the event that the APA Notes remain outstanding
	at May 11, 2016, Pharmsynthez shall be granted an additional warrant to purchase an additional number of shares of the Company&rsquo;s
	common stock equal to 50% of the number of shares issuable under the APA Notes. The APA Notes will be issued under similar terms
	and conditions as the SPA Note. No APA Notes were issued by the Company during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	9.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Fair Value Measurements
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	ASC Topic 820,
<I>
	Fair Value Measurement,
</I>
	defines fair value as the price that would be received to sell an asset or be paid to transfer a liability
	in an orderly transaction between market participants at the measurement date. The Company applies the following fair value hierarchy,
	which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon
	the lowest level of input that is available and significant to the fair value measurement. Level 1 inputs are quoted prices in
	active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
	Level 2 utilizes quoted market prices in markets that are not active, broker or dealer quotations, or alternative pricing sources
	with reasonable levels of price transparency. Level 3 inputs are unobservable inputs for the asset or liability in which there
	is little, if any, market activity for the asset or liability at the measurement date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company&rsquo;s
	cash and restricted cash are measured at fair value and are classified as Level 1 in the fair value hierarchy.
	The carrying amount of certain of the Company&rsquo;s financial instruments approximate fair value due to their short maturities.
	The Company&rsquo;s derivative liabilities are measured at fair value on a recurring basis and are classified as Level 3 in the
	fair value hierarchy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The following table
	provides a summary of the changes in fair value of the compound derivative measured at fair value on a recurring basis using significant
	unobservable inputs during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	Balance as of January&nbsp;1, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 65%; TEXT-ALIGN: LEFT">
	Issuance of compound derivative instrument
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(1,419,105
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Change in fair value of compound derivative instrument
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(2,125,117
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance as of December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(3,544,222
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	There were no financial
	instruments classified as Level 3 in the fair value hierarchy during the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	10.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Income Taxes
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company accounts
	for income taxes using the liability method under ASC Topic 740,
<I>
	Income Taxes
</I>
	. Under this method, deferred tax assets and
	liabilities are determined based on temporary differences resulting from the different treatment of items for tax and financial
	reporting purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income
	in the years in which those temporary differences are expected to reverse. Additionally, the Company must assess the likelihood
	that deferred tax assets will be recovered as deductions from future taxable income. The Company has provided a full valuation
	allowance on the Company&rsquo;s deferred tax assets because the Company believes it is more likely than not that its deferred
	tax assets will not be realized. The Company evaluates the recoverability of its deferred tax assets on a quarterly basis. Currently,
	there is no provision for income taxes as the Company has incurred losses to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The components of
	(loss) before income taxes are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT">
	Domestic (U.S.)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(7,724,418
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(4,040,654
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Foreign (U.K.)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,767,363
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,003,427
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Foreign (Germany)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,690
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(263,023
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Loss before income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(12,507,471
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(14,307,104
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	reconciliation of income tax provision (benefit) at the U.S. corporation tax rate, being the rate applicable to the country of
	domicile of Xenetic Biosciences, Inc. to net income tax provision (benefit) is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%">
	Federal
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(4,252,540
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(4,860,256
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	State
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(276,601
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(145,209
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase in tax losses not recognized
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,238,879
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,949,805
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Permanent differences, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	800,891
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,529,190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Mark to market
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	722,540
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Foreign rate differential
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	502,357
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,184,770
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share-based payments, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	308,888
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	505,035
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Other
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,273
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Enhanced research and development tax credits
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(44,414
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(112,228
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Net provision (benefit) for income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	Deferred
	tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities
	for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&rsquo;s deferred
	tax assets are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Deferred tax assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	U.K. net operating loss carryforwards
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	9,402,398
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	9,198,798
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	U.K. capital loss carryforwards
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,775,932
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,874,254
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	U.S. federal net operating loss carryforwards
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,659,050
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	923,816
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Share-based payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,313,226
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	52,320
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Enhanced research and development tax credits
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	852,272
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	786,342
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Germany net operating loss carryforwards
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	401,906
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	393,638
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	U.S. state net operating loss carryforwards
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	422,622
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	233,825
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Accrued expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	44,557
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	157,329
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Depreciation
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	25,823
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,703
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	4,998
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	115,384
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Total deferred tax assets before valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	15,902,784
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	13,773,409
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	Deferred tax liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Indefinite-lived intangible asset
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,918,518
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,080,096
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Debt discount
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(578,346
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Total deferred tax liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,496,864
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,080,096
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PT">
	Less valuation allowance
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(15,324,438
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(13,773,409
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 2.5PT">
	Total net deferred tax liability
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(2,918,518
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	(3,080,096
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	For
	the years ended December 31, 2015 and 2014, the Company had U.K. net operating loss carryforwards of $47.01 million and $45.99
	million, respectively, U.S. federal net operating loss carryforwards of $5.30 million and $2.95 million, respectively, U.S. state
	net operating loss carryforwards of $5.28 million and $2.92 million, respectively, and Germany net operating loss carryforwards
	of approximately $1.27 million and $1.25 million, respectively. The U.K. and Germany net operating loss carryforwards can be carried
	forward indefinitely. The U.S. federal and state net operating loss carryforwards begin to expire in 2032.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	Company&rsquo;s ability to use its operating loss carryforwards and tax credits generated in the U.S. to offset future taxable
	income is subject to restrictions under Section&nbsp;382 of the United States Internal Revenue Code (the &ldquo;Internal Revenue
	Code&rdquo;). These restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership
	changes described in the Internal Revenue Code occur. Future changes in stock ownership may occur that would create further limitations
	on the Company&rsquo;s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required
	to pay income taxes, even though significant operating loss carryforwards and tax credits exist.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	Company&rsquo;s ability to use its operating loss carryforwards and tax credits generated in the U.K. are subject to restrictions
	under U.K. tax legislation. These regulations may limit the future use of operating loss carryforwards if there is a change in
	ownership and a change in the nature or conduct of the business carried on by the Company, and in certain circumstances where there
	is a change in the nature or conduct of the business only. In such cases the carryforwards would cease to be available to set against
	future income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	Company&rsquo;s ability to use its operating loss carryforwards and tax credits generated in Germany are also subject to restrictions
	under German tax legislation. These regulations may limit the future use of operating loss carryforwards if there is a change in
	ownership. In such cases the carryforwards would cease to be available to set against future income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	As of December&nbsp;31,
	2015 and 2014, the Company did not record any uncertain tax positions. As of January 1, 2014, the Company had recorded an uncertain
	tax position due to a claim for research and development tax credits with a full valuation allowance. During 2014, the Company
	determined that it is unable to obtain and compile the necessary information to support and defend the recoverability of the research
	and development tax credits, resulting in the write-off of the previously fully reserved balance. The changes to uncertain tax
	positions for 2015 and 2014 were as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%">
	Uncertain tax benefits as of January 1
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	185,961
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Gross adjustments in tax positions
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(185,961
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Uncertain tax positions as of December 31
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The
	Company files income tax returns in the U.S. federal tax jurisdiction and Massachusetts state tax jurisdiction, and certain
	foreign tax jurisdictions. The Company is subject to examination by the U.S. federal, state, foreign, and local income
	tax authorities for calendar tax years ending 2012 through 2015 due to available
	net operating loss carryforwards and research and development tax credits arising in those years. The Company has not been notified of any examinations by the
	Internal Revenue Service or any other tax authorities as of December 31, 2015. The Company has not recorded any interest or
	penalties for unrecognized tax benefits since its inception.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
<I>
	Potential 382 Limitation
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company&rsquo;s
	net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service.
	&nbsp;The Company&rsquo;s ability to utilize our net operating loss (&ldquo;NOL&rdquo;) and alternative minimum tax (&ldquo;AMT&rdquo;)
	and research and development credit (&ldquo;R&amp;D&rdquo;) carryforwards may be substantially limited due to ownership changes
	that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended
	(the &ldquo;Code&rdquo;), as well as similar state provisions. &nbsp;These ownership changes may limit the amount of NOL, AMT and
	R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. &nbsp;In general,
	an ownership change, as defined in Section 382 of the Code, results from a transaction or series of transactions over a three-year
	period resulting in an ownership change of more than 50% of the outstanding stock of a company by certain stockholders or public
	groups.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company has not
	completed a study to assess whether one or more ownership changes have occurred since we became a loss corporation as defined in
	Section 382 of the Code, but we believe that it is likely that an ownership change has occurred. &nbsp;If we have experienced an
	ownership change, utilization of the NOL, AMT and R&amp;D credit carryforwards would be subject to an annual limitation, which
	is determined by first multiplying the value of our common stock at the time of the ownership change by the applicable long-term,
	tax-exempt rate, and then could be subject to additional adjustments, as required. &nbsp;Any such limitation may result in the
	expiration of a portion of the NOL, AMT or R&amp;D credit carryforwards before utilization. &nbsp;Until a study is completed and
	any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit
	under ASC 740. &nbsp;Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred
	tax assets with a corresponding adjustment to the valuation allowance. &nbsp;Due to the existence of the valuation allowance, it
	is not expected that any potential limitation will have a material impact on our operating results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	From time to time
	the Company may be assessed interest or penalties by major tax jurisdictions, namely the state of Massachusetts. As of December
	31, 2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required.
	No interest and penalties have been recognized by the Company to date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	The Company net operating
	loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and are subject to certain limitations
	in the event of cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of
	50%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	11.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Stockholders&rsquo; Equity
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Common Stock
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	Each
	share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&rsquo;s stockholders. Common
	stockholders are entitled to dividends when and if declared by the Board of Directors. In the event of any voluntary or involuntary
	liquidation, dissolution or winding-up of the Company, the holders of common stock are entitled to share ratably in the assets
	of the Company available for distribution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	On September 30, 2015,
	the Company filed an Amendment to the Articles of Incorporation with the Secretary of State of the State of Nevada to increase
	the authorized shares of common stock of the Company and change the par value per share of common stock (the &ldquo;Amendment&rdquo;).
	The Amendment authorizes the Company to issue 1,500,000,000 shares of Common Stock and changes the par value to $0.001 per share.
	Prior periods have been reclassified to reflect the change in the par value per share to conform to the presentation in the present
	period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	On
	January 30, 2014, the Company announced the amendment of the licensing agreement with Baxter in which certain financial and timing
	aspects of the agreement were modified. As a result, the Company is entitled to receive certain amounts in development, regulatory
	and sales milestone payments as well as increased royalties on potential net sales. In addition, Baxter SA made a direct equity
	investment of $10 million in cash in exchange for 10,695,187 shares of the Company&rsquo;s common stock. During June 2015, in connection
	with the separation of its biopharmaceuticals business to form Baxalta Incorporated (&ldquo;Baxalta&rdquo;), Baxter assigned all
	of its rights and obligations under its existing agreement with the Company to Baxalta.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	December 2015, 11 million shares of new common stock were issued to Dr. Genkin and Mr. Surkhov in connection with the APA. As a
	result, the Company recorded approximately $3.74 million, the fair value of the proportional consideration provided, as a prepayment
	within current assets on the consolidated balance sheet as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Warrants
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	connection with the Company&rsquo;s collaboration and consultant agreements and financing arrangements, the Company issues warrants
	to purchase shares of common stock. These warrants were fair valued at issuance date using the Black-Scholes option pricing model.
	The warrants are subject to re-measurement at each reporting period until the measurement date is reached. Expense is recognized
	on a straight-line basis over the expected service period or at the date of issuance, if there is not a service period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Warrants
	Related to Collaboration and Consulting Agreements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	2010, the Company granted Baxter SA a warrant to purchase 4,588,298 new shares of common stock. During June 2015, in connection
	with the separation of its biopharmaceuticals business to form Baxalta, Baxter assigned the warrant to Baxalta. The warrant was
	exercisable immediately after issuance and had an initial expiration date of June 30, 2015, which the Company expects to extend
	subsequent to December 31, 2015. These warrants, which were fair valued at $932,000 at the time of issuance, were not exercised
	during the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	2011, the Company granted SynBio a warrant to purchase 3,545,600 new shares of common stock, which was exercisable two years after
	issuance and expires on December 2, 2016 (&ldquo;SynBio 2011 Warrant&rdquo;). On December 31, 2014, SynBio was granted a warrant
	to purchase 6,745,000 new shares of common stock at an exercise price of $0.77 per share (&ldquo;SynBio 2014 Warrant&rdquo;). The
	SynBio 2014 Warrant is exercisable in four equal tranches, each with separate non-market, performance-based vesting criteria. The
	Company uses its judgment to assess the probability and timing of SynBio achieving this vesting criteria and estimated that it
	is not probable that the vesting criteria for any tranche will be achieved. As a result, the Company did not recognize expense
	related to this warrant during the years ended December 31, 2015 and 2014. These judgments are reassessed at each reporting period
	until the measurement date is reached. Upon issuance of the SynBio 2014 Warrant on December 31, 2014, the SynBio 2011 Warrant was
	canceled and of no further force and effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	connection with the SynBio 2014 Warrant grant, warrants to purchase 320,000 aggregate new shares of common stock were issued to
	SynBio and Pharmsynthez non-director designees (&ldquo;SynBio Partner Warrants&rdquo;) on December 31, 2014 under the same terms
	and conditions of the SynBio 2014 Warrant. The Company estimated that it is not probable that the vesting criteria for any trance
	will be achieved and, as a result, the Company did not recognize expense related to the SynBio Partner Warrants during the years
	ended December 31, 2015 and 2014. The SynBio 2014 Warrant and SynBio Partner Warrants expire on December 30, 2019 and no warrants
	were exercised during the years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	On
	December 31, 2014, the Company granted Serum Institute a warrant to purchase 3,200,000 new shares of common stock at an exercise
	price of $0.77 per share (&ldquo;Serum Institute 2014 Warrant&rdquo;). The Serum Institute 2014 Warrant, which was fair valued
	at approximately $480,000 at the time of issuance, is exercisable in two equal tranches, each with separate non-market, performance-based
	vesting criteria. The Company uses its judgment to assess the probability and timing of Serum Institute achieving this vesting
	criteria and estimated that it is probable that the vesting criteria will be achieved for each tranche. These judgments are reassessed
	at each reporting period until the measurement date is reached.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	connection with the Serum Institute 2014 Warrant grant, warrants to purchase 160,000 aggregate new shares of common stock were
	issued to Serum Institute employees (&ldquo;Serum Institute Partner Warrants&rdquo;) on December 31, 2014 under the same terms
	and conditions of the Serum Institute 2014 Warrant. The Serum Institute Partner Warrants were fair valued at approximately $24,000
	at the time of issuance. The Company recognized warrant expense of $706,500 and zero during the years ended December 31, 2015 and
	2014, respectively, related to the Serum Institute 2014 Warrant and Serum Institute Partner Warrants. The Serum Institute 2014
	Warrant and Serum Institute Partner Warrants expire on December 30, 2019 and no warrants were exercised during the years ended
	December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	On
	December 31, 2014, the Company granted a non-employee director a warrant to purchase 1,600,000 new shares of common stock at an
	exercise price of $0.77 per share for services provided to the Company. The warrant is a standalone instrument that is not puttable
	or mandatorily redeemable by the holder and is classified as an equity award. The Company determined that the fair value of the
	warrant is more reliably measureable than the fair value of the services received. As a result, the warrant was fair valued at
	approximately $240,000 at the time of issuance. As performance was completed and the measurement date reached at the time of issuance,
	the Company recorded expense of approximately $240,000 to general and administrative expenses in the consolidated statement of
	comprehensive loss during the year ended December 31, 2014. The warrant is exercisable two years after issuance and expires on
	December 30, 2019.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In August 2015, the
	Company issued a warrant to purchase approximately 833,000 shares of common stock to a consultant upon engagement of services to
	be provided to the Company. The warrant has a term of five years and an exercise price of $0.77. The warrant is a standalone instrument
	that is not puttable or mandatorily redeemable by the holder and is classified as an equity award. The Company determined that
	the fair value of the warrant is more reliably measureable than the fair value of the services received. As a result, the warrant
	was fair valued at approximately $227,000 at the time of issuance using the Black-Scholes option pricing model. As all services
	were completed as of December 31, 2015, the warrant expense was recognized during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	Key
	assumptions used in the Black-Scholes option pricing model for warrants related to collaboration and consultant agreements granted
	during the years ended December 31, 2015 and 2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average expected dividend yield (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 42%; TEXT-ALIGN: LEFT">
	Weighted-average expected volatility (%)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	104.81
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	103.32
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average risk-free interest rate (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.03
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.96
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average expected life of option (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	Weighted-average exercise price ($)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.77
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.77
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Model used
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Black-Scholes
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Black-Scholes
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
<B>
<I>
	Warrants Related
	to Financing Arrangements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	In connection with
	the Company&rsquo;s issuance of the SPA Note on July 1, 2015, the Company issued a warrant to purchase 10 million shares of common
	stock in accordance with the terms of the SPA (the &ldquo;Warrant&rdquo;). The Warrant has a five-year term and is exercisable
	commencing January 1, 2016. The exercise price per share under the Warrant is the lessor of $0.20 or 120% of the Capital Raise
	price, in the event there is a Capital Raise. If the SPA Note is not repaid or converted on or before six months from the date
	of issuance, the Holder will be issued an additional warrant to purchase 10 million shares of common stock under the same terms
	as the Warrant (the &ldquo;Contingent Warrant&rdquo;, or together referred to as the &ldquo;Warrants&rdquo;). The Company determined
	there is a high probability that the SPA Note will not be repaid or converted within the period six months from the date of issuance,
	resulting in the issuance of the Contingent Warrant. As such, the Company concluded the Contingent Warrant is considered to be
	issued and outstanding as of the SPA Note issuance date in accordance with ASC 815. The fair values of the Warrants were calculated
	using the Black-Scholes option pricing model. The key valuation assumptions used consist of the Company&rsquo;s stock price, a
	risk free rate of 1.70% and an expected volatility of 125%. Using an allocation of the SPA Note proceeds between the relative fair
	values of the Warrants and the SPA Note, the Company recorded the Warrants at a value of $1.6 million on the consolidated balance
	sheet as equity paid-in-capital. This created a debt discount of $1.6 million that will amortize from the date of issuance through
	the term of the SPA Note.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 26.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In November 2015,
	the Company entered into the APA with Kevelt and Pharmsynthez, which provided for the issuance of certain warrants to purchase
	a number of share of the Company&rsquo;s common stock equal to 50% of the number of shares issuable under the APA Notes. In the
	event that the APA Notes remain outstanding at May 11, 2016, Pharmsynthez shall be granted an additional warrant to purchase an
	additional number of shares of the Company&rsquo;s common stock equal to 50% of the number of shares issuable under the APA Notes.
	The warrants will be issued under the same terms and conditions as the warrants under the SPA. No warrants under the APA were issued
	by the Company during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	12.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Share-Based Payments
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Total share-based
	payments related to employee and non-employee stock options, common stock awards and JSOP awards was $2,594,113 and $1,513,238
	for the years ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Share-based payments
	is classified in the consolidated statements of comprehensive loss as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: LEFT">
	Research and development expenses
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	229,964
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	952,829
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	General and administrative expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	2,364,149
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	560,409
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	2,594,113
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	1,513,238
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 22.5PT">
<B>
<I>
	Stock Option Modifications
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Prior to the Acquisition
	in 2014, the Company had two incentive stock plans, the Lipoxen plc Unapproved Share Option Plan (the &ldquo;2000 Stock Plan&rdquo;)
	and the Xenetic Biosciences plc 2007 Share Option Scheme (the &ldquo;2007 Stock Plan&rdquo;). Subsequent to the Acquisition, the
	2000 and 2007 Stock Plans were converted to reflect the new shares issued by the Company under the Scheme of Arrangement related
	to the Acquisition. As part of the conversion, option holders under the 2000 and 2007 Stock Plan have the right to subscribe for
	a number of shares of common stock in the Company (the &ldquo;Replacement Option Shares&rdquo;) in exchange for the cancellation
	and surrender by the option holder of the original options granted by the 2000 and 2007 Stock Plans. The number of Replacement
	Option Shares is determined in the same manner in which the shareholders of Xenetic UK were given the right to acquire shares of
	common stock in the Company according to the Acquisition. The aggregate exercise price payable in U.S. dollars for Replacement
	Option Shares is the same as the aggregate exercise price in pounds sterling of the original options, using a foreign currency
	exchange rate for pounds sterling into U.S. dollars quoted by Barclays Bank plc at 12 noon Greenwich Mean Time (&ldquo;GMT&rdquo;)
	on January&nbsp;23, 2014, the date of the Acquisition. The conversion of the options is treated as an option modification. The
	Company accounted for the option modification under ASC Topic 718,
<I>
	Compensation &ndash; Stock Compensation
</I>
	, and determined
	the option modification did not result in incremental stock compensation cost that is material to the Company&rsquo;s results of
	operations during the year ended December 31, 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the year ended
	December 31, 2015, the Company modified 688,408 employee stock option awards to extend the expiry dates through March 31, 2016.
	The Company accounted for the option modification under ASC Topic 718,
<I>
	Compensation &ndash; Stock Compensation
</I>
	, and as a
	result, recognized $25,008 in incremental compensation expense during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Stock Options
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company grants
	stock option awards to employees and non-employees with varying vesting terms under the Xenetic Biosciences, Inc. Equity Incentive
	Plan (&ldquo;Stock Plan&rdquo;). The Company measures the fair value of stock option awards using the Black-Scholes option pricing
	model, which uses the assumptions noted in the tables below, including the risk-free interest rate, expected term, share price
	volatility, dividend yield and forfeiture rate. The risk-free interest rate is based upon the U.S. Treasury yield curve in effect
	at the time of grant, with a term that approximates the expected life of the option. For employee stock options issued in 2015
	and 2014 that qualify as &ldquo;plain vanilla&rdquo; stock options in accordance with Staff Accounting Bulletin No. 110 (&ldquo;SAB
	110&rdquo;), the expected term is based on the simplified method, as defined by SAB 110. The Company has a limited history of stock
	option exercises, which does not provide a reasonable basis for the Company to estimate the expected term of employee stock options.
	For all other employee stock options, the Company estimates the expected life using judgment based on the anticipated research
	and development milestones of the Company&rsquo;s clinical projects and behaviour of the Company&rsquo;s employees. The expected
	life of non-employee options is the contractual life of the option. The Company determines the expected volatility based on a blended
	volatility rate of its own historical volatility with that of comparable publicly traded companies with product candidates in similar
	therapeutic areas and stages of nonclinical and clinical development to the Company&rsquo;s product candidates. The Company has
	applied an expected dividend yield of 0% as the Company has not historically declared a dividend and does not anticipate declaring
	a dividend during the expected life of the options. Further, the Company has applied a forfeiture rate of 0% as the Company has
	not historically experienced forfeitures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Employee Stock Options
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the years ended
	December 31, 2015 and 2014, 16.3 million and 1.08 million total stock options to purchase shares of common stock were granted under
	the Stock Plan, respectively, with a weighted average grant date fair value per option share of $0.28 and $0.23, respectively.
	During the year ended December 31, 2014, 1,984,080 stock options were exercised and cash received from those stock option exercises
	was $101,933. No stock options were exercised during the year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the year ended
	December 31, 2015 and 2014, 5.33 million and 0.68 million total stock options vested, with total fair values of $1,391,450 and
	$115,864, respectively. As of December 31, 2015, there was $2,931,117 of unrecognized share-based payments related to employee
	stock options that are expected to vest. The Company expects to recognize this expense over a weighted-average period of approximately
	2 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	Key
	assumptions used in the Black-Scholes option pricing model for options granted to employees during the years ending December 31,
	2015 and 2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 21.25PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average expected dividend yield (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 42%; TEXT-ALIGN: LEFT">
	Weighted-average expected volatility (%)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	124.17
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	103.36
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average risk-free interest rate (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.44
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average expected life of option (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.50
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.33
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	Weighted-average exercise price ($)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.42
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Model used
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Black-Scholes
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Black-Scholes
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 28.35PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 28.35PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	The following is a summary of employee
	stock option activity for the years ended December 31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average exercise price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average remaining life (years)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: -9PT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Aggregate intrinsic value
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 40%">
	Outstanding as of January 1, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	5,222,430
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.47
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,080,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,984,080
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.05
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	509,622
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Expired
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(132,422
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	0.93
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Outstanding as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,185,928
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.86
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80,338
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,300,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.42
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Expired
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(51,072
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.47
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Outstanding as of December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,434,856
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,915,942
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Vested or expected to vest as of December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,434,856
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.46
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.92
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,915,942
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Exercisable as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,630,024
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	5.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	80,338
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Exercisable as of December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,913,567
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.52
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.78
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	688,343
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	A
	summary of the status of the Company&rsquo;s non-vested employee stock option shares as of December 31, 2015 and the changes during
	the year ended December 31, 2015 is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average grant date fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%">
	Balance as of January 1, 2015
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1,555,904
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.15
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16,300,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.28
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Vested
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(5,334,615
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	0.26
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance as of December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	12,521,289
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	0.28
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<B>
<I>
	Non-Employee
	Stock Options
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Share-based payments
	expense related to stock options granted to non-employees is recognized as the services are rendered on a straight-line basis.
	The Company determined that the fair value of the stock options is more reliably measurable than the fair value of the services
	received. Compensation expense related to stock options granted to non-employees is subject to re-measurement at each reporting
	period until the options vest.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the years ended
	December 31, 2015 and 2014, 1 million and 0.48 million non-employee stock options were granted under the Stock Plan, respectively,
	with a weighted average grant date fair value per option share of $0.40 and $0.23, respectively. No non-employee stock options
	were exercised during years ended December 31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the year ended
	December 31, 2015 and 2014, 0.59 million and 0.26 million total stock options vested, with total fair values of $195,575 and $62,121,
	respectively. As of December 31, 2015, there was $263,778 of unrecognized share-based payments related to non-employee stock options
	that are expected to vest. The Company expects to recognize this expense over a weighted-average period of approximately 1.5 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	Key
	assumptions used in the Black-Scholes option pricing model for non-employees options during the years ended December 31, 2015 and
	2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 21.25PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended December 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average expected dividend yield (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&ndash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 42%; TEXT-ALIGN: LEFT">
	Weighted-average expected volatility (%)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	120.51
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	116.22
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average risk-free interest rate (%)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.54
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1.62
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Weighted-average expected life of option (years)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	10.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	Weighted-average exercise price ($)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.42
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Model used
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Black-Scholes
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Black-Scholes
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	following is a summary of non-employee stock option activity for the years ended December&nbsp;31, 2015 and 2014:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 21.25PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average exercise price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average remaining life (years)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Aggregate intrinsic value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; WIDTH: 40%">
	Outstanding as of January 1, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	415,520
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.52
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	5.90
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	49
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	480,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Outstanding as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	895,520
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.39
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	159
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	1,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.42
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Outstanding as of December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,895,520
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.41
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.23
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	220,764
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Vested or expected to vest as of December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,895,520
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.41
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8.23
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	220,764
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Exercisable as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	383,664
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.42
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	159
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Exercisable as of December 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	972,926
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.41
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	119,164
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	A
	summary of the status of the Company&rsquo;s non-vested non-employee stock option shares as of December 31, 2015 and the changes
	during the year ended December 31, 2015 is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted-average grant date fair value
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 50%">
	Balance as of January 1, 2015
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	511,856
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	0.21
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,000,000
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.40
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Vested
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(589,262
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	0.33
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	Balance as of December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	922,594
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: RIGHT">
	0.36
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Common Stock Awards
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company granted
	common stock awards to several non-employees in exchange for services provided. The Company measures the fair value of these awards
	using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The
	fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the
	awards is recognized as services are rendered on a straight-line basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	A summary of the Company&rsquo;s
	common stock awards granted and issued during the years ended December 31, 2015 and 2014 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 65%">
	Balance as of January 1, 2014
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	460,116
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,432,190
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Issued
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(3,244,784
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Balance as of December 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	647,522
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD>
	Granted
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,135,280
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Issued
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	(1,027,535
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="PADDING-BOTTOM: 1PT">
	Balance as of December 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	755,267
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company granted
	1,135,280 and 187,406 shares of common stock during the years ended December 31, 2015 and 2014, respectively, in exchange for professional
	services. As all services were rendered in each respective period, expense related to common stock awards of $392,661 and $102,000
	was recognized during the years ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In December 2014,
	3,244,784 shares of new common stock were granted and issued to FDS Pharma ASS (&ldquo;FDS&rdquo;) in consideration for the performance
	of services and termination of a prior collaboration agreement between Lipoxen and FDS. The Company determined that the fair value
	of the shares of common stock granted is more reliably measurable than the fair value of the services received. The Company assessed
	the fair value of one share of common stock on the measurement date to be $0.25. As performance by FDS was complete at the issuance
	date, the Company recorded expense of approximately $812,000 to research and development expense in the consolidated statement
	of comprehensive loss during the year ended December 31, 2014. FDS is a related party of SynBio, an affiliate of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.45PT">
<B>
<I>
	&nbsp;
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
<B>
<I>
	Joint Share Ownership
	Plan
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In 2010 and 2012,
	the Company issued 1,701,913 and 8,986,281 JSOP awards, respectively, to two senior executives under the JSOP. Under the JSOP,
	shares in the Company are jointly purchased at fair market value by the participating executives and the trustees of the JSOP trust,
	with such shares held in the JSOP trust. For US GAAP purposes the awards were valued as employee options and recorded as a reduction
	in equity as treasury shares until such time as they are exercised by the employee.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During 2011, the 2010
	JSOP awards fully vested under the terms of the JSOP due to a significant change in beneficial ownership of the Company and the
	related compensation charges were fully recorded during periods prior to 2013 related to this accelerated vesting. During the first
	quarter of 2014, the 2012 JSOP awards fully vested under the terms of the JSOP due the achievement of specific share price hurdles
	and the related compensation charges were fully recorded during the first quarter of 2014 related to this accelerated vesting.
	As of December 31, 2014, all JSOP awards were fully vested. The Company recognized zero and $344,905, respectively, of JSOP compensation
	expense during the years ended December 31, 2015 and 2014. As of December 2015 and 2014, there were 10,688,194 JSOP awards issued.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	13.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Employee Benefit Plans
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	Company has a defined contribution 401(k) savings plan (the &ldquo;401(k) Plan&rdquo;). The 401(k) Plan covers substantially all
	U.S. employees, and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions
	to the 401(k) Plan may be made at the discretion of the Board of Directors. During the year ended December 31, 2015 and 2014, the
	Company made contributions of approximately $34,000 and $32,000, respectively, to the 401(k) Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	In
	the U.K., the Company has adopted a defined contribution plan (the &ldquo;UK Plan&rdquo;) which qualifies under the rules established
	by HM Revenue &amp; Customs. The UK Plan generally allows all U.K. employees to contribute a minimum of 3% of salary with no maximum
	limit. The Company contributes to the plan between 8% and 12% of the employee&rsquo;s salary, depending upon seniority of the employee.
	The Company, at its discretion, may also contribute to an employee&rsquo;s personal pension plan. The Company paid total contributions
	of approximately $144,000 and $108,000 during the years ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	14.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Commitments and Contingent Liabilities
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Lease
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In August 2013, the
	Company entered into an agreement to lease office and laboratory space in Lexington, Massachusetts under an operating lease with
	a commencement date of January&nbsp;1, 2014 and a termination date of January&nbsp;31, 2019. With the execution of this lease,
	the Company is required to maintain a $66,000 letter of credit as a security deposit, which is classified as a current asset within
	the consolidated balance sheet. In connection with the Lexington lease, the Company recorded $90,838 as prepaid rent as of December
	31, 2015, with $61,377 recorded as a non-current asset. The Company also incurred a liability of $89,074 with respect to the Company&rsquo;s
	contribution to the landlord&rsquo;s leasehold improvements, of which $56,538 is outstanding as of December 31, 2015, with $38,791
	recorded as a non-current liability. This liability is repayable as additional rent expense over the term of the lease and bears
	interest at 6%. In addition, the Company leased office space in London, U.K. during 2014 and 2015. The U.K. lease was terminated
	in March 2015 in accordance with the terms of the lease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	The
	Company&rsquo;s contractual commitments under all non-cancelable operating leases as of December 31, 2015 are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 75%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	As of December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total Operating Leases
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="WIDTH: 60%; TEXT-ALIGN: LEFT">
	2016
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	98,645
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2017
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	102,604
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	106,563
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	2019
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	8,908
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	Total minimum lease payments
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	316,720
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Rent expense is calculated
	on a straight-line basis over the term of the lease. Rent expense under the Company&rsquo;s operating leases was $134,875 and $172,821
	for the years ended December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<B>
<I>
	Employment Agreements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company has contingent
	bonus compensation agreements with certain of the Company&rsquo;s employees. The bonuses become payable upon the achievement of
	certain capital raise and stock listing metrics. The amount of contingent bonuses that may be paid out in future periods is&nbsp;a
	range of approximately $380,000 to $680,000 as of December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.45PT">
<B>
	15.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Related Party Transactions
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	In May 2011, the Company
	received a short term unsecured loan facility of up to $1.7 million from SynBio, an affiliate of the Company, of which $395,000
	was outstanding as of December&nbsp;31, 2015 and 2014, respectively. A payment of $286,124 on the outstanding loan was made to
	SynBio during the year ended December 31, 2014. No payments were made during the year ended December 31, 2015. The loan had an
	interest rate of 8.04% per annum as of the date of grant, with interest payable upon repayment of the loan, which was to be seven
	months after the closing date of the loan. During 2012, the loan matured and it was agreed by both parties that the loan can be
	called due with full repayment of the outstanding principal including accrued interest upon future agreement by both parties. It
	was also agreed as of July&nbsp;1, 2012 that no further interest on the outstanding loan balance would be accrued. The loan is
	recorded in &ldquo;Loans due to related parties&rdquo; within current liabilities as of December 31, 2015 and 2014. The loan does
	not bear interest at the prevailing market rate for instruments with similar characteristics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the years ended
	December 31, 2015 and 2014, the Company received research and consulting services from a non-employee director of the Company.
	The total amount of services received was $72,594 and $74,582 for the years ended December 31, 2015 and 2014, respectively, with
	$17,791 and zero included in accounts payable on the consolidated balance sheet as of December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	During the years ended
	December 31, 2015 and 2014, the Company also received consulting services from a firm owned by a non-employee director of the Company.
	The total amount of services received was $4,000 and $133,381 for the years ended December 31, 2015 and 2014, respectively, with
	zero and $51,708 included in accounts payable on the consolidated balance sheet as of December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	Please refer
	to Note 4,
<I>
	Significant Strategic Drug Development Collaborations,
</I>
	and Note 11,
<I>
	Stockholder&rsquo;s
	Equity
</I>
	, for details on arrangements with collaboration partners and non-employee
	directors that are also related parties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 24.45PT">
<B>
	16.
</B>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<B>
	Subsequent Events
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 24.45PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	The Company performed
	a review of events subsequent to the balance sheet date through the date the financial statements were issued and determined, except
	as disclosed herein, that there were no other such events requiring recognition or disclosure in the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.45PT; TEXT-ALIGN: JUSTIFY">
	During the first quarter of 2016, the
	Company received total proceeds of $3.5 million in connection with the APA financing arrangement. The APA provided for the issuance
	of certain warrants to purchase a number of share of the Company&rsquo;s common stock equal to 50% of the number of shares issuable
	under the APA Notes. The Warrant has a five-year term and is exercisable commencing March 31, 2016. The exercise price per share
	under the Warrant is the lessor of $0.20 or 120% of the Capital Raise price, in the event there is a Capital Raise. If the APA
	Note is not repaid or converted on or before six months from the date of issuance, the Holder will be issued an additional warrant
	under the same terms as the Warrant.
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_FINANCIAL_STATEMENTS>
</EFX_PART_II>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
</P>
<EFX_VALUATION_AND_QUALIFYING_ACCOUNTS>
<A NAME="FIS_VALUATION_AND_QUALIFYING_ACCOUNTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	XENETIC
	BIOSCIENCES, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SCHEDULE
	II
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	VALUATION
	AND QUALIFYING ACCOUNTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	FOR
	THE YEARS ENDED DECEMBER 31, 2015 AND 2014
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 20%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Valuation
	Allowance on Deferred Tax Assets
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 3%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 19%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Balance
	Beginning of Period
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 19%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Additions
	(Deductions) Charged to (from) Income Tax Expense
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 15%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.3PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Other
	Changes to Valuation Allowance
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 18%; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; TEXT-INDENT: -9PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Balance
	End of Period
</B>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2015
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(13,773,409)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1,551,029)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(15,324,438)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2014
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(9,521,260)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(4,252,149)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(13,773,409)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_VALUATION_AND_QUALIFYING_ACCOUNTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; OPTIONS: NEWSECTION; VALUE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II_2"></A>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	9 &ndash; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company, as reported in its Current Report filed on Form 8-K on June 25, 2015, changed its accountants to Marcum LLP. The Company
	has no disagreements with the current or predecessor accountants on any accounting and financial disclosure matters.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	9A &ndash; CONTROLS AND PROCEDURES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Evaluation
	of Disclosure Controls and Procedures
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of
	our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934,
	as amended (the &ldquo;Exchange Act&rdquo;), as of the end of the period covered by this Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on this evaluation our management, including our Chief Executive Officer and Chief Financial Officer concluded that, as of the
	end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures are designed at a reasonable
	assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that
	we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in
	the SEC&rsquo;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief
	Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Management&rsquo;s
	Report on Internal Control over Financial Reporting
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is
	defined in Rule 13a-15(f) of the Exchange Act. Management under the supervision and with the participation of our Chief Executive
	Officer and Chief Financial Officer, conducted an assessment of the design and effectiveness of our internal control over financial
	reporting as of the end of the period covered by this Annual Report on Form 10-K. In making its assessment of internal control
	over financial reporting, management used the criteria set forth by the Committee of Sponsoring Organizations (&ldquo;COSO&rdquo;)
	of the Treadway Commission in
<I>
	Internal Control &mdash; Integrated Framework
</I>
	. Based on this assessment, our management concluded
	that, as of the end of the period covered by this Annual Report on Form 10-K, our internal control over financial reporting was
	effective based on the criteria set forth by COSO of the Treadway Commission in
<I>
	Internal Control &mdash; Integrated Framework
</I>
	.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This
	annual report does not include an attestation report of our registered public accounting firm regarding internal control over
	financial reporting. Management&rsquo;s report was not subject to attestation by our registered public accounting firm pursuant
	to an exemption for non-accelerated filers set forth in Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection
	Act.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Changes
	in Internal Control Over Financial Reporting
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	have been no changes in our internal control over financial reporting that occurred during the period covered by this Annual Report
	on Form 10-K that have materially affected, or are reasonably likely to materially affect, our internal control over financial
	reporting.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Limitations
	on Effectiveness of Controls and Procedures
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter
	how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. The Company&rsquo;s
	internal control over financial reporting includes those policies and procedures that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 24.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Pertain
	to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions
	of the Company&rsquo;s assets;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Provide reasonable
	assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
	accepted accounting principles, and that the Company&rsquo;s receipts and expenditures are being made only in accordance with
	authorizations of the Company&rsquo;s management and directors; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Provide reasonable
	assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&rsquo;s
	assets that could have a material effect on the financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Management,
	including the Company&rsquo;s Chief Executive Officer and Chief Financial Officer, does not expect that the Company&rsquo;s internal
	controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide
	only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system
	must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
	Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance
	that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls
	in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions,
	or that the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	9B &ndash; OTHER INFORMATION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<B>
	PART
	III
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ITEM 10 &ndash; DIRECTORS, EXECUTIVE OFFICERS
	AND CORPORATE GOVERNANCE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	The
	information required by this Item is incorporated by reference from the Company&rsquo;s proxy statement for the 2016 annual meeting
	of stockholders or a Form 10-K/A, to be filed with the Securities and Exchange Commission within 120 days of the end of the Company&rsquo;s
	fiscal year ended December 31, 2015, except for certain information with respect to our executive officers, which is included in
	&ldquo;Part I &ndash; Item 1&rdquo; of this Annual Report on Form 10-K under the caption &ldquo;Directors and Executive Officers&rdquo;.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ITEM 11 &ndash; EXECUTIVE COMPENSATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	The
	information required by this Item is incorporated by reference from the Company&rsquo;s proxy statement for the 2016 annual meeting
	of stockholders or a Form 10-K/A, to be filed with the Securities and Exchange Commission within 120 days of the end of the Company&rsquo;s
	fiscal year ended December 31, 2015.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ITEM 12 &ndash; SECURITY OWNERSHIP OF CERTAIN
	BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	The
	information required by this Item is incorporated by reference from the Company&rsquo;s proxy statement for the 2016 annual meeting
	of stockholders or a Form 10-K/A, to be filed with the Securities and Exchange Commission within 120 days of the end of the Company&rsquo;s
	fiscal year ended December 31, 2015.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ITEM 13 &ndash; CERTAIN RELATIONSHIPS AND
	RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	The
	information required by this Item is incorporated by reference from the Company&rsquo;s proxy statement for the 2016 annual meeting
	of stockholders or a Form 10-K/A, to be filed with the Securities and Exchange Commission within 120 days of the end of the Company&rsquo;s
	fiscal year ended December 31, 2015.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
<B>
	ITEM 14 &ndash; PRINCIPAL ACCOUNTING FEES
	AND SERVICES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	The
	information required by this Item is incorporated by reference from the Company&rsquo;s proxy statement for the 2016 annual meeting
	of stockholders or a Form 10-K/A, to be filed with the Securities and Exchange Commission within 120 days of the end of the Company&rsquo;s
	fiscal year ended December 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 84 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PART
	IV
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ITEM
	15 &ndash; EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
</FONT>
</TD>
<TD COLSPAN="2">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	following is filed as part of this Annual Report on Form 10-K:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 4%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 4%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 92%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Consolidated
	Financial Statements:
</I>
	The consolidated financial statements and report of independent registered public accounting firm
	required by this item are included in Part II, Item 8;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#183;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Financial
	Statement Schedules:&nbsp;&nbsp;
</I>
	Schedule II, Valuation and Qualifying Accounts, is included in Part II, Item 8.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
</I>
	All
	other schedules are omitted because they are not applicable or not required, or because the required information is shown either
	in the consolidated financial statements or in the notes thereto.
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibits:
</B>
	The
	attached list of exhibits in the &ldquo;Exhibit Index&rdquo; immediately preceding the exhibits to this Annual Report on
	Form 10-K is incorporated herein by reference in response to this item.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
	to be signed on its behalf by the undersigned, thereunto duly authorized.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 45%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XENETIC BIOSCIENCES,
	INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	March 30, 2016
</FONT>
</TD>
<TD>
	By:
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/
	MICHAEL SCOTT MAGUIRE
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Michael Scott Maguire
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Chief Executive
	Officer and President
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	POWER
	OF ATTORNEY AND SIGNATURES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We,
	the undersigned officers and directors of Xenetic Biosciences, Inc., hereby severally constitute and appoint Michael Scott Maguire,
	our true and lawful attorney, with full power to him, to sign for us in our names in the capacities indicated below, all amendments
	to this report, and generally to do all things in our names and on our behalf in such capacities to enable Xenetic Biosciences,
	Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all requirements of the Securities
	and Exchange Commission.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 24.1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
	of the registrant and in the capacities indicated below on the 30th day of March, 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 30%; FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Signature
</U>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-DECORATION: UNDERLINE; TEXT-ALIGN: CENTER; WIDTH: 36%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Title(s)
</U>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 30%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/S/
	MICHAEL SCOTT MAGUIRE
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD ROWSPAN="2" STYLE="VERTICAL-ALIGN: TOP">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	President,
	Chief Executive Officer and Director
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Principal
	Executive Officer)
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Michael Scott Maguire
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/S/
	FIRDAUS JAL DASTOOR FCS
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Firdaus Jal Dastoor
	FCS
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/S/
	DMITRY GENKIN
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Dmitry Genkin
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/S/
	ROMAN KNYAZEV
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Roman Knyazev
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/S/
	DARLENE DEPTULA-HICKS
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Darlene Deptula-Hicks
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/S/
	ROGER KORNBERG
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Roger Kornberg
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 48 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBIT
	INDEX
</B>
</FONT>
</P>
</EFX_EXHIBIT_INDEX>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; FONT: 10PT CAMBRIA, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12%; FONT-WEIGHT: BOLD; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBIT
<BR>
	NUMBER
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 86%; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	DESCRIPTION
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.01
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Asset Purchase
	Agreement, dated as of November 13 2015, by and among Xenetic Biosciences, Inc., Lipoxen Technologies, LTD, a U.K. corporation,
	AS Kevelt, an Estonian company and OJSC Pharmsynthez (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.02
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Ten Percent
	Senior Secured Convertible Promissory Note (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.03
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Common Stock
	Purchase Warrant&nbsp;(1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.04
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Management
	Common Stock Purchase Warrant (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.05
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Amended
	and Restated Ten Percent Senior Secured Convertible Promissory Note (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.06
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Amended
	and Restated Common Stock Purchase Warrant (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.07
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Amendment
	to Securities Purchase Agreement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.08
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Amendment
	to Registration Rights Agreement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.09
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Amendment
	to Security Agreement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.10
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Amendment
	to Subsidiary Guarantee (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.11
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Transition
	Services and Resupply Agreement (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.12
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Securities Purchase
	Agreement (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.13
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Ten Percent Senior
	Secured Collateralized Convertible Promissory Note, dated July 1, 2015 (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.14
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Registration Rights
	Agreement (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.15
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Security Agreement
	(2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.16
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Subsidiary Guarantee
	(2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.17
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Common Stock Purchase
	Warrant (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10.18
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Form of Assignment
	and Assumption Agreement (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.1 *
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of
	Michael Scott Maguire, Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31.2 *
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of
	Michael Scott Maguire, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32.1 **
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certifications of
	Michael Scott Maguire, Chief Executive Officer and Chief Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: RGB(238,238,238)">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101 *
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The following materials
	from Xenetic Biosciences, Inc.&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2015, formatted in XBRL
	(Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Comprehensive
	Loss, (iii) the Consolidated Statements of Cash Flows, (iv) the Consolidated Statements of Changes in Stockholders&rsquo;
	Equity, and (v) Notes to Consolidated Financial Statements.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 96%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Incorporated
	by reference to Current Report on Form 8-K filed November 13, 2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Incorporated by
	reference to Current Report on Form 8-K filed July 3, 2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Furnished
	herewith
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; OPTIONS: LAST -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 28.35PT; BACKGROUND-COLOR: WHITE">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage88"></A>
<A NAME="XENETIC_10K-EX3101_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBIT
	31.1
</B>
</FONT>
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATION
	OF PRINCIPAL EXECUTIVE OFFICER
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PURSUANT
	TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AS
	ADOPTED PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SECTION
	302 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	I,
	Michael Scott Maguire, certify that:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 30.6PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	I have
	reviewed this Annual Report on Form 10-K of Xenetic Biosciences, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on my knowledge, this report does not contain any untrue statement of a material fact
	or omit to state a material fact necessary to make the statements made, in light of the
	circumstances under which such statements were made, not misleading with respect to the
	period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on my knowledge, the financial statements, and other financial information included in
	this report, fairly present in all material respects the financial condition, results
	of operations and cash flows of the registrant as of, and for, the periods presented
	in this report;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s
	other certifying officer and I are responsible for establishing and maintaining disclosure
	controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
	internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
	and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures
	to be designed under our supervision, to ensure that material information relating to
	the registrant, including its consolidated subsidiaries, is made known to us by others
	within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	b.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Designed
	such internal control over financial reporting, or caused such internal control over
	financial reporting to be designed under our supervision, to provide reasonable assurance
	regarding the reliability of financial reporting and the preparation of financial statements
	for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	c.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Evaluated
	the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
	in this report our conclusions about the effectiveness of the disclosure controls and
	procedures, as of the end of the period covered by this report based on such evaluation;
	and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	d.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Disclosed
	in this report any change in the registrant&rsquo;s internal control over financial reporting
	that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
	fourth fiscal quarter in the case of an annual report) that has materially affected,
	or is reasonably likely to materially affect, the registrant&rsquo;s internal control
	over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s
	other certifying officer and I have disclosed, based on our most recent evaluation of
	internal control over financial reporting, to the registrant&rsquo;s auditors and the
	audit committee of the registrant&rsquo;s board of directors (or persons performing the
	equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	significant deficiencies and material weaknesses in the design or operation of internal
	control over financial reporting which are reasonably likely to adversely affect the
	registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	b.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	fraud, whether or not material, that involves management or other employees who have
	a significant role in the registrant&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
	March 30, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
<U>
	/s/ Michael Scott Maguire
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Michael
	Scott Maguire
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Principal
	Executive Officer and President
</FONT>
</P>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage89"></A>
<A NAME="XENETIC_10K-EX3102_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBIT
	31.2
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	&nbsp;
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATION
	OF PRINCIPAL FINANCIAL OFFICER
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PURSUANT
	TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AS
	ADOPTED PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SECTION
	302 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	I,
	Michael Scott Maguire, certify that:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 30.6PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	I have
	reviewed this Annual Report on Form 10-K of Xenetic Biosciences, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on my knowledge, this report does not contain any untrue statement of a material fact
	or omit to state a material fact necessary to make the statements made, in light of the
	circumstances under which such statements were made, not misleading with respect to the
	period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based
	on my knowledge, the financial statements, and other financial information included in
	this report, fairly present in all material respects the financial condition, results
	of operations and cash flows of the registrant as of, and for, the periods presented
	in this report;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s
	other certifying officer and I are responsible for establishing and maintaining disclosure
	controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and
	internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
	and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures
	to be designed under our supervision, to ensure that material information relating to
	the registrant, including its consolidated subsidiaries, is made known to us by others
	within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	b.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Designed
	such internal control over financial reporting, or caused such internal control over
	financial reporting to be designed under our supervision, to provide reasonable assurance
	regarding the reliability of financial reporting and the preparation of financial statements
	for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	c.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Evaluated
	the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
	in this report our conclusions about the effectiveness of the disclosure controls and
	procedures, as of the end of the period covered by this report based on such evaluation;
	and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	d.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Disclosed
	in this report any change in the registrant&rsquo;s internal control over financial reporting
	that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
	fourth fiscal quarter in the case of an annual report) that has materially affected,
	or is reasonably likely to materially affect, the registrant&rsquo;s internal control
	over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 12PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The registrant&rsquo;s
	other certifying officer and I have disclosed, based on our most recent evaluation of
	internal control over financial reporting, to the registrant&rsquo;s auditors and the
	audit committee of the registrant&rsquo;s board of directors (or persons performing the
	equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	significant deficiencies and material weaknesses in the design or operation of internal
	control over financial reporting which are reasonably likely to adversely affect the
	registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
</TD>
<TD STYLE="WIDTH: 30.6PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	b.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	fraud, whether or not material, that involves management or other employees who have
	a significant role in the registrant&rsquo;s internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
	March 30, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
<U>
	/s/ Michael Scott Maguire
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Michael
	Scott Maguire
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Principal
	Financial Officer
</FONT>
</P>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage90"></A>
<A NAME="XENETIC_10K-EX3201_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBIT
	32.1
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATION
	PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	18
	U.S.C. SECTION 1350,
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AS
	ADOPTED PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SECTION
	906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 30.6PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	connection with the Annual Report of Xenetic Biosciences, Inc. (the &ldquo;Company&rdquo;) on Form 10K for the fiscal year ended
	December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, the
	undersigned officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
	Act of 2002, that, to the best of my knowledge:
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Report
	fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange
	Act of 1934, as amended; and
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0%">
</TD>
<TD STYLE="WIDTH: 24.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The information
	contained in the Report fairly presents, in all material respects, the financial condition
	and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
	March 30, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
<U>
	/s/ Michael Scott Maguire
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Michael
	Scott Maguire
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Chief
	Executive Officer, President and Chief Financial Officer
</FONT>
</P>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
